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ABSTRACT OF DISSERTATION 
 
 
DEVELOPMENT OF DIVERSE SIZE AND SHAPE RNA NANOPARTICLES AND 
INVESTIGATION OF THEIR PHYSICOCHEMICAL PROPERTIES FOR 
OPTIMIZED DRUG DELIVERY 
 
RNA nanotechnology is an emerging field that holds great promise for advancing 
drug delivery and materials science. Recently, RNA nanoparticles have seen increased use 
as an in vivo delivery system. RNA was once thought to have little potential for in vivo use 
due to biological and thermodynamic stability issues. However, these issues have been 
solved by: (1) Finding of a thermodynamically stable three-way junction (3WJ) motif; (2) 
Chemical modifications to RNA confer enzymatic stability in vivo; and (3) the finding that 
RNA nanoparticles exhibit low immunogenicity in vivo. 
In vivo biodistribution and pharmacokinetics are affected by the physicochemical 
properties, such as size, shape, stability, and surface chemistry/properties, of the 
nanoparticles being delivered. RNA has an inherent advantage for nanoparticle 
construction as each of these properties can be finely tuned. The focus of this study is as 
follows: (1) Construction of diverse size and shape RNA nanoparticles with tunable 
physicochemical properties; (2) Investigation of the effect that size, shape, and nanoparticle 
properties have on in vivo biodistribution; (3) Development of drug encapsulation and 
release mechanism utilizing RNA nanotechnology; and (4) Establishment of large-scale 
synthesis and purification methods of RNA nanoparticles. 
In (1), RNA triangle, square, and pentagon shaped nanoparticles were constructed 
using the phi29 pRNA-3WJ as a core motif. Square nanoparticles were constructed with 
sizes of 5, 10, and 20 nanometers. The RNA polygons were characterized by AFM to 
demonstrate formation of their predicted geometry per molecular models. Furthermore, the 
properties of RNA polygons were tuned both thermodynamically and chemically by 
substitution of nucleic acid type used during nanoparticle assembly. 
In (2), the biodistribution of RNA nanosquares of diverse sizes and RNA polygons 
of diverse shapes were investigated using tumor models in nude mice. It was found that 
increasing the size of the nanosquares led to prolonged circulation time in vivo and higher 
apparent accumulation in the tumor. However, it was observed that changing of shape had 
little effect on biodistribution. Furthermore, the effect of the hydrophobicity on RNA 
 
 
nanoparticles biodistribution was examined in mouse models. It was found that 
incorporation of hydrophobic ligands into RNA nanoparticles causes non-specific 
accumulation in healthy organs, while incorporation of hydrophilic ligands does not. Lower 
accumulation in vital organs of hydrophobic chemicals was observed after conjugation to 
RNA nanoparticles, suggesting RNA has the property to solubilize hydrophobic chemicals 
and reduce accumulation and toxicity in vital organs. 
In (3), a 3D RNA nanoprism was constructed to encapsulate a small molecule 
fluorophore acting as a model drug. The fluorophore was held inside the nanoprism by 
binding to an RNA aptamer. The ability of the stable frame of the nanoprism to protect the 
fragile aptamer inside was evidenced by a doubling of the fluorescent half-life in a 
degrading environment. 
In (4), a method for large-scale in vitro synthesis and purification of RNA 
nanoparticles was devised using rolling circle transcription (RCT). A novel method for 
preparing circular double stranded DNA was developed, overcoming current challenges in 
the RCT procedure. RCT produced more than 5 times more RNA nanoparticles than 
traditional run-off transcription, as monitored by gel electrophoresis and fluorescence 
monitoring. Finally, large-scale purification methods using rate-zonal and equilibrium 
density gradient ultracentrifugation, as well as gel electrophoresis column, were developed. 
 
 
 
KEYWORDS: RNA Nanotechnology, Bionanotechnology, Nanoparticle Properties, Drug 
Encapsulation, Rolling Circle Transcription 
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Chapter 1: Introduction and Literature Review 
 
Chapter 1 was reproduced (with some modification) with permission from Jasinski, 
D; Haque, F; Binzel, DW; and Guo, P. “Advancement of the Emerging Field of RNA 
Nanotechnology.” ACS Nano, 2017. DOI: 10.1021/acsnano.6b05737. Copyright 2017 
American Chemical Society. 
 
SUMMARY: 
Chapter 1 begins this thesis with an overview on nanotechnology and its application 
to advancing the field of drug delivery. The creation of RNA nanotechnology is then 
discussed, and previous and current RNA nanoparticle construction methods are 
introduced. Next, ways in which RNA nanotechnology overcomes current challenges in 
nanotechnology drug delivery are outlined. Finally, the importance of nanoparticle 
physical properties, such as size, shape, stability, and surface chemistry/properties, for in 
vivo drug delivery are discussed. 
Chapter 2 introduces a method for the construction of RNA nanoparticles with 
diverse size, shape, and thermodynamic and chemical stability. RNA triangles, squares, 
and pentagons were constructed using the three-way junction (3WJ) motif from the 
packaging RNA (pRNA) of bacteriophage phi29. It was found that the inner angle of the 
3WJ could be tuned from its native angle of 60°, ideal for triangle geometry, to 90° and 
108°, ideal for square and pentagon geometry, respectively. The resulting nanoparticles 
display high thermodynamic stability despite stretching of the 3WJ from its ideal geometry. 
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RNA nanosquares with sizes of 5, 10, and 20 nm were constructed. Sizes were tuned by 
simply increasing or decreasing the number of RNA duplex turns between each corner of 
the square. Furthermore, nanosquare stability was tuned by chemically modifying one 
RNA strand used during construction. Nanosquare thermodynamic and serum stability was 
decreased and increased by modifying the structure with DNA and 2’-fluorine modified 
(2’F) RNA, respectively, thus demonstrating the tunable nature of RNA nanoparticles. 
Chapter 3 considers how physical properties of RNA nanoparticles affect in vivo 
biodistribution. 2’F modified and fluorescently labeled nanosquares of different sizes were 
injected into tumor bearing nude mice and analyzed for tumor accumulation and 
nanoparticle clearance. A strong correlation between nanoparticle size, circulation time, 
and tumor accumulation was found. An increase in both tumor accumulation and 
circulation time is seen from the larger nanoparticles. However, the RNA nanosquares still 
show little fluorescence in healthy organs such as the liver and kidneys, compared to 
tumors, after 24 hours (h). Finally, the hydrophobic effects of externally conjugated 
chemicals on biodistribution was examined. It was found that increased hydrophobicity of 
conjugates caused accumulation of RNA nanoparticles in healthy tissue and organs, while 
more hydrophilic ligands showed weaker accumulation signal in vital organs. 
Chapter 4 demonstrates a novel method for the encapsulation and controlled release 
of a model small molecule drug using RNA nanotechnology. Using previously designed 
RNA triangles, a three-dimensional (3D) nanoprism was constructed and characterized. A 
fluorogenic RNA aptamer was then encapsulated inside the nanoprism, allowing capture 
of a small molecule fluorophore, acting as a model drug, by binding to the aptamer. It was 
shown that the stable nanoprism frame protected the fragile RNA aptamer, which holds the 
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model drug, from degradation due to steric hindrance of degrading enzymes. Tuning the 
amount of 2’F modified nucleotides in the frame led to a controlled degradation profile of 
the nanoprism frame, allowing controlled release of the model fluorophore encapsulated 
within the nanoprism. 
Chapter 5 details the development of large-scale synthesis and purification of RNA 
nanoparticles. A large-scale in vitro method for RNA nanoparticle synthesis was developed 
using rolling circle transcription (RCT) of a fully double stranded (ds) DNA template. This 
method overcomes current challenges associated with RCT to synthesize RNA 
nanoparticles from a single stranded (ss) DNA template displaying stable secondary 
structure, which hinders the progress of bacterial RNA polymerases. RNA nanoparticles 
were then purified by two large-scale methods: 1) rate-zonal and equilibrium density 
ultracentrifugation and 2) column gel electrophoresis. Both methods resulted in the 
purification of large amounts of pure RNA nanoparticles, paving the way towards pre-
clinical development. 
Chapter 6 summarizes the major findings and advancements of the research 
discussed in this thesis dissertation. Furthermore, the future direction of this work is 
described providing a prospective on research that is still needed to fully prove the benefits 
of RNA nanotechnology. Finally, the current state of RNA nanotechnology is discussed 
looking at the major hurdles that have been overcome, and the challenges that still need to 
be faced.  
HYPOTHESIS: 
 The 3WJ motif from bacteriophage phi29 pRNA provides a stable RNA motif from 
which to build diverse size and shape, yet physicochemically tunable, RNA nanoparticles. 
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Different physical properties of RNA nanoparticles will affect biodistribution and 
pharmacokinetic profiles.  
INTRODUCTION: 
Nanotechnology and drug delivery 
Nanotechnology can be defined as the science of engineering materials and 
systems; the ultimate goal being control over specific functions and properties of 
nanoparticles on a molecular scale. While the field of nanotechnology was conceived in 
1959 by Richard Feynman’s lecture “There’s Plenty of Room at the Bottom” (1) it took 
more than two decades before one of Feynman’s challenges, proposed during his lecture, 
was completed. Tom Newman, then a graduate student at Stanford, successfully printed 
the first paragraph of A Tale of Two Cities at 1/25000th scale (2). Nanotechnology was later 
defined by the National Nanotechnology Initiative to be the manipulation of materials with 
the size range of 1 – 100 nm in size. As imaging technology progressed, so did 
nanotechnology, as the development of techniques such as atomic force microscopy 
(AFM), transmission electron microscopy (TEM), and scanning tunneling microscopy 
(STEM) allowed researches more detailed imaging and analysis of nanoparticles. 
Nanoparticles have since been created from a wide variety of materials such as lipids (3); 
polymers (4); proteins and peptides (5); viruses and viral components (6); carbons (7); 
heavy metals, such as gold (8) and silver (9); iron oxide (10); deoxyribonucleic acid (DNA) 
(11); and ribonucleic acid (RNA) (12). 
 One major focus for the implementation of nanotechnology has been the 
advancement of drug delivery, and while nanoparticles are used in many applications, 
nanoparticle drug delivery is among the most promising (13,14). In traditional drug 
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delivery, therapeutic agents, such as small molecule drugs, are cleared from the body rather 
quickly. This results in low accumulation of the therapeutic agent at the target site, 
requiring increased dosage, which increases toxicity. A key feature of nanoparticles is their 
extended half-life in vivo compared to therapeutic agents, which increases the circulation 
time and bioavailability of therapeutic agents conjugated to or encapsulated within the 
nanoparticles (15,16). Many drugs currently under development are not soluble and cause 
off-target toxicity issues, limiting their practical application for the treatment of disease 
(17). Nanoparticles have previously shown the ability to conjugate or encapsulate 
hydrophobic and toxic drugs, with hopes to increase therapeutic dose to the disease site 
(18-23). Nanoparticles have shown to increase the solubility of highly hydrophobic drugs; 
deliver a high dosage of therapeutic to the disease site using release mechanisms such as 
pH sensitive linkages (24-28); and provide targeting to cells by use of cell specific peptides 
(29-31) and aptamers, specific RNA sequences selected to bind chemical or protein 
ligands, such as cell-surface receptors (32,33). As a result, the amount of therapeutic 
getting to the diseased site is increased, allowing lower dosage and decreased toxicity. 
Many different materials are used to construct nanoparticles, each offering their 
own advantages and disadvantages, and nanotechnologists are continually searching for an 
ideal candidate to improve the current state of drug delivery. Lipid based nanoparticles 
allow for high therapeutic loading and delivery of payloads through membrane fusion with 
cells while remaining nontoxic and non-immunogenic (34,35). However, lipids have 
shown issues with thermodynamic stability, releasing their payload before reaching the 
target site (36). Also, reproducibility during nanoparticle construction results in 
inconsistent products (37). Similarly, polymer based nanoparticles allow for high levels of 
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therapeutic encapsulation (38). Moreover, polymers display a significant increase in 
thermodynamic stability and can easily be functionalized on the surface for targeting 
capabilities (39). Yet, polymers have shown issues with batch reproducibility, water 
solubility, and overall bioavailability. Biologically derived nanoparticles such as viruses, 
viral components, and proteins or peptides, illicit immune responses and generate toxicity. 
But, targeted delivery of these nanoparticles allows for a lower overall dose while having 
a high accumulation in targeted tissues (40-43). Inorganic nanoparticles such as carbon 
structures and metal ions can be created with high reproducibility at a lower cost than most 
nanoparticles. Additionally, these particles can be functionalized through chemical 
modifications. However, their accumulation in healthy organs such as kidneys, lungs, and 
liver result in toxicity and limit their overall potential for therapeutic delivery. DNA 
nanostructures are constructed with defined shape, size, and stoichiometry (44-46) and can 
achieve targeted delivery with the functionalization of DNA aptamers (47,48). However, 
relatively low thermodynamic stability limits DNA’s ability for in vivo applications. 
Cationic nanoparticles, such as metal ions, some polymers, and proteins, display an overall 
positive charge allowing for endosomal escape through the proton sponge effect (49). 
However, positive charge also causes passive attraction with negatively charged cell 
membranes, thus leading to non-specific binding and cell entry.   
Conception of RNA nanotechnology 
 The idea of RNA nanotechnology was first conceived in 1998(12) when the pRNA 
from bacteriophage phi29 was engineered to form a hexameric RNA nanoparticle from six 
copies of pRNA. Each of the pRNA monomers interacts using loop-loop complementary 
base-pairing, referred to as hand-in-hand interactions (50). The intermolecular connections 
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between adjacent pRNA units was the first demonstration of specific arrangement of RNA 
into an engineered nanoparticle. pRNA is a 120 nucleotide (nt) RNA that adopts a stable 
secondary structure. Its function is to act as a connector between the portal proteins and 
ATPase in the bacteriophage phi29 DNA packaging motor (51-54).  
 Within the pRNA is a unique three-way junction (3WJ) motif, which drives the 
assembly of the pRNA structure (55). The 3WJ has been extracted from the pRNA and 
used as a nanoparticle for drug delivery (56-61). It is thermodynamically stable (62,63), 
enzymatically stable with chemical modification (64), assembles without metal ions from 
its three component RNA oligomers (3WJ-a, 3WJ-b, 3WJ-c), and can accommodate the 
addition of multiple functional groups while still retaining folding and stability (55). 
RNA’s versatility in structure and function, propensity for bottom-up self-
assembly, defined size and structure, favorable in vivo attributes, and large potential as a 
therapeutic modality make it an attractive candidate as a biomaterial for nanoparticle drug 
delivery. RNA’s ability to adopt complex quaternary structures (12,65-69), to base stack 
(70,71), to form canonical Watson-Crick (A‒U; G‒C) and non-canonical (ex. G‒U 
wobble) base pairing (72,73), leads to a variety of natural structural motifs (74,75). RNA 
nanotechnology uses such properties to construct nanoparticles for use in nanomedicine 
and bionanotechnology applications. 
Beneficial properties of RNA for nanoparticle construction 
Nanotechnology that revolves around the manipulation of biological materials is 
referred to as bionanotechnology, which includes the field of nucleic acid nanotechnology. 
First envisioned over 30 years ago (76), DNA self-assembly was exploited to form 
nanoparticles using base-pairing mechanism (A‒T, G‒C)(77,78). DNA nanostructures 
8 
 
including nano-capsules and other nano-carriers for drug delivery applications have since 
been constructed (79-81). DNA origami was developed as a powerful tool to build large 
2D (82) and 3D architectures including tetrahedrons (83), nano-robots (84), helix bundles 
(85), and tensegrity-based shapes (86). Although DNA nanostructures have exemplified 
the power of the base-pairing mechanism for structure design, DNA cannot match the 
thermostability and structural and functional diversity of its nucleic acid counterpart, RNA. 
 Like DNA, RNA is a chain-like biopolymer composed of nucleotide subunits 
joined by phosphodiester bonds. Each nucleotide is composed of a ribose sugar, phosphate 
group, and nitrogenous base. The most common bases are cytosine (C), guanine (G), 
adenine (A), and uracil (U). The basis of RNA secondary structure is hydrogen bonding 
occurring between complementary nucleotides, G‒C and A‒U, analogous to that of 
canonical base pairing found in DNA. Furthermore, the presence of the 2’‒OH in RNA has 
dramatic effects on its properties. The C3’‒endo sugar conformation in RNA leads to A-
type helical formation (11 bp/turn), offering improved thermostability over DNA B-type 
helix.  
 RNA was first characterized as the link between genomic DNA and protein, 
transferring the genomic code for proteins to the cell’s translation machinery. Investigation 
of RNA structure revealed the catalytic nature of RNA with the discovery of ribozymes 
(87). The revolutionary finding of catalytic RNA, an attribute thought only to belong to 
proteins, led to a shift in the thought of the functions of RNA. In addition to functions 
generated by elaborately structured RNA molecules, specific base-pairing interactions 
mediated by single stranded regions of unstructured RNA have further expanded RNA's 
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functional repertoire (88). Years of research found that RNA performs diverse functions in 
biology, juggling tasks from catalysis to protein synthesis to gene regulation. 
 An emerging class of targeted therapeutic molecules has been developed based on 
RNA aptamers (89); single-stranded RNA sequences that fold into specific 3D 
configurations and bind with high selectivity and affinity to extracellular domains of cell 
surface receptors. A combination of electrostatic interactions, hydrogen bonding, and van 
der Waals forces mediates binding. Aptamers possess many advantages as targeting 
reagents including low cost, fast selection and optimization, convenient synthesis and 
modification with high batch fidelity, low immunogenicity, and long term stability (90,91). 
The development of the systematic evolution of ligands by exponential enrichment 
(SELEX) (92,93) process has made aptamer development possible for many proteins and 
peptides. Currently, tens of RNA aptamers are available for targeting specific cell surface 
receptors followed by subsequent internalization of RNA nanoparticles. RNA aptamers 
offer unique advantages to RNA nanotechnology, as the aptamer can easily incorporated 
into RNA nanoparticles by sequence fusion. 
Ribozyme-based therapeutic strategies have emerged as powerful tools for the 
treatment of cancer and viral infections. Ribozymes are RNA motifs that possess catalytic 
properties much like those of proteins. Ribozymes targeting mRNA show promise for gene 
therapy of breast cancer and hepatocellular carcinoma in animal models as they display 
similar effectiveness as RNAi, while exhibiting less off-target effects (94).  
 Riboswitches offer therapeutic avenues for addressing a wide range of diseases by 
regulating gene expression. Riboswitches are composed of two domains, a sensor portion 
(a natural aptamer) for ligand recognition, and an expression platform that can adopt two 
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mutually exclusive conformations based on ligand binding for controlling gene expression 
(without the need for protein cofactors) (95). Based on simplistic design principles, RNA 
nanotechnology can be applied not only to deliver the RNA switches in vivo but also to 
rationally engineer synthetic riboswitches to repress or activate gene expression in a ligand-
dependent fashion. 
 The discovery of the RNA interference (RNAi) pathway in 1998 (96) created an 
avenue of treatments for many diseases, including cancer. RNAi is the process by which 
the expression of a gene is modulated by short double stranded RNA sequences, typically 
21-23 nucleotides in length. There are two central molecules to RNAi, miRNA and siRNA 
(97). While miRNAs are endogenous to cells, and target multiple genes, siRNAs are mostly 
artificial sequences (some endogenous siRNAs do exist in cells (98)) that are designed to 
target a specific mRNA. Theoretically, any known mRNA sequence can be targeted using 
siRNAs and miRNAs, making diseases previously thought to be undruggable susceptible 
to RNAi therapy. RNA nanoparticles are designed such that endonuclease Dicer can access 
the dsRNA sequences encoding for the siRNAs and miRNAs and cleave them to generate 
functional miRNA and siRNA, which are then loaded into the RNA induced silencing 
complex (RISC) and thereby regulate gene expression by selectively targeting mRNAs.  
 RNA’s negatively charged phosphate backbone renders RNA nanoparticles highly 
anionic, disallowing non-specific targeting to all cells. Furthermore, the high 
thermostability of RNA allows for the construction of stable RNA nanoparticles. While 
RNA is quickly digested in vivo by numerous of RNA specific nucleases, modifications to 
the 2’ of the ribose sugar render RNA more thermodynamically and enzymatically stable. 
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One modification is substitution of fluorine for the hydroxyl at the 2’ sugar positons of the 
pyrimidines, cytosine and uracil. 
 RNA’s anionic charge, versatile structure, myriad of functional RNA motifs 
available for nanoparticle construction, and the availability of chemical modifications, 
which endow stability, contribute towards the fact that RNA is a unique biomaterial that 
can be utilized in nanotechnology and bionanotechnology. 
RNA nanoparticles 
 While RNA nanoparticles were initially constructed to study RNA structure (99-
101), advancements in the technology, such as improvements in stability, have allowed 
RNA nanotechnology to be developed with more biomedical applications in mind. There 
are three major challenges associated with using RNA as a nanoparticle: (1) 
Thermodynamic stability; (2) Enzymatic stability; and (3) immune response elicited by 
dsRNA. However, these issues have been overcome by the finding of an unusually stable 
3WJ motif suitable for nanoparticle construction (55), chemical modifications to RNA 
allowing prolonged stability in serum (64,102), and studies showing the immunogenicity 
of RNA nanoparticles are very low in vivo (103). 
 Because of the versatility of RNA structure, many different methods have been 
developed over the years for RNA nanoparticle construction. Some of the most popular 
methods for RNA nanoparticle construction are through intermolecular interactions, 
computer aided design, RNA tectonics, rolling circle transcription (RCT), and modular 
design approach, the last method of which this thesis will focus. 
 The use of intermolecular interactions to construct RNA nanoparticles was 
pioneered by the Guo lab using pRNA as a monomer unit. The pRNA was engineered to 
12 
 
contain complementary kissing loops, which interact to form dimers, trimers, tetramers, 
pentamers, hexamers, and heptamers using “hand-in-hand” interactions (12,50,104,105). 
Furthermore, pRNA monomers were functionalized with palindrome sticky ends 
sequences to interact “foot-to-foot” to form nanoparticles (50,104,105). 
 RNA tectonics is a field pioneered by Neocles Leontis, Eric Westhof, and Luc 
Jaeger. Tectonics is a RNA nanoparticle construction method by which different RNA 
motifs, or tecto units, are arranged to interact and form nanoparticles. RNA nanoparticles 
can be constructed using motifs such as kissing loops, dovetails, pseudoknots, kink turns, 
and multi-way junctions (74,75,99,101,106).  Increasing knowledge of RNA folding and 
the availability of databases such as the Nucleic Acid Database (NAD) (107) and the 
RNAjunction database (68) have increased the power of tectonics, as the number of motifs 
that can be used as potential tectoRNAs is quite large. Examples include the tecto RNA 
squares and cubes designed from tRNA and nanoprisms designed from pRNA 
(100,101,104,108-117). 
 Computer based nanoparticle design has become extremely powerful due to the 
predictive abilities of the software programs written specifically for RNA nanoparticle 
design. Several software programs have been developed over the years such as Nanotiler 
(118), Assemble2 (119), RNA2D3D (120), INFO-RNA (121), and NUPACK (122), which 
are useful to design de novo RNA nanoparticles. Examples are a six-membered RNA 
nanoring (123) and an RNA nanocube generated using Nanotiler (124). Long sequences as 
well as individual monomer units that contain internal structures can be computationally 
designed and experimentally assembled in a one-pot manner including co-transcriptional 
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assembly. Computer aided design is especially useful as RNA folding is complicated and 
engineering sequences for correct folding enhances stability for biomedical applications. 
 RCT produces large amounts of concatemeric RNA sequences from a circular DNA 
template using in vitro transcription (125). A ssDNA oligomer anti-sense to the target 
sequence is circularized through ligation, while a short splint ssDNA containing the RNA 
polymerase promoter sequence is annealed to the circular DNA allowing RNA polymerase 
initiation. After ligation, in vitro transcription occurs in a continuous fashion. RCT has 
been used to synthesize RNA microsponges containing thousands of copies of siRNA, 
which were then delivered to tumor bearing mice showing efficient tumor regression (38). 
 The focus of this thesis is a modular design approach using a natural 3WJ RNA 
motif, derived from the pRNA of bacteriophage phi29, as the core for nanoparticle 
construction (126). While similar to RNA tectonics, the modular design approach avoids 
the use of sticky end, loop-loop, or other intramolecular interactions resulting in more 
stable nanoparticles. Despite increased knowledge of RNA structure and folding, de novo 
design of RNA remains difficult. Using a RNA motif, of which the crystal structure is 
known, molecular modeling software can be used to design RNA nanoparticles. This 
technique was first used to construct RNA triangles (126). To do this, three 3WJ motifs 
were aligned in a planar configuration, and adjacent helices were attached using dsRNA. 
To construct the nanoparticle, four strands were used: three external short strands and one 
internal long core strand to tether all strands together. This method results in a fully double 
stranded RNA nanoparticle, held together by hundreds of hydrogen bonds.  
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Importance of nanoparticle physical properties  
 Nanoparticle properties such as size, shape, charge, surface chemistry/properties, 
and construction material, govern how the nanoparticles interact with their in vivo 
environment, mainly the mononuclear phagocytic system (MPS) (127), and largely control 
uptake and elimination pathways. In turn, the behavior of the nanoparticles, such as 
circulation time and biodistribution, are determined. The properties of nanoparticles are of 
paramount importance, as in vivo behavior is a determining factor of success for a particular 
nanoparticle.  
 One of the most important properties that determines how nanoparticles interact 
once in circulation is their size. Importantly, the size of nanoparticles determines the 
pathways in which they are taken into cells, such as pino- and phagocytosis (128), and 
which parts of the MPS they interact with, such as the liver or the kidneys. Smaller 
nanoparticles, less than 15 nm, are excreted quickly through the kidneys (129) while larger 
particles, 15-100 nm, have more interaction with macrophages, and are excreted more 
slowly through the liver (130). Interactions with the MPS dictate the circulation time of 
nanoparticles, as well as how long they stay in organs once they have reached their 
destination. For example, gold nanoparticles 50 nm in size accumulated in the liver and 
spleens of beagles, and remained in said organs for more than six months (131). Circulation 
time is extremely important for nanoparticles relying on the enhanced permeability and 
retention (EPR) effect, as longer circulation times gives the nanoparticles a higher chance 
to accumulate at the tumor site. In addition to circulation time, the size of nanoparticles 
also affects their entry into the tumor. It has been shown that smaller nanoparticles, less 
than 10 nm, have the highest penetration into the tumor tissue (132). Additionally, smaller 
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nanoparticles are taken into the cells of tumors, not just the tumor site, more rapidly and in 
higher amounts (133). Size also affects the composition and extent to which the protein 
corona forms. The protein corona has drastic effects on the “stealthiness” of a nanoparticle, 
and higher amounts of protein corona formation on a nanoparticle will results in faster 
removal by the MPS (128). 
 Along with size, shape is also an important factor for nanoparticle behavior in vivo 
(134). The geometry of a particle has a large effect on its interaction with macrophages. 
Studies have shown that less angular nanoparticles, side angles less than 45˚, are 
completely enveloped by macrophages, whereas particles with shaper angles, side angles 
more than 45˚, are unable to be completely phagocytized (135,136). Shape also affects 
where the particles accumulate as short rod particles have been shown to accumulate in the 
liver while longer rods go to the spleen (137). Furthermore, particles that display a higher 
aspect ratio, such as rods, are more efficient at accumulating in the tumor than spherical 
particles and plate shaped particles (128,132). Yet, higher aspect ratio nanoparticles also 
result in higher inflammation and stimulation of pro-inflammatory cytokines (128). As 
with size, shape also affects the formation of a protein corona, affecting the stealth nature 
of nanoparticles (138). 
  The surface charge of a nanoparticle can also affect its circulation, biodistribution, 
and cellular uptake. Neutral particles circulate the longest, while anionic and cationic 
particles see reduced circulation times (139). Particles that carry a charge have increased 
protein corona and protein opsonization, causing higher macrophage recognition and faster 
clearance (128). Cationic particles enter cells more rapidly and to a higher degree than 
neutral and anionic particles due to fusion with the negatively charged cell membrane. 
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However, cationic particles show high toxicity and significant immune reactions, thus, 
negatively charged and neutral particles are generally preferred. The charge of particles 
also affects the mechanism of uptake into cells, which has a large effect on their 
intracellular fate and drug delivery efficacy (132). 
 Surface functionalization and surface properties also play a role in interaction with 
the immune system. Generally, hydrophilic particles are preferred over hydrophobic, as 
hydrophilic particles see an increase in circulation time over their hydrophobic counterparts 
(140). Hydrophobicity of nanoparticles increases protein adsorption significantly, leading 
to faster clearance (141). Protein adsorption can also increase non-specific accumulation 
in vital organs. Increased hydrophobicity has also been linked to increased activation of 
immune system cytokines, both in vitro and in vivo (142). Surface functionalization, such 
as PEGylation, can drastically alter the way nanoparticles interact with their environment. 
Increased PEG density leads to higher uptake by liver kupffer cells, while lower PEG 
density increases uptake by kidney phagocytes (143,144). Also, albumin (BSA) coating 
can lead to aggregation of nanoparticles, and accumulation in the liver and spleen resulting 
in toxicity (145). Polymer coatings decrease protein binding and phagocytosis compared 
to their non-coated counterparts, and show resistance to accumulation in the spleen and 
liver (146,147). 
 Finally, the material chosen for nanoparticle construction has a large effect on 
interaction with the immune system and accumulation in vivo. Analysis of the 
accumulation of many different types of nanoparticles in tumors showed that inorganic 
materials have the highest percent accumulation (132). Even inside the realm of inorganic 
nanoparticles, gold nanoparticles seem to be better than QDs or iron oxide nanoparticles. 
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However, as inorganic materials degrade slowly over time, there are potential hazards with 
repeated administration and buildup of inorganic material. However, universal throughout 
all these studies is that cancer type and tumor model are the two most important factors 
when determining nanoparticle accumulation in tumors (132). This suggests that for each 
type of cancer, the ideal nanoparticle is not identical. 
The tunable nature of RNA nanoparticles advances drug delivery  
 The fact that tumors arising from different cancer types are so diverse is a big 
challenge in cancer nanotechnology drug delivery. It is difficult to decide which 
nanoparticle system to use for each situation, due to the heterogeneity of different tumor 
types as well as heterogeneity within a single tumor. One major finding of this thesis is that 
the properties of RNA nanoparticles can be controlled during design and construction. As 
discussed above, the properties of nanoparticles have a huge effect on in vivo behavior. 
RNA nanoparticles are defined in size, shape, and properties, and are highly consistent in 
their assembly. Their properties are near identical from particle to particle, as the base 
pairing mechanism allows controlled self-assembly, not a random and aggregative 
assembly like in some other nanoparticles. It is possible that the in vivo behavior of RNA 
nanoparticles can be optimized based on the controllable size, shape, and properties that 
the nanoparticle engineer has on the system. 
The nanoparticle designer can easily scan through varieties of RNA secondary and 
tertiary structural motifs from which to design and construct an RNA nanoparticle (ex. 
bulges, stems, hairpin, loops, and junctions). Such motifs are used as building blocks to 
design nanoparticles with diverse size and shape by engineering parameters such as motif 
angle and sequence length (103,126,148-150). Other parameters such as nucleotide type 
18 
 
can alter nanoparticle properties, including enhancing chemical stability using base or 
backbone modifications, or incorporating fluorescent dyes for nanoparticle tracking. The 
physiochemical properties of RNA nanoparticles can easily be fine-tuned to tailor-make 
the nanoparticle for desired applications in vitro and in vivo. 
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Chapter 2: Design, Construction, and Characterization of RNA 
Nanoparticles with Tunable Size, Shape, and Physicochemical Properties 
Based on phi29 pRNA-3WJ Core Motif 
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Chapter 2.1: Design and Construction of RNA Nanoparticles with Tunable Shape 
INTRODUCTION: 
One area of biomimetic nanotechnology involves the construction of nano-scale, 
supramolecular architectures utilizing modular units of functional nucleic acids. The aim 
is to design nanostructures that undergo self-assembly in controllable and recyclable 
fashion. RNA was discovered as an attractive material to build nanoparticles via 
nanotechnology (12), offering a variety of structural modules and motifs that can be 
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manipulated into 1D, 2D, and 3D architectures (for review see reference (90)). In the past 
decade, a variety of geometric RNA nanoparticles and nano-scaffolds have been obtained 
via the approaches of hand-in-hand (12,105,151), foot-to-foot (50,104), branch extension 
(55,116,152,153), loop-receptor contact (113,154), loop-loop (108,114), “sticky” or 
“dangling" ends (104,124), and synthetic RNA-protein complex interactions (155).  These 
motifs are available in data bases and can be used to build artificial nanostructures by 
manipulating their interchangeable units (156,157). Recently, RNA rolling circle 
transcription has been utilized to generate RNA sponges (38,158).  In RNA tectonics, 
structural motifs like double helices, loops, and junctions can be isolated from large and 
complex RNA molecules appearing in structural data bases and used to build artificial 
nanostructures by manipulating their interchangeable units (99,159). As such, previously 
reported designs of RNA nanoparticles, e.g. tecto-square (109), square-shaped nano-
scaffolds (110,111), RNA nano-rings (108), pRNA dimmers, tetramers, and hexamers 
(12,160-162), as well as RNA nano-cubes (124), RNA polyhedron (116), RNA bundles 
(163), RNA filaments (113,154), utilize fundamental principles of RNA structure and 
folding (75,164-167). Overall stability of conventional constructs though, mainly relies on 
the stability of canonical and non-canonical base pair (bp) forming by loop-loop, receptor-
loop, or “sticky-ends” with only a few pairing nucleotides usually not exceeding six. A 
new approach is needed to increase overall stability of RNA nanoparticles, one that uses 
naturally-selected stable RNA building blocks for structure building, one example being 
the 3WJ motif from pRNA of bacteriophage phi29 DNA packaging motor. In addition to 
discovering that the pRNA-3WJ shows exceptional stability under physiological 
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conditions and in the presence of strong denaturing agents (55,152), recent studies also 
suggest that the thermodynamic stability of the 3WJ is entropy driven (63).    
Previous studies constructed RNA triangles form the pRNA-3WJ module (Fig 2.1). 
In this report, we introduce a conceptual approach to the rational design of stable RNA 
architectures by stretching the 60°AOB angle () (Fig 2.2) of the thermodynamically 
stable pRNA 3WJ motif utilizing a modular design technique (Fig 2.3).  We demonstrate 
that it can be stretched to wide conformations resulting in different 2D polygons: triangle 
(AOB =60°), square (AOB = 90°), and pentagon (AOB = 108°). Intermolecular 
interactions such as kissing loops, receptor loop, or “sticky-ends” were avoided by 
introducing linkages through base pairing between corners of the polygons using RNA 
double helices. Therefore, this system is advantageous with an increased thermo-stability 
in the overall construct. 
MATERIALS AND METHODS: 
RNA nanoparticles design, synthesis, and self-assembly 
The 3WJ crystal structure of the pRNA molecule (PDB ID: 4KZ2) was primarily 
used for designing polygon models using Swiss PDB viewer, as previously described 
(168). RNA strands for corresponding triangle, square, and pentagon, were synthesized by 
in vitro T7 transcription using polymerase chain reaction (PCR) generated DNA templates. 
RNAs were purified by denaturing polyacrylamide gel electrophoresis (PAGE) and were 
either Cy5 whole chain RNA labeled (Mirus Bio LLC) or 5′-end [-32P] ATP (PerkinElmer) 
labeled, as previously described (151). 
RNA polygons were assembled in one pot by mixing equimolar concentrations 
(final concentration of 1 µM) of four RNA strands for the triangle, five RNA strands for 
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the square, and six RNA strands for the pentagon in 1 X TMS buffer (50 mM Tris pH = 
8.0, 100 mM NaCl, and 10 mM MgCl2). Samples were annealed for 1 h in a thermocycler 
with controlled, slow cooling (1 °C/ min) from 80 - 4 °C. 
Native PAGE, TGGE, and boiling resistance assays 
RNA assemblies were evaluated on 7% (29:1) native polyacrylamide gels in the 
presence of 1 X TBM (89 mM Tris, 200 mM boric acid, 5 mM MgCl2) buffer. Gels were 
run at constant 90 V, +4°C. Gels were imaged with Typhoon FLA 7000 (GE Healthcare) 
to visualize RNA strands. Temperature gradient gel electrophoresis (TGGE) analysis was 
performed on 7% native PAGE in a buffer containing 50 mM TRIS pH = 8.0, 100 mM 
NaCl, and 0.2 mM MgCl2, as previously described (109,110,116). A gradient temperature 
of 30-70°C was applied perpendicular to electrical current, and the experiment was run for 
1 h at 20 W. A total RNA concentration of 100 nM was used in TGGE analysis. Apparent 
TM values corresponded to the temperature at which half of the polygons fractions were 
dissociated, and apparent KD values for multiple RNA strands were calculated, as described 
previously (50). 
Boiling resistance assay was performed in 10 µL containing 1 µM preassembled 
polygons in TMS buffer or in the presence of 8 M urea. Samples were incubated at 100°C 
for five minutes, then snap cooled on dry ice to prevent refolding following evaluation on 
7% native PAGE at 4 °C. Boiling experiments were repeated 3 times and standard deviation 
measurements are indicated by error bars. 
Quantification analysis was performed using ImageJ (169). Equal-sized boxes were 
drawn around the lanes corresponding to the triangle, square, or pentagon complexes and 
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corresponding quantified values for each type of polygon were divided by the sum of the 
values presented in the corresponding lane. 
RESULTS: 
RNA polygons: triangle, square, and pentagon fabrication and self-assembly   
The structural features of the recently discovered ultrastable pRNA 3WJ module 
from the bacteriophage Phi29 DNA packaging motor were utilized for in silico design of 
the RNA triangle, square, and pentagon 2D polygons. During computer modeling we used 
the angle of the 3WJ formed by H1 and H2 as an inner angle of the polygons as we 
hypothesized that the angle could be stretched to a more open conformation.  Throughout 
this report the intra-helical angle between H1 and H2 is denoted as AOB, as shown in 
figure 2.2A. Each RNA model contained a pRNA 3WJ motif at each vertex, and the inner 
angles correspond to AOB. The resulting 3D models exhibited flat conformations, as 
expect from the plane geometry of the 3WJ motif (168) (Fig 2.4A). 
Each polygon was composed of a different number of RNA strands classified as 
short strands (external) and long strands (internal) (Fig 2.4B). By increasing the number of 
external strands and the propagation of the central strand, the tension on the inter-helical 
AOB increased to 60°, 90°, and 108°, allowing for 2D formation of corresponding 
triangle, square, and pentagon shapes. The measured widths, from one corner to another, 
were 10.2 nm, while the heights differed as follows: triangle = 9.1 nm, square = 10.2 nm, 
and pentagon = 12.7 nm. Following the transcription of individual RNA strands, self-
assembly properties of the triangle, square, and pentagon designs were evaluated on 7% 
native polyacrylamide gel electrophoresis (PAGE) (Fig 2.4C). All polygon formations 
were obtained by one-step self-assembly (50,55,124,152). Each component strand of each 
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nanoparticle was whole chain labeled with Cy5 to evaluate participation of all RNA strands 
in their corresponding assemblies. Yield of correctly assembled polygons was estimated to 
be >90% based on native PAGE gel evaluations (Fig A.1.1). Equilibrium constants of 
dissociation were obtained from apparent KD gels, and KD values were determined to be 
18.8 nM, 20.3 nM, and, 22.5 nM for triangles, squares, and pentagons, respectively (Fig 
A.1.2).  
These results demonstrate that each RNA nanoparticle assembles into the desired 
nanostructure, and indicates stretching of the 60°AOB to wider conformations. The 
assembly of RNA strands into specific-shaped nanoparticles based on the 60°AOB of the 
pRNA 3WJ motif was controlled by modulating the number of short external stands and 
the length of the long internal strand. 
Structural characterization of polygons by AFM and DLS 
To further evaluate the size and shape of the resulting RNA assemblies, structural 
characterization of each polygon was conducted using atomic force microscopy (AFM). 
AFM images of the pRNA 3WJ based polygons revealed that the shapes of resulting 
polygons were similar to their predicted, theoretical 3D models (Fig 2.5A). The estimated 
average dimensions were found to be 13 ± 1.1 nm, 14 ± 1.8 nm, and 17 ± 1.6 nm for 
triangles, squares, and pentagons, respectively. These values do not reflect the true sizes of 
the RNA polygons due to the AFM tip convolution, but rather demonstrate that the average 
size of the nanoparticles increases from triangle to pentagon. In addition, the central cavity 
of each RNA shape is visible, and the size of the cavity gradually increased with the number 
of polygon vertices. The measured heights for all nanoparticles was found to be ~2 nm, in 
agreement with previously reported heights of nucleic acid double helices (109,170).  
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Quantification analysis was performed to compare apparent yields between 
polygons observed on AFM mica surface. Equal concentrations (1 nM) of the polygons 
were deposited on a mica surface and correctly folded polygons were manually counted in 
a 0.5 µm2 area, resulting in 48 triangular particles, 33 square particles, and 17 pentagon 
nanoparticles (Fig A.1.3). The estimated number of triangular nanoparticles adsorbed on 
the mica was ~1.5 times more than that of the square, and three times more than that of the 
pentagon. However, native PAGE revealed that the yields among the three polygons were 
almost equal. The difference in adsorption amounts between polygons on the mica surface 
was presumably due to variation in their sizes and 3D conformations, resulting in different 
dynamic and physical properties.  
DLS was performed to determine the apparent hydrodynamic diameters for each of 
the polygons. The diameters were found to be 9.1, 11.2, and, 13.5 nm for triangles, squares, 
and pentagons, respectively (Fig 2.5B). The increase in number of 3WJ cores corresponds 
with the larger observed diameter. The measured diameters agreed with their 
corresponding 3D models. However, there was a discrepancy between polygon sizes 
determined by AFM and DLS. This could be attributed to the fundamentally different 
techniques, as DLS determines the average size distribution profile of nanoparticles in 
solution assuming that the polygons have globular shapes [refer to manual at 
http://www.malvern.com], while AFM imaging can produce images larger than the real 
diameter due to tip size used (171) and the resolution of imaging equipment. Nevertheless, 
the two techniques demonstrated that the relative size of the nanoparticles increased from 
triangle to square to pentagon.    
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Accordingly, native PAGE, AFM, and DLS showed the formation of compact 
molecular 2D assemblies of triangle, square, and pentagon based on the pRNA 3WJ 
AOB. Consequently, the naturally preserved 60° AOB could be stretched to reach the 
formation of square and pentagon. The stretching, or tension, that the angle underwent 
could have had a significant impact on the overall stability of the nanoparticles. Therefore, 
it was of great interest to evaluate and compare the polygon's stabilities.    
Stability comparison between triangle, square, and pentagon  
The stabilities of polygons were studied using a perpendicular temperature gradient 
gel electrophoresis (TGGE) (Biometra GmbH). This convenient technique has garnered 
widespread use for measuring melting temperatures of RNA nanoparticles with multiple 
strands (50,108-110,116,172). The preassembled polygons were subjected to 7% native 
TGGE with a gradient temperature of 30-70 °C perpendicular to electrical current. The 
following apparent TM values were obtained for the polygons at 100 nM total concentration 
(Ct) in presence of 0.2 mM MgCl2: triangle TM = 56 °C, square TM = 53 °C, and pentagon 
TM = 50 °C (Fig 2.6A). The triangular nanoscaffolds were more stable than squares and 
pentagons, although the number of RNA bp was much higher in the pentagon construct, as 
compared to the square and triangle. Usually, the stability of nucleic acids with the same 
base-pair content is directly dependent on metal ion and total nucleic acid concentrations. 
Since these two criteria were the same, it was assumed that the higher the number of bp in 
each RNA structure the higher the stability. Therefore, the most stable shape produced 
should be the pentagon. However, based on TGGE data the opposite was found. This was 
likely due to the tension caused by the stretching of the native pRNA 3WJ 60° AOB. The 
triangular construct angle was preserved (60°), the square and pentagon angles were 
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stretched to the wider conformations of 90° and 108°, respectively. Previously it has been 
shown that any nucleotide mutations or deletions within the native core structure of the 
pRNA 3WJ motif would also result in the loss of its thermodynamic stability (55).  
Interestingly, the measured triangle and square TM values differed by +3 °C, as did the 
square and pentagon. Boiling resistance assay in the presence and absence of 8 M urea 
further confirmed that the triangle was the most stable nanoparticle (Fig 2.6B). The 
quantification of nanoparticle bands after heating to 100 °C resulted in 75 ± 4% recovery 
of the triangular assembly, suggesting a TM >100 °C. By definition, TM is the measured 
temperature when half the RNA concentration has melted, i.e. 50% recovery. The 
percentage of recovery for square was 28 ± 2% and for pentagon was 16 ± 5%, much lower 
than the value estimated for triangle recovery. The experiment with the presence of 8 M 
urea in boiling solution showed that the overall trend of stability remained the same, but 
the percentage of recovery was 55 ± 4% for triangle, 8 ± 3% for square, and no pentagon 
fraction was detected. Overall, the nanoparticle with fewer 3WJ motifs (triangle) resulted 
in a higher thermostability and resistance in chemical degradation, and the change in 
stability was in large part due to the stretching of the AOB. 
DISCUSSION AND CONCLUSIONS: 
Artificial construction of RNA nanoparticles requires knowledge of the structural 
properties of RNA motifs, such as interhelical or intrahelical distances, X-Y and X-Y-Z 
angles, number and orientations of RNA branches in multi-way junctions, canonical and 
non-canonical interactions, binding sites for proteins, metal ions, and small molecules 
(75,90,154,159,160,173). Progression in RNA structural biology allowed for the analysis 
of RNA 3D motifs from existing RNA structures at atomic resolution and various data 
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bases, including www.pdb.com, RNA multi-way junction (68), and find RNA motif 
(174,175). This study, based on the previously reported versatile pRNA 3WJ 3D motifs 
(PDB accession ID: 4KZ2), shows that the 3WJ structure can be folded into desired 
conformations based on the dynamics of the 60°AOC, demonstrating the ability to tune 
the physical and structural properties of RNA polygons for a variety of technological, 
biological, and medicinal needs. This approach, based on the propagation of the central 
RNA strand used to direct the folding of corresponding short or external strands into planar 
triangle, square, and pentagon conformations, resulted in the 60º, 90º and 108º bending of 
interhelical AOB of the pRNA 3WJ. This is especially important for medical applications 
where one needs to construct different RNA nano-scaffolds based on a non-toxic and 
thermodynamically stable building block. The following advantages result from this 
technique: i) the number and combination of therapeutic molecules can be tuned to an 
RNA-based nano-carrier; ii) the nano-scaffold has a controllable size and shape; and iii) 
variable thermodynamic and RNase resistance properties can be applied depending on the 
application of the nano-scaffold. 
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Chapter 2.2: Design and Construction of Physicochemically Tunable RNA 
Nanoparticles with Controllable Size 
INTRODUCTION: 
DNA, RNA, and proteins from living systems produce a variety of highly ordered 
nano-scale structures to perform diverse functions (55,90,176-178). The intricacies of these 
natural biomaterials have inspired their applications as building blocks to fabricate 
sophisticated nanodevices (99,115,156,179-187). In nanotechnology, RNA can be 
manipulated to assemble nanostructures with simple approaches as in DNA 
nanotechnology, while displaying versatility in structure and function similar to proteins. 
Thus, RNA has the advantage of two worlds, which garners tremendous interest in the 
directed design of a variety of RNA nanoarchitectures. Natural RNA molecules form a 
wide variety of complex structures by hierarchical folding that generates different motifs 
or modular units (75,106). These modular units can be “manually” extracted and used to 
fabricate artificial self-assembling RNA complexes of diverse 1D, 2D, and 3D 
nanoarchitectures with novel and unique functional features (50,55,99,152). Many RNA 
motifs exhibit phenomenal flexibility (68,168,188) and the angles needed to form many 
nanoassemblies are encoded in the primary sequence of the structural motifs. The structure 
of a complex RNA architecture can be engineered by programming the information of a 
3D structural motif into the nanoparticle's primary sequences. However, the flexibility of 
RNA motifs has seldom been used to construct diverse shaped nanoparticles utilizing the 
same core structure. 
Previous work in this lab has detailed the construction of RNA nanoparticles 
utilizing the pRNA from bacteriophage phi29 DNA packaging motor. Dimers, trimers, 
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tetramers, and hexamers have been constructed utilizing hand-in-hand and foot-to-foot 
interactions as well as arm extension technologies which implement kissing-loop, sticky-
end, and complementary interactions(12,50,55,90,91,104,105,152,168,189,190). 
Additionally, the 3WJ and X-way motifs from the phi29 motor pRNA, themselves, have 
proven successful as therapeutic delivery systems (50,55,63,105,152). Other RNA 
nanoparticle-based delivery systems have shown potential as therapeutic carriers 
(108,110,113,116,124,187,191-193). 
Size and shape play an important role in the delivery efficacy, biodistribution and 
circulation time of nanoparticles (194). Control over these properties can be of paramount 
importance for in vivo applications. However, in many cases fine tuning of size, shape, and 
physicochemical properties of nanoparticles is difficult to achieve. Having a library of 
diverse size nanoparticles with tunable properties is advantageous as pharmacokinetic 
mechanisms of drug delivery, distribution, and clearance are hard to predict (194-197). 
These facts are the motivation behind the development of a simple method to tune the size 
and thermodynamic and chemical properties of RNA nanoparticles. 
The complexity of RNA's tertiary structure complicates de novo design of such 
nanostructures; however, by utilizing a pre-defined 3D motif as the design template many 
complications can be avoided. This approach utilizes a modular design technique, 
sometimes referred to as RNA biomimetics. It involves the use of pre-defined structural 
motifs taken from biology as building blocks to construct RNA nanostructures of defined 
shape and size for a variety of applications including nanomedicine (156,198). The use of 
pre-defined RNA motifs has shown to be a successful method towards the rational design 
of RNA nanoarchitectures (50,90,99,108). Naturally, the first step in applying the pRNA 
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3WJ in modular design was to construct triangles based on the native 60° angle of the 
pRNA 3WJ motif (Fig 2.7A) (168), ideal for the construction of an equilateral triangle. 
Utilizing this native angle triangular nanoparticles were constructed using the modular 
design technique (126). To create more diversity in size and shape, square shaped geometry 
was the next goal. By stretching the 3WJ, triangle, square, and pentagon can be formed 
(103).  The next question to be addressed is whether we can tune the size of one polygon 
by using the same 3WJ while altering the length of each side. 
In this report, we show the construction of multiple variants of square-shaped RNA 
architectures based on a modular design technique using the same core structure, the pRNA 
3WJ. By simply increasing or decreasing the length of the RNA duplex between each 
corner of the square, nanoparticles of 5, 10, and 20 nanometers (nm) were constructed with 
diverse thermal stabilities. The thermodynamic stability of certain RNA tertiary motifs and 
the strong Watson-Crick base pairing in RNA folding ensure predictability in structure that 
make it possible to increase or decrease size by simply adding or removing nucleotides, 
directly affecting size. Further control over nanoparticle stability was demonstrated by 
modulating the oligonucleotide used as the “core” strand during construction of the square 
nanoparticle. Exploiting the different stabilities of RNA, DNA, and 2’-fluorine modified 
(2’F) RNA it is possible to add another dimension of regulation over the physicochemical 
properties of RNA nanoparticles. Moreover, due to the unique construction technique used, 
we show that it is possible to completely avoid intermolecular interactions such as kissing 
loop and sticky-end interactions during construction of the nanoparticles. The potential of 
using the resulting RNA square assembly for biomedical and imaging applications is 
evidenced by the incorporation of therapeutic RNA, ribozyme, and fluorogenic aptamers. 
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As shown here, the assembly properties and tunability of RNA nanoparticles can be easily 
exploited to determine a suitable combination of size and stability for a wide array of 
applications.  
MATERIALS AND METHODS: 
RNA synthesis, purification and labeling. 
  RNA oligomers were prepared by in vitro T7 transcription from dsDNA containing 
the T7 promoter prepared by polymerase chain reaction (PCR). Single-stranded (ss) DNA 
oligomers were purchased from Integrated DNA Technologies (IDT). Cy5 whole chain 
labeling was carried out on the RNA oligomers following the Mirus Cy5 Label IT Nucleic 
Acid whole chain labeling procedure. For TGGE analysis of core strand hybrid squares, 
Perkin Elmer [γ-32P]-ATP was used to label one of the short external strands at the 5’ end.  
Assembly of RNA Nanoparticles  
Equimolar amounts of RNA oligomers were mixed to a final concentration of 1 µM 
in 1 X TMS buffer. The mixture was heated to 80°C for 5 minutes and then slowly cooled 
to 4°C over one hour using an Eppendorf Mastercycle Thermocycler. Confirmation of the 
assembly products were then run on native PAGE.  
Native PAGE and TGGE analysis  
 All assembly experiments were performed on 7% (29:1) native PAGE and run at 
100 V in a 4°C cold room for 120 minutes. Cy5 labeled RNAs were then scanned on the 
Typhoon FLA 7000 and total RNAs were stained with ethidium bromide (EB). 
 TGGE analysis was performed on 7% native PAGE in a buffer containing 50 mM 
TRIS pH = 8.0, 100 mM NaCl, and 0.2 mM MgCl2. A gradient temperature of 40-75°C 
was applied perpendicular to electrical current, and experiment was run for 1 h at 20 W. A 
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total RNA concentration of 80 nM was used in TGGE analysis of the core strand hybrid 
constructs and 100 nM RNA concentration was used for TGGE comparison of the different 
sized squares. Apparent TM values corresponded to the temperature at which half of the 
square fractions were dissociated, and apparent TM values for multiple RNA strands were 
calculated, as described previously (50).  
 Quantification analysis was performed using ImageJ software (169). Equal-sized 
boxes were drawn around the lanes corresponding to the square complexes and 
corresponding quantified values for each hybrid square were divided by the sum of the 
values presented in the corresponding lane. All plots were generated using OriginPro 8 
software. 
AFM Imaging 
 AFM images were taken using a MultiMode AFM NanoScope IV system (Veeco), 
as per previously reported methods (199). Briefly, the RNA samples were diluted with 1 X 
TMS buffer to a final concentration of 3-5 nM. Then, the droplet of samples (5-10 μL) was 
immediately deposited on the specifically modified APS mica surface (170,171), excess 
samples were washed with DEPC treated water and dried under a flow of Argon gas. AFM 
images in air were acquired using MultiMode AFM NanoScope IV system (Veeco/Digital 
Instruments, Santa Barbara, CA) operating in tapping mode. 
FBS resistance assay 
 The square nanoparticles with RNA, 2’F RNA, and DNA core strands were 
incubated in 2% FBS solution at 37°C for 14 hours. After removal from 37°C incubation 
at their respective time points, samples were frozen on dry ice to prevent any further 
degradation. The samples were then analyzed on 7% Native PAGE. ImageJ software was 
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used to integrate the intensities of the assembled square nanoparticles in the gel. Integration 
areas for each time point were compared to the integration area for the 0 minute time point 
to construct an RNAse degradation comparison between the RNA, DNA, and 2’F-RNA 
hybrids. All plots were generated using OriginPro 8 Software. 
Spinach and Malachite Green Aptamer Fluorescence Measurements 
 Native 7% PAGE was used to detect the fluorescence emission of fluorogenic 
nanoparticles. The gel was stained simultaneously in a mixture of 5 μM MG and 5 μM 
DFHBI and scanned for the MG-apt fluorescence λexc centered at 635 nm, and for 
SPINACH-APT fluorescence λexc centered at 473 nm. After recording images at different 
excitation wavelengths, total RNA staining in EB solution was performed to detect all 
RNAs in the gel. 
Fluorescence emission in solution was measured, as previously reported (153). Briefly, 
assembled square nanoparticles (0.1 μM) harboring MG and SPINACH aptamers in TMS 
buffer were mixed with MG (2 M) and DFHBI (2 M) (Lucerna, Inc, 
http://www.lucernatechnologies.com) and incubated at room temperature for 30 min. 
Fluorescence was measured using a fluorospectrometer (Horiba Jobin Yvon), excited at 
450 nm (565–750 nm scanning for emission) for SPINACH and 615 nm (625–750 nm 
scanning for emission) for MG dyes.  
Dual Luciferase Assay 
 Experiments were carried out as previously described (200). For square 
experiments carried out here, controls of cell only, plasmid only, and Lipofectamine 
2000(Lipo) only were used. Cell only contains luminescence data of cells only, with no 
transfection reagent or plasmid DNA. Lipo only samples contained just Lipofectamine 
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2000 transfection reagent. The plasmid only samples contained DNA plasmid only, which 
were transfected into the cell utilizing the transfection reagent Lipofectamine 2000. For 
RNA controls, the 3WJ with luciferase siRNA was used, which has previously been shown 
to cause knockdown (201). Square scaffold and a square utilizing scrambled siRNA 
sequence were utilized as negative controls. 
HBV Ribozyme Activity Assay 
 HBV ribozyme activity assay was carried out as previously detailed (66). Briefly, 
HBV RNA substrate was 5’-Cy5 labeled using the Mirus Cy5 labeling kit. The labeled 
substrate was incubated with square nanoparticle conjugated with HBV ribozyme for 60 
minutes at 37°C in buffer containing 20 mM MgCl2, 20 mM NaCl, and 50 mM Tris-HCl 
(pH 7.5). pRNA conjugated to HBV ribozyme served as a positive control and pRNA with 
a disabled HBV ribozyme was used as a negative control. The cleaved fragments were 
analyzed on the Typhoon Fluorescent Imaging system. 
RESULTS AND DISCUSSION: 
RNA Square Design 
 Square-shaped RNA nanoarchitectures were designed in silico utilizing planar 
geometry of the 3WJ structural motif. Swiss PDB Viewer (www.spdbv.vital-it.ch) was 
used to align four 3WJ building blocks (PDB ID: 4KZ2) (168) in a planar configuration 
utilizing the internal ~60° angle, created by helix one (H1) and helix two (H2), at each 
corner of the square (Fig 2.7A). A-type duplex RNA was then inserted to connect helix 
one H1 and H2 (Fig 2.7A). The resulting design featured a square with four "arms" 
extruding outwards from each of vertex of the square, facilitating the incorporation of 
additional RNA sequences, motifs, or functionalities. The final square contains five RNA 
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strands, whereby four short strands (A, B, C, D) are complimentary to one long “core” 
strand E (Fig 2.7B, Fig A.1.4). This results in a nanoparticle containing a 3WJ at each 
vertex and A-type duplex RNA along each edge. Extension of both the core and external 
strands by increasing the number of complementary nucleotides was exploited to obtain 
RNA squares with variable but predictable sizes (Fig 2.8A). By such means, small, 
medium, and large square architecture were designed using Swiss PDB Viewer and the 
sequences for all five strands were optimized to avoid non-specific interactions using the 
Mfold program (202). 
Structural Characterization 
Based on models, the sizes of the resulting square structures should be 5.1 nm, 10.2 
nm and 20.1 nm along each edge. The size increase results from extension of the duplex 
RNA connecting the 3WJs at each corner. Based on nearest-neighbor thermodynamic 
parameters, larger size squares are expected to exhibit increased thermodynamic stability. 
As none of the 3WJ angles have a right angle according to its crystal structure (Fig 2.7A) 
the 3WJ motif must be stretched from ~60° to ~90° to accommodate square geometry. As 
a result, efficiency of self-assembly might be decreased. Consequently, our first 
experiments were aimed at characterizing the physical properties of the square constructs. 
 Native PAGE was first used to test the assembly and analyze assembly efficiency. 
Nanoparticle assembly was performed via “one-pot” self-assembly procedure by thermal 
denaturation of all RNA strands in TMS buffer and gradual cooling over one hour. ImageJ 
software was used to analyze the intensity of gel bands and the yield of correctly folded 10 
and 20 nm squares was estimated to be more than 90% with a slight decrease in folding 
efficiency observed for the 5 nm square (Fig 2.7C). Additionally, the hypothesis that each 
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strand was involved in the assembly, and that strand substitution was not occurring, was 
tested. For this assay, each strand A through E was fluorescently labeled. Five different 
squares, each with one of five strands labeled, were then assembled and analyzed by native 
PAGE. The results demonstrate that each strand contributes to the assembly and therefore 
the overall stability of the square (Fig A.1.5).  
 While native PAGE experiments suggest the formation of compact, homogeneous, 
and distinct RNA nanoparticles, atomic force microscopy (AFM) was performed to 
demonstrate the formation of the square shaped RNA nanoarchitecture (Fig. 2.8B). 
Resulting AFM images strongly support the formation of the medium and large square 
shaped RNA architecture. Image resolution of RNA nanostructures is in many cases limited 
by tip size. Due to the resolution limits of the AFM images shown in this report, the small 
square only appears as dots with no square geometry obviously visible. The results are 
expected as the size of the small square model is 5.2 nm, a size too small to be clearly 
resolved. A small percentage of squares appear as diamond shape straying from square 
geometry. This can be attributed to the fact that AFM images were taken in air and not in 
solution, distorting shape when the nanoparticles are dried onto the mica surface. 
Alternatively, diamond shapes could be due to the flexibility of the 3WJ (168). Using the 
large square AFM images, particles were manually counted to determine efficiency of 
assembly by AFM. It was revealed that the large square formed with 70% efficiency. 
When considering a nanoparticle for use as an in vivo therapeutic the size of the 
particle greatly affects the delivery efficacy. Too small a size and the particle will simply 
be excreted; too large a size and entry into the cell will be greatly hindered. Previous studies 
showed that the optimal size for the cellular uptake of nanoparticles is 10-50 nm (90,203-
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206). Using dynamic light scattering (DLS), the average hydrodynamic diameters (Dh) of 
RNA square nanoparticles were determined to be 4.0 ± 0.9 nm, 11.2 ± 1.3 nm, and 24.9 ± 
0.5 nm for the small, medium, and large size squares, respectively (Fig 2.8C). These values 
are in close agreement with the predicted size of the model structures. At sizes of 4.0 nm, 
11.2 nm, and 24.9 nm we have constructed variable size nanoparticles with potentially 
diverse physicochemical properties.  
We have presented a simple method to adjust the size of RNA nanoparticles, 
however we aim to show that adjustment of size leads to diverse thermodynamic properties 
among square variants. To compare the thermodynamic stability of the squares, 
temperature gradient gel electrophoresis (TGGE) was used to determine the melting 
temperatures (TM) of each square (TM = 50% square formation). A temperature gradient 
perpendicular to electrical current was applied and increasing TM corresponding to an 
increase in size was observed (Fig A.1.6). Since each of the square constructs contains four 
3WJ motifs, the increase in melting temperature can be attributed directly to an increase in 
the amount of base-pairing in the structures. This trend follows the nearest-neighbor 
predictions for increasing of thermodynamic stability.  
 Taken together, structural analysis by computer modeling, DLS, and AFM suggest 
the formation of compact, flat, square RNA nanoparticles. The native geometry, 
determined by crystallization, has H1 and H2 of the 3WJ in planar configuration (168). 
The computer model also results in planar geometry based on duplex alignment of 
connecting helices H1 and H2, strongly supporting the formation of planar square 
nanoparticles. Furthermore, the presence of square structures on AFM, and not triangular 
shapes, which would result from a 3D tetrahedron like structure (207), also supports flat, 
39 
 
square geometry. As expected, AFM imaging demonstrates the size differences among the 
small, medium, and large squares. 
 Previously, RNA triangles have been constructed using the same pRNA-3WJ (126). 
After analysis of the square nanoparticle, it was determined that the square and triangle 
display diverse properties in thermodynamic stability, size, shape, and stoichiometry: 
functions possible per nanoparticle. Although not explored in depth in this study, it is 
possible that utilizing these particles in different applications, where size and shape play 
an important role, could be beneficial. 
Physicochemical Properties are Tunable 
Native RNA structures are inherently sensitive to degradation by cellular nucleases, 
potentially limiting the application of RNA nanoparticles in clinical applications. 
Modifications to RNAs, such as 2’F on the ribose sugar of the RNA backbone, have been 
shown to reduce their sensitivity to cellular nucleases (55,64). These same 2’F 
modifications have also been shown to increase the thermodynamic stability of RNA 
nanoparticles (63). DNA has also proven to be more resistant to the degradation caused by 
cellular nucleases (55,90). To be useful as an in vivo therapeutic, modifications must be 
made to the native square nanoparticles to gain resistance to RNase while retaining the 
same structure. Previous studies demonstrating different chemical and thermodynamic 
stabilities of the pRNA 3WJ constructed of RNA, DNA, and 2’F-RNA were the driving 
force behind the replacement of the core strand of the square nanoparticle (63,64). Due to 
these diverse stabilities, it was predicted that replacement of the core strand with different 
oligonucleotides would result in a nanoparticle with diverse physicochemical properties.  
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To impart tunable chemical and thermodynamic stabilities onto the 10 nm square 
nanoparticle the internal core strand E was replaced with both 2’F-C/U modified RNA and 
with single stranded DNA. Analysis by native PAGE demonstrated that all the nanosquares 
co-migrated indicating formation of the same geometry (Fig 2.9A). Moreover, all 
nanoparticles assembled with comparable yields of ~90% as determined by integration of 
the intensity of gel bands (Fig 2.9A).  
A degradation assay in fetal bovine serum (FBS) was performed on each 10 nm 
hybrid square assembly. It was observed that substitution of 2’F modified core strand for 
unmodified RNA greatly enhances the stability of the nanoparticles in FBS (Fig 2.9B). 
After 14 hours, ~92% of square nanoparticles with 2’F modified core strand remained, as 
compared to ~20% for square nanoparticles with RNA and DNA core strands (Fig 2.9B, 
Fig A.1.7). While different hybrid duplexes exhibit different stabilities or susceptibilities 
to different RNases (208,209), serum comparison mimics more closely an in vivo 
environment and allows the direct comparison of each hybrid square. Overall, resistance 
to nuclease degradation was enhanced by replacing the core strand with 2’F modified RNA.  
To further examine the effect the core strand has on nanoparticle stability, TGGE 
analysis was performed to determine the TM of each hybrid. A temperature gradient, 
perpendicular to electrical current, was applied from 40°C-80°C. The TM’s for the 2’F-
RNA, RNA, and DNA hybrid square nanoparticles were calculated to be 68.4 ± 0.1 °C, 
57.7 ± 0.2 °C, and 51.8 ± 0.1 °C, respectively (Fig 2.9C, Fig A.1.8). Melting temperatures 
were determined at 0.2 mM MgCl2, simulating physiological conditions in which the 
cytoplasmic magnesium ion concentration is generally lower than 1 mM. At 10 mM 
magnesium concentrations, no melting below 80 °C was observed (Fig A.1.8D-F). Tertiary 
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structure greatly affects the melting temperature, and therefore thermodynamic stability, of 
an RNA structure. The duplex cannot be solely responsible for the trend in melting 
temperature from 2’F-RNA hybrid to DNA-RNA hybrid as a large portion of each structure 
is 3WJ. It has been shown that complicated tertiary structures are more stable in RNA than 
DNA resulting in a less stable a DNA-RNA hybrid 3WJ (63). Interestingly, the melting 
temperatures correlate with the FBS resistance assay indicating that the 2’F-RNA hybrid 
square was the most stable, followed by the native RNA square, and the DNA hybrid 
architecture was the least stable.  
In clinical applications, considering pharmacokinetics, biodistribution, and 
toxicity, the most stable nanoparticles will not always be the most effective treatment (195-
197). Our results show that it is possible to tune the stability characteristics of the RNA 
square nanoparticles by substituting the core strand and varying the ratio of 2’F 
nucleotides. This simple modification produces physicochemically diverse structures that 
can be easily tuned based on application. 
Functionalizing the Square Scaffold 
For the square architecture to be useful as a potential therapeutic in nanomedical 
applications, functional molecules (RNAi, aptamers, ribozymes) must be successfully 
fused into the core structure while it retains native folding and properties. Thus, the 
question of whether the RNA scaffold can harbor different RNA functional moieties such 
as siRNA, ribozymes, and RNA fluorogenic aptamers was addressed. More importantly, if 
the functional molecules retain their activity when incorporated into the square scaffold. 
As such, four functional RNA groups, RNA spinach (SPIN) aptamer (210), RNA 
malachite green (MG) aptamer (211,212), hepatitis B virus (HBV) ribozyme (213), and 
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siRNA targeting luciferase gene (160) were incorporated at each corner of the 10 nm square 
nanoparticle (Fig 2.10A, Fig A.1.9). The multi-functional square assembly showed more 
than 90% efficiency as analyzed by integration of gel bands (Fig 2.10B). Additional AFM 
imaging was performed to demonstrate the retention of square geometry with the fused 
functionalities (Fig 2.10C).  
The MG and SPIN aptamers are synthetic RNA aptamer sequences, previously 
obtained through SELEX (Systematic Evolution of Ligands by Exponential Enrichment) 
(92) that bind the malachite green and DFHBI dyes respectively (210,212). Free 
fluorophores in solution do not exhibit fluorescence and emit light only upon binding to 
their correctly folded RNA aptamer structures (210,214). To assay if folding was retained 
when incorporated into the multi-functional square, fluorometer measurements were taken 
for the malachite green and DFHBI chemicals alone and in the presence of the functional 
RNA square (Fig 2.11). The multi-functional square was simultaneously incubated with 
both fluorophores and fluorescence measurements were then taken. Both aptamers retained 
their folding and bound their respective fluorophore as evidenced by an increase in 
malachite green and DFHBI emission upon binding. As a positive control, a 3WJ with the 
MG aptamer and the SPINACH aptamer were used, both of which have been previously 
shown to exhibit increased fluorescence signal when incubated with their respective 
fluorophores (55,153). Furthermore, we aimed to show the simultaneous dual-mode 
fluorescent properties of the functional square architecture. The PAGE gel was stained for 
both MG and spinach aptamer dyes. Individual fluorescence of each aptamer was detected 
when incorporated into the same nanoparticle (Fig A.1.10). 
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 The HBV ribozyme is a hammerhead ribozyme that cleaves hepatitis B genomic 
RNA. Ribozymes show potential as therapeutic agents; however, they traditionally have 
shown low efficiency when tested in vivo. This can be attributed to the misfolding of 
ribozymes in an intracellular environment and their susceptibility to exonucleases (215). 
One method to protect ribozymes and prevent their misfolding is to harbor them in larger, 
more complex structures. However, ribozymes must maintain their native folding, to retain 
functionality, when fused to RNA or incorporated into nanoparticles (101). Upon 
incubation of the multi-functional square with HBV genomic RNA, cleavage of the RNA 
genome occurs. Figure 2.12A demonstrates that the HBV ribozyme retains its catalytic 
activity when fused with the RNA square, as the cleaved products are clearly seen on the 
gel and the bands are comparable with a positive pRNA-HBV control construct (66).  
To test the ability of the RNA square to carry siRNA for gene silencing effects, an 
in vitro assay was performed with a dual-luciferase reporter system (201). An siRNA anti-
sense strand, which targets the firefly luciferase gene, was hybridized with its 
complimentary sense strand used as a sticky end fused onto the multi-functional square 
(Fig 2.10A). A decrease in target gene, firefly, luminescence compared to reference gene, 
renilla, indicates a decrease in target gene protein production, designating a positive result. 
In comparison to the positive control, a 3WJ nanoparticle with fused luciferase siRNA 
(201), the multi-functional square harboring luciferase siRNA caused a similar decrease in 
luminescence indicating similar gene knockdown activity (Fig 2.12B). Overall, the results 
indicated that the RNA square nanoparticles carrying luciferase siRNA displayed ~40% 
gene knockdown activity.  
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 For DICER to recognize and process double stranded (ds) RNA, the 3’-overhang 
must be accessible and not trapped inside the inner cavity of the square nanoparticle. This 
possible obstruction proves to be no problem. This newly constructed square makes it 
simple to incorporate other diverse functional moieties into one of the four "arms" of the 
square. This can be done by simply fusing siRNA into one of the four external scaffold 
strands.  
 The results demonstrate that diverse functionalities retain their activity when 
incorporated into the square scaffold, making the RNA square an addressable and 
programmable poly-functional nanoscaffold for potential delivery of RNA therapeutics for 
application in medicine. Due to the unique five-strand construction of the square 
architecture functionalities such as RNA aptamers and siRNA for gene therapy can be 
added by simply encoding for functionalities in the primary sequence of one strand in the 
square. 
CONCLUSIONS: 
Here we report the design and construction of poly-functional RNA square 
architectures utilizing the 3WJ motif of bacteriophage phi29. The conserved 60° angle from 
the 3WJ was expanded to 90°, and formation of square geometry was achieved. The length 
of the connecting helix was increased or decreased to generate three distinct sizes of 
nanoparticles. These three sizes of nanoparticles demonstrate diverse thermodynamic 
stabilities. By modulating the oligonucleotide used as the core strand we tuned the 
physicochemical properties of the square scaffold. The four arms extending from the four 
corners of the square were used to incorporate RNA functionalities, each of which was 
demonstrated to fold independently and correctly while retaining their authentic 
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functionalities. The square nanoscaffold shows great promise for biomedical and imaging 
applications due to its tunable thermodynamic and biochemical stabilities. The technique 
shown here for simple design to finely tune physicochemical properties adds a new angle 
to exploit RNA nanoparticles in a clinical setting. 
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Figure 2.1. RNA triangle design scheme. Design scheme of triangular nanoparticle. Step 
#1: the atomic resolution structure of pRNA 3WJ motif highlighted by the rectangle was 
obtained and analyzed. The flexible angle ~60° formed by H1 and H2 was used for triangle 
design on Swiss-PDB viewer as shown in following step. Step #2: The 3D model of triangle 
shape was designed by carefully joining extended helices (H1 and H2) using Swiss PDB 
viewer software. Step #3: the sequences and secondary structure of the triangle is obtained 
based on free energy sequence optimization algorithm using mfold. The resulting 
secondary structure contains four RNA strands: three identical in length (48 nt) A (red), B 
(blue), and C (brown) as well as longer strand D (green 66 nt). Figure reproduced from 
(126) copyright American Chemical Society 2014. 
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Figure 2.2. Structural features of the pRNA 3WJ motif. (A) Secondary structure of 3WJ 
motif with base pairs annotated with Leontis-Westhof nomenclature56. (B) Tertiary 
structure of 3WJ motif with indication of AOB ~ 60 ° angle formed between H1 and H2. 
Angle corresponds to inner angles of polygons. 
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Figure 2.3. Modular design technique. Using the pRNA-3WJ as the vertex, diverse 
polygons were constructed. This figure represents the design scheme used for the initial 
design of RNA triangles from the 3WJ. 
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Figure 2.4. Design of Polygons and assembly properties. (A) 3D modeled structures of 
polygons with 3WJ motif located at vertices, inner angle corresponds to   AOB ~60°. (B) 
The increasing length of the internal strand (green) stretches the 3WJ  AOB at which the 
nanoparticles assemble, along with increasing number of external “short” strands. (C) 
Assembly properties of polygons evaluated on 7% native PAGEs. Asterisks “*” indicate 
the Cy5 labeled strands utilized on each type of polygon assembly.  
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Figure 2.5. Structural characterization of polygons. (A) AFM images of triangular, 
square, and pentagonal nanoparticles derived from the pRNA 3WJ motif. (B) Polygons 
size distribution histogram obtained via dynamic light scattering. 
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Figure 2.6. Comparison of polygon stabilities. (A) Melting temperatures of triangle, 
square, and pentagon measured by 7% perpendicular TGGE and boiling resistance assay 
in absence (B) and presence (C) of 8 M urea. Calculated percentage of recovery for 
polygons after boiling is shown below the each gel with error bars calculated from several 
independent experiments.   
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Figure 2.7. Design and assembly of the RNA squares. (A) Crystal structure of pRNA-
3WJ showing the three component strands of the pRNA-3WJ, 3WJ-a (blue), 3WJ-b 
(purple), and 3WJ-c (green). (B) Three-dimensional structure of square shaped 
nanoparticle modeled on Swiss PDB Viewer, based on pRNA-3WJ. (C) Native PAGE 
assembly gel with ethidium bromide total RNA staining showing assembly of each square 
structure: Lane 1 is 5 nm square, Lane 2 is 10 nm square, and Lane 3 is 20 nm square. 
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Figure 2.8. Physical Properties of the squares.  (A) Schematic of small, medium, and 
large squares drawn to scale for size comparison.  Four external strands (blue, purple, red, 
orange) are complimentary to the core internal strand (green). (B) AFM imaging of small, 
medium, and large RNA squares. Zoomed pictures of individual squares located on the 
right. On the far right is a mixture of squares, each square is indicated by arrows. (C) 
Dynamic light scattering (DLS) to determine the size of square nanoparticles. Far right 
panel shows comparison of all three square constructs. 
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Figure 2.9. Comparison of RNA, 2’F-RNA, and DNA core strand hybrids. (A) 
Structure and native PAGE assembly of square nanoparticle hybrids.  Blue strands 
represent RNA, red strands represent 2’F-RNA, black strands represent DNA. Lane 1 
through 4 show the stepwise assembly from monomer to tetramer. (B) Nanoparticle 
stability in serum was compared among the square hybrid constructs (C) TGGE melting 
temperature profiles of square RNA nanoparticle along with 2’F and DNA core strand 
hybrids.  
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Figure 2.10. Design and assembly of multifunctional square. (A) Illustration of square 
structure with Spinach (SPIN) aptamer, malachite green (MG) aptamer, hepatitis B virus 
(HBV) ribozyme, and Luciferase siRNA incorporated into the square. (B) Assembly of the 
square nanoparticle and multi-functional square assessed by 7% native PAGE. (C) AFM 
images of multi-functional square nanoparticle with functional moieties visible on the 
corners of the nanoparticles.  
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Figure 2.11. Fluorescence assays for multi-functional square. (A) Spinach aptamer 
assay.  Increased fluorescence is shown upon incubation with DFHBI dye. (B) Malachite 
green aptamer assay.  Increased fluorescence is shown upon incubation with malachite 
green dye. 
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Figure 2.12. Ribozyme and siRNA activity assay. (A) Catalytic activity of the HBV 
ribozyme.  Cleaved products are boxed. pRNA-HBV-Rbz was used as a control (B) 
Luciferase siRNA activity assay. Gene knockdown was measured by a decrease in 
luminescence.  Cell only, Lipofectamine(Lipo) only and plasmid only were used as 
controls. Plasmid only control will exhibit the highest luminescence as the cells are only 
transfected with plasmid and no RNA.  For a positive control 3WJ-siRNA showing 
knockdown was used. As negative control, naked square (no luciferase siRNA) and a 
scrambled siRNA sequence fused onto square were used.  The square tested contained all 
four functional moieties. RLU is relative luminescence units. 
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Chapter 3: Effect of Nanoparticle Size, Shape, and Physical Properties 
on Biodistribution in Mouse Tumor Models 
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Chapter 3.1: The Effect of RNA Nanoparticle Size and Shape on Biodistribution  
INTRODUCTION: 
The past decades have seen the emergence of nanotechnology as the next potential 
solution for advancing the field of medicine (13,14). Diverse types of nanoparticle 
platforms have been developed (3,4,7-12) that display distinct advantages over traditional 
treatments due to their increased circulation time, high therapeutic payload, and ability to 
harbor multiple functional groups (15,16). When combined with targeting ligands, 
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peptides, or aptamers, nanoparticles possess the potential for cell-specific drug delivery 
(29,32). The enhanced permeability and retention (EPR) effect allows even non-targeted 
nanoparticles to accumulate in tumor tissue due to the large amount of vascularization at 
the tumor site (216). However, many nanoparticles, while effectively targeting tumor and 
cancerous cells, accumulate non-specifically in healthy tissues, causing toxicity and off 
target effects (132). Non-biocompatible materials cause toxicity as they are never fully 
excreted from the body. Particles that do not cause toxicity, such as DNA and lipid based 
particles, then suffer from low stability in vivo. 
Size and shape have been shown to greatly affect pharmacokinetics and 
biodistribution profiles of nanoparticles (127,128,134). Small particles (< 5 nm) are filtered 
by the kidneys and excreted in the urine (129). Large particles are engulfed by macrophages 
or sequestered in healthy tissue, never successfully navigating to the desired target (130). 
Many nanoparticles currently under investigation are rigid in nature, allowing no 
deformation from their size and shape. Rigid nanoparticles cannot penetrate pores smaller 
than themselves in size, resulting in low amounts of nanoparticles at the tumor site, which 
is normally heterogeneous in its structure. Alternatively, large, rigid particles that get stuck 
in healthy organs cannot escape, remaining trapped. 
RNA nanotechnology, where the scaffold and ligands are composed solely of RNA, 
is an emerging technology that has shown promise to overcome several current challenges 
in nanotechnology (55,90). RNA nanoparticles can be engineered to diverse size and shape 
while retaining high thermostability necessary for in vivo applications (50,103,126,150). 
Simple sequence engineering can be used to employ the same RNA motif for construction 
of multiple RNA nanoparticles, reducing the number of single stranded RNA oligomers 
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needed for the construction of myriad of RNA nanoparticles. Furthermore, modifications 
to the ribose sugar (such as 2’ fluorine, 2’F) of RNA bases confers stability in serum for 
more than 24 hours (h) (64,217). The unique base pairing mechanism that occurs during 
the assembly of RNA nanoparticles leads to consistent assembly properties, resulting in 
defined size nanoparticles with a narrow size distribution. Thus, a particular RNA 
nanoparticle will display homogeneity from batch to batch of assembly. In order to 
optimize drug delivery, it is important to have nanoparticles that are consistent in assembly 
that will display a narrow size distribution, as this will lead to consistent pharmacokinetic 
and biodistribution in vivo (218). Furthermore, RNA is a flexible biomaterial by nature, 
therefore allowing some structure deformity, unlike many rigid nanoparticles under 
development (219,220). 
The pRNA three-way junction (3WJ) derived from the packaging RNA (pRNA) of 
bacteriophage phi29 has recently been shown to display high thermostability (55,63), fast 
kinetic assembly (62), and has been successfully used in vivo for miRNA and siRNA 
delivery and tumor growth suppression (56-58). The addition of aptamers and targeting 
ligands allow the 3WJ to successfully enter tumor cells specifically. Interestingly, 3WJ 
particles have repeatedly displayed little to no accumulation in healthy tissue, including the 
liver, kidneys, lung, and spleen (55,57,58). Despite the small size of the nanoparticles (<5 
nm), total clearance by the kidneys does not occur while accumulation in tumor tissue is 
still observed (56-58).  
The effects of RNA nanoparticle size and shape on biodistribution were 
investigated using previously constructed and characterized RNA triangles, squares, and 
pentagons (103,150). Analysis by fluorescence imaging of whole mice and their organs 
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demonstrated a strong correlation between increased size and increased circulation time 
using RNA nanosquares. However, shape showed to have less of an effect on 
biodistribution, despite the appearance of different elimination routes. Unlike many 
nanoparticle systems where it is hard to study size and shape independently, RNA 
nanoparticle size and shape is precisely controlled from nanoparticle conception. 
Therefore, in this study, different size nanoparticles that have identical shape could be 
studied.  
MATERIALS AND METHODS: 
RNA Nanoparticle Synthesis and Assembly 
 RNA strands were prepared as previously detailed (105) by either T7 in vitro 
transcription (strands longer than 70 nucleotides) or typical phosphoramidite 
oligonucleotide chemical synthesis (strands shorter than 70 nucleotides) using an 
automated oligo-synthesizer. DNA strands used as primers for dsDNA transcription 
templates were ordered from Integrated DNA Technologies (IDT). Assembly was carried 
out by mixing equimolar amounts of RNA strands followed by thermal denaturation at 
85C for 5 minutes and then slow cooling to 4 C over one hour. For each nanoparticle, 
one strand was fluorescent labeled with AlexaFluor647 for fluorescent tracking in vivo.  
In Vivo Biodistribution Experiments 
 KB cells were cultured in vitro and subcutaneously injected under the skin of 4-
week old male nude mice (NU/NU, Taconic). A total of 2 X 106 cells were injected into 
each mouse. Tumors were grown for 2 weeks before mice were injected IV through the tail 
vein. Mice were administered with PBS as a blank control. Mice were imaged for whole 
body fluorescence at time points of 0.5, 1, 2, 4, 8, 12, and 24 h with an In Vivo Imaging 
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System (IVIS) imager (Caliper Life Sciences, Waltham, MA). For this study, two mice 
were used for the 0.5 through 12 h time points. At the 12 h time point, one mouse was 
sacrificed and its organs removed. At 24 h the second mouse was sacrificed and its organs 
removed and imaged. Tumors, hearts, kidneys, livers, spleen, and lungs were collected and 
imaged on the IVIS system. 
Serum Stability Assays 
 2’F nanosquares were assembled and purified using polyacrylamide gel 
electrophoresis prior to serum degradation testing. After purification, 0.5 M fluorescently 
labeled squares were incubated at 37C in 10% fetal bovine serum (FBS). Enzymatic 
degradation was stopped by freezing on dry ice at 0, 1, 2, 4, 8, 16, and 32 h. Samples were 
then analyzed using 2% agarose gel electrophoresis. Gels were then scanned for 
AlexaFluor647 fluorescent signal. Gel band intensity was integrated using ImageJ software 
(169). Values were normalized to initial band intensity and then plotted using OriginPro. 
RESULTS: 
Design and assembly of RNA polygons with variable size and shape  
 In vivo biodistribution studies of RNA nanoparticles was carried out using 
previously designed, constructed, and characterized RNA polygons (150). The 
nanosquares tested were designed to be 5, 10, and 20 nm along each edge (Fig 3.1A), and 
were previously measured by dynamic light scattering (DLS) to be 4.0 ± 0.9, 11.2 ± 1.3, 
and 24.9 ± 1.5 nm (150) while RNA triangle, square, and pentagons were each designed to 
be 10 nm along each edge (Fig 3.1B) (103). Throughout this paper, the nanosquares will 
be referred to by their designed edge length (5, 10, 20 nm). As previously described, RNA 
polygon size is determined by selecting the number of base pairs between each 3WJ at each 
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vertex, and the shape is determined by selecting the number of total 3WJs in the particle 
(103,126,150). Each polygon is constructed from multiple single stranded (ss) RNA 
oligonucleotides: short external strands (one along each edge), and one long core strand 
connecting each external strand. RNA strands were chemically synthesized with fluorine 
modifications at the 2’ sugar position of cytosine and uracil, which confers enzymatic and 
thermodynamic stability (64). Polygons were assembled by mixing equimolar amounts of 
each strand in buffer followed by thermal denaturation at 85 ºC and slow cooling to 4 ºC 
over one hour.  
A bi-partite fluorophore labeling approach, where only one of five strands was 
fluorescently labeled with AlexaFluor 647, was used to confirm that the particles were not 
dissociating in vivo. It has been shown previously that single stranded 2’F RNA is 
eliminated within five minutes after intravenous (IV) injection (184). Therefore, if the 
nanosquares were indeed dissociating, signal would have been lost within five minutes of 
polygon injection.  
In vivo biodistribution of RNA polygons with variable sizes    
Subcutaneous xenograft tumors were developed in male nude mice with KB cells. 
After tumors were fully developed (~2 weeks), 100 µL of 15 µM nanosquares harboring 
chemically conjugated AlexaFluor647 were injected IV via the tail vein. Whole body 
fluorescent images were taken at 0.5, 1, 2, 4, 8, 12, and 24 h (Fig 3.2). A diverse set of 
biodistribution profiles is seen when comparing different size 2’F nanosquares. 20 nm 
nanosquare fluorescence is observed throughout the mice at four hours, while both the 5 
and 10 nm nanosquares are mainly sequestered in the tumor. As seen previously, the 3WJ 
nanoparticle shows no accumulation in vital organs in mice (55-58). 
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The same trend is seen from the organ images as from whole body scans of the 
mice. At 12 and 24 h, mice were sacrificed and their liver (Li), spleen (S), kidneys (K), 
heart (H), lung (Lu), and tumors (T) were collected (Fig 3.3). The 5 nm nanosquare is 
eliminated quickly from vital organs, localizing in only the tumor after 12 h. For the 10 
and 20 nm nanosquares, fluorescence is much more intense in organs, especially after 12 
h. However, 10 nm nanosquares localize only to the tumor after 24 h. Some fluorescence 
is still seen in the liver and kidneys of mice injected with 20 nm nanosquares after 24 h, 
however, we expect at longer time points the nanosquares would circulate out of all healthy 
organs. 
Serum degradation testing was performed on the 2’F nanosquares (Fig 3.4). 
Nanosquares labeled with AlexaFluor647 were incubated at 37 ºC in 10% fetal bovine 
serum (FBS) solution and time points were taken by immediately freezing the samples on 
dry ice to stop enzymatic degradation. After incubation, nanosquares were analyzed using 
2% agarose gels scanned for AlexaFluor647 fluorescent signal (Fig 3.4A). ImageJ was 
used to quantify gel band intensity and values were plotted (Fig 3.4B). Gel band intensity 
was normalized to the well displaying highest fluorescence intensity. The results indicate 
half-lives in excess of 12 h for all nanosquare constructs. It is important to note that the 
half-lives of each nanoparticle are far greater than their apparent fluorescent half-lives seen 
during in vivo biodistribution experiments.  
In Vivo Biodistribution of RNA polygons with variable shapes   
Next, we investigate the role that shape plays in biodistribution profiles of RNA 
nanoparticles using previously constructed RNA polygons: triangle, square, and pentagon. 
The shape of RNA nanoparticles is easily controlled by modulating the inner angle of the 
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3WJ motif, which was used as the module for polygon construction. The inner angle is 
increased by extending the core strand by 22 nt, corresponding to two helix turns of A-type 
RNA duplex, and adding one external strand (103). RNA polygons were assembled using 
the same method as the nanosquares, mentioned above. 2’F modified polygons were used 
for in vivo biodistribution analysis. 
Subcutaneous xenograft tumors were developed in male nude mice with KB cells. 
After tumors were fully developed (~2 weeks), 100 µL of 15 µM 2’F polygons harboring 
chemically conjugated AlexaFluor647 were injected IV via the tail vein. After 12 and 24 
h, mice were sacrificed, their organs collected, and imaged for AlexaFluor647 signal (Fig 
3.5). 
It is evident that shape plays some part in the excretion routes and times of 2’F 
nanoparticles. Triangular nanoparticles appear to clear the fastest, showing only low 
fluorescent signal in the kidneys after 12 h, and only fluorescence in the tumor after 24 h. 
Square shaped nanoparticles show high fluorescent signal in the kidneys and low 
fluorescent signal in the spleen after 12 h. However, after 24 h fluorescent signal only 
remains in the tumor. Pentagon shaped nanoparticles show low signal in the kidneys after 
12 h, with higher fluorescence seen in the spleen. Importantly, pentagonal, along with 
triangular and square- shaped nanoparticles only show fluorescence in the tumors after 24 
h of circulation. 
DISCUSSION: 
Effect of Size on RNA Nanoparticle Biodistribution 
 In cancer treatment, nanoparticles accumulate at solid tumors by taking advantage 
of the EPR effect. However, EPR is principally affected by the circulation time of 
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nanoparticles (216). Larger nanoparticles generally show much higher circulation times, 
allowing them to capitalize on the EPR effect. Therefore, size is an important factor for 
nanoparticles that rely on the EPR effect to localize at tumors.  
 RNA nanoparticle size is easily controlled, and the assembly process is highly 
reproducible and homogenous, resulting in narrow size distributions and batch-to-batch 
reproducibility. This is an advantage of RNA nanoparticles over other systems, whose 
assembly processes are less controlled. Demonstrated by in vivo biodistribution results, the 
size of RNA nanoparticles greatly affects circulation time and accumulation in healthy 
organs and tumors. A strong correlation between increased nanosquare size and increased 
circulation time is seen, indicated by higher fluorescent signal in whole body and organ 
images of mice (Fig 3.2, 3.3). There are numerous reasons for these observations. Particles 
less than 15 nm, such as the 5 nm nanosquare, are excreted primarily through the kidneys, 
a quicker route of elimination compared to liver excretion (129). Larger particles up to 100 
nm, such as the 10 and 20 nm nanosquares, have more interaction with macrophages, and 
are excreted more slowly through the liver (130). Another reason for different observed 
rates of RNA nanoparticle clearance is protein binding to the nanosquares, referred to as 
the protein corona (138). Differences in nanoparticle size have shown to dictate the amount 
and identity of proteins bound to nanoparticles, affecting their circulation time and 
excretion pathways (218). It is possible that differences in protein binding to the 
nanosquares greatly effects their elimination routes and therefore how long they stay in 
circulation. 
 Due to the high-fidelity assembly of RNA nanoparticles, they have a high 
likelihood to display consistent and controllable in vivo properties. Therefore, the same 
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nanoparticle system can be employed, easing nanoparticle preparation strategies, while 
displaying diverse but controllable in vivo properties. Based on the trend found in this 
study, it is possible that the construction of larger RNA nanoparticles would extend their 
circulation times even further.  
Effect of Shape on RNA Nanoparticle Biodistribution 
 While size is a determining factor of in vivo circulation properties of nanoparticles, 
shape is also very important. Like size, the shape of RNA nanoparticles can be easily tuned. 
In this study, RNA polygons of different shape but same size along each edge, were 
analyzed in mouse models. The organ biodistribution was similar among the particles after 
24 h, however, after 12 h there appears to be differences in biodistribution, per the intensity 
of fluorescent signal in different organs (Fig 3.5). For example, nanosquares show high 
fluorescence in kidneys after 12 h, while the triangle shows none, and the pentagon very 
little. And in the spleen, the highest fluorescence is seen in mice injected with pentagon 
nanoparticles. 
 Different shaped nanoparticles interact very differently with the in vivo 
environment (134). The protein corona is drastically changed by the shape of nanoparticles, 
which will affect the elimination pathways of nanoparticles. Additionally, previous studies 
have shown that symmetric nanoparticles can increase interaction with the immune system 
and trigger toxicity due to similarity in size and shape to pathogenic microorganisms (221). 
While RNA nanoparticles have been proven to trigger very low immune responses (103), 
shape is still something to consider and each nanoparticle should be tested to determine 
immune responses. 
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 Additionally, when considering entry into cells, both size and shape will be very 
important. Cell receptors vary in size and shape, and it will be beneficial to design 
nanoparticles that can fit precisely into the receptor binding pockets, enhancing recognition 
and uptake (222). This is an area where RNA nanoparticles could potentially excel, as size, 
shape, and properties of RNA nanoparticles can be controlled and finely tuned to fit 
specific receptors. 
CONCLUSIONS: 
 Herein, we have shown that size of RNA nanoparticles have a large effect on 
circulation time and biodistribution in vivo. A strong correlation between increased size 
and increased circulation time was observed, evidenced by the increased duration of 
fluorescent signal in whole body images of tumor bearing nude mice over 24 h. Despite 
increased size, there was still minimal fluorescent signal in healthy organs such as the liver 
and kidneys after 24 h compared to tumors. Here, shape was seen to have less effect on the 
biodistribution of RNA nanoparticles. However, fluorescent signal after 12 h suggests that 
elimination pathways could be different based on the shape of RNA nanoparticles. This 
study demonstrates a unique property of RNA nanoparticles that allows them to evade 
accumulation in healthy organs while still accumulating in tumor tissue by the EPR effect. 
Importantly, we have shown that the circulation time of RNA nanoparticles can be tuned 
simply by modulating their size. Circulation time is an important factor in drug delivery, 
as sometimes a short-lived particle is preferred to reduce toxicity, and other times a long 
circulating particle could be beneficial for slow acting therapies. RNA is an advantageous 
biomaterial for nanoparticle construction, as the base pairing self-assembly mechanism 
results in defined size and shape nanoparticles. Thus, in vivo drug delivery attributes, such 
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as circulation time, can be controlled from the conception of the design of a nanoparticle. 
It will be possible to utilize this unique property of RNA nanoparticles to enhance the 
current state of nucleic acid nanotechnology and drug delivery. 
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Chapter 3.2: The Effect of RNA Nanoparticle Hydrophobicity on Biodistribution  
INTRODUCTION:  
 Interactions of nanoparticles with their in vivo environment is an important factor 
and affects nanoparticle characteristics such as protein binding, toxicity, pharmacokinetics, 
and biodistribution (127,128,131-133,137,141,142). Accumulation of nanoparticles in 
healthy organs, such as the liver, kidneys, spleen, and lungs can lead to toxicity and lower 
efficacy of the administered dose of nanoparticles. While researchers are attempting to 
overcome this challenge with myriad of different nanoparticle systems, generally, less than 
2% of the administered dose reaches the treatment site with the remaining dose sequestered 
by filtration organs, which leads to toxicity and off-target drug effects (132). 
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Recently, RNA nanoparticles derived from the packaging RNA (pRNA) of 
bacteriophage phi29 have seen increased use as an in vivo delivery system (50,55-
58,103,126,148,150). RNA was once thought to have little potential for in vivo use due to 
biological and thermodynamic stability issues. However, these issues have been solved 
systematically by: (1) Finding of a thermodynamically stable three-way junction (3WJ) 
motif (55); (2) Findings that chemical modifications to RNA nanoparticles confer 
enzymatic stability in vivo (64); and (3) Finding that RNA nanoparticles exhibit little to no 
immunogenicity in vivo (103). RNA nanoparticles are also water soluble and anionic due 
to the charged phosphate backbone. RNA nanoparticles show no accumulation in healthy 
organs, navigating to tumors after four hours of circulation (55,57,58). 
It is well known that a nanoparticle’s size, shape, and physical properties affect 
interactions in vivo, and will therefore play a large role in determining their 
pharmacokinetics and biodistribution(128,134,140). Thus, tremendous efforts are made by 
nanoparticle engineers to overcome inherent downfalls in nanoparticle construction. For 
example, polyethylene glycol (PEG) is frequently used to increase water solubility of 
otherwise insoluble nanoparticles (143,144).  
Conjugation of chemicals, such as fluorophores, drugs, and targeting ligands, is a 
popular method to decorate nanoparticles with functional moieties. However, many studies 
using hydrophobic fluorophores (fluors) show nanoparticle accumulation in vital organs 
such as the liver, kidneys, lung, and spleen (223-227). It is possible that the hydrophobic 
conjugates, in this case fluors, are promoting interaction with cell membranes and plasma 
proteins, causing accumulation of the nanoparticles in organs. In order for a nanoparticle 
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to display low toxicity and low accumulation in vital organs, it is important to understand 
how conjugation of chemicals to nanoparticles affects their in vivo properties. 
Previous in vivo studies using pRNA nanoparticles were carried out using charged 
and water soluble fluors to make sure the properties of the nanoparticles were not changed 
drastically (55,57,58,228). However, as RNA nanotechnology progresses it will be 
important to know to what extent an RNA nanoparticle can be decreased in water solubility 
before accumulating in vital organs. Many potential applications such as chemical drug 
delivery and ligand based targeting involve conjugation of chemical groups to RNA 
nanoparticles. When chemicals are conjugated externally and not encapsulated, the impact 
of the conjugate is likely to be more significant.  
To investigate this, three fluors of different hydrophobicities were conjugated to 
the 3WJ RNA nanoparticle to serve as model chemicals: Cyanine5.5 (C5.5); Sulfonated-
Cyanine 5.5 (SC5.5); and AlexaFluor700 (A700). All three fluors display similar excitation 
and emission spectra, despite minimal differences in their structures and solubility 
(229,230). HPLC analysis demonstrated that conjugation of the fluors increased RNA 
nanoparticle hydrophobicity to differing extents. Hydrophobicity induced by chemical 
conjugates resulted in higher accumulation of RNA nanoparticles in vital organs of mice.  
Additionally, we observed weaker organ accumulation for hydrophobic chemicals after 
they were conjugated to RNA nanoparticles, suggesting that RNA can increase the 
solubility of hydrophobic chemicals. To offer a physical explanation for in vivo results, 
predictive compound logP (ClogP) values of the fluors and 3WJs were compared to 
experimentally determined hydrophobicity scales of amino acids, which are used to predict 
trans-membrane protein residues (231-234). This study offers insight into drug 
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development concerning the reduction of organ accumulation and drug toxicity or side 
effects of nanoparticles that are modified with chemical conjugates such as targeting 
ligands, fluors for tracking, and chemical drugs. 
MATERIALS AND METHODS: 
RNA Synthesis and Fluor Conjugation 
 RNA oligomers were chemically synthesized using typical phosphoramidite 
chemical synthesis on an automated oligo synthesizer. Following synthesis, oligomers 
were deprotected and desalted using conventional methods (235). Each 3WJ strand was 
synthesized using 2’-fluorinated cytidine and uracil. 3WJ-c strand was 5’ modified with a 
primary amine (Cat. No: 10-1947-90, Glen Research). Cyanine5.5-NHS ester and Sulfo-
Cyanine5.5-NHS ester were purchases from Lumiprobe. AlexaFluor700-NHS Ester was 
purchased from Molecular Probes. Conjugation reactions were carried out by mixing a 1:10 
molar ratio of primary amine labeled 3WJ-c: NHS Ester-Fluorophore in 0.1 M sodium 
bicarbonate buffer, pH = 8.5. The conjugation reactions were incubated at room 
temperature for 16 hours while protected from light. Following incubation, the reactions 
were ethanol precipitated and washed twice with cold 75% ethanol to remove the majority 
of unreacted fluorophore, facilitating purification.  
HPLC Purification and Analysis of RNA-Fluor Conjugates 
Samples were purified using IPRP-HPLC. Due to different hydrophobicities of 
each RNA-fluor conjugate, different HPLC gradient methods were used for each conjugate. 
Buffer A was 0.1 M triethylamine acetate (TEAA) (Glen Research) in water and buffer B 
was 0.1 M TEAA in 75% acetonitrile and 25% water. All purifications were performed 
using an Agilent 1260 HPLC and Agilent PLRP-S HPLC column (Agilent Cat. No: 
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PL1512-5500). A flow rate of 1.5 mL/min was used throughout all HPLC methods and 
absorbance was monitored at 260 nm (RNA), 675 nm (C5.5, SC5.5), and 700 nm (A700). 
3WJ-c-C5.5 was purified by a 5-100% gradient of buffer B over 15 minutes. 3WJ-c-SC5.5 
was purified by 5-18% gradient of buffer B over five minutes followed by an 18-39% 
gradient over 15 minutes. 3WJ-c-A700 was purified by 5-18% gradient of buffer B over 
five minutes followed by an 18-38% gradient over 15 minutes. Fractions were collected 
when RNA absorbance and fluor absorbance eluted simultaneously. After fraction 
collection, RNA-fluor conjugates were dried to completion under vacuum. 
For %ACN elution comparison, an identical gradient of 5-100% buffer B over 20 
minutes was used to analyze 3WJ-fluor nanoparticles, 3WJ-c-fluor conjugates, and fluors. 
%ACN elution was calculated based on elution times of RNA oligoes or 3WJ complexes. 
Delay time was calculated by injection of an RNA sample in a high hydrophobic 
environment (100% acetonitrile) to prevent interaction with the column. The 
experimentally determined delay time was then subtracted from sample elution time, which 
was then used to calculate %ACN elution. 
Chromatograms were plotted using OriginPro. Plots comparing 3WJ %ACN 
elution show 3WJ absorbance at 260 nm, 3WJ-Cy5.5 and 3WJ-SCy5.5 absorbance at 675 
nm, and 3WJ-A700 absorbance at 700 nm. Comparison of %ACN elution of dye species 
were values taken from analysis chromatograms of dye species (Fig A.2.1B, C, D). Values 
were plotted and then slope determined using a linear fit.  
Determination of Predictive ClogP Values 
 ChemDraw Professional 16 was used to predict ClogP values of amino acids, 
fluors, and nucleotide-fluor conjugates. Amino acids, fluors, and nucleotide-fluor 
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conjugates were drawn with charges analogous to their charged state at physiological pH 
= 7.4. Only the side chains of the amino acids were used for predictive ClogP calculations. 
Predicted ClogP values of amino acid side chains were then plotted versus previously 
published hydrophobicity scales of amino acids (233,234,236,237). Four different 
hydrophobicity scales were chosen for comparison (Fig A.2.2) and it was found that the 
Cornette hydrophobicity scale was the best match to predictive ClogP values. The Cornette 
scale is based on 28 published scales and demonstrates one of the best overall scales of 
amino acid hydrophobicity. High values indicate higher degree of hydrophobicity. 
In vivo Biodistribution 
 Male BALB/c mice, 5 weeks old, (Taconic) were injected intravenously (IV) 
through the eye using retrorbital injection (238). At 1, 4, and 8 hours mice were sacrificed 
and their hearts, kidneys, livers, spleen, and lungs collected and imaged for Cy5.5, SCy5.5, 
and A700 fluorescent signal using an In Vivo Imaging System (IVIS) imager (Caliper Life 
Sciences). Mice were administered PBS as a blank control. 100 L of 20 M nanoparticle 
sample or dye sample were injected. It is important to note that the concentrations of dyes 
was kept consistent in all in vivo experiments. 
RESULTS AND DISCUSSION: 
3WJ-fluor HPLC analysis 
 The 3WJ is composed of three component RNA oligomers: 3WJ-a, 3WJ-b, and 
3WJ-c (Fig 3.6A). Mixing equimolar amounts of each component strand at room 
temperature in physiological buffer yields homogeneous RNA nanoparticles (Fig 3.6B) 
(55). To fluorescently label the 3WJ nanoparticles, NHS-Ester derivatives of C5.5, SC5.5, 
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and A700 were conjugated to primary amine labeled 3WJ-c strand (Fig 3.6C). Fluor 
conjugated oligomers were purified from un-labeled RNA by IPRP-HPLC.  
Following assembly of fluor labeled 3WJ nanoparticles (3WJ-C5.5, 3WJ-SC5.5, 
3WJ-A700), polyacrylamide (PAGE) gel analysis was used to determine assembly 
efficiency. A decrease in migration rate of fully assembled 3WJ nanoparticles compared to 
monomer and dimer species indicates successful formation at high yield (Fig 3.7A). Gels 
were stained with ethidium bromide (EB) for total RNA visualization followed by scanning 
for EB and fluor signal. Co-migration of EB and fluor signal indicates successful 
incorporation of fluor-labeled oligomers into 3WJ nanoparticles. 
3WJ particles were then analyzed by IPRP-HPLC to compare elution times and 
%ACN elution (Fig 3.7B). Table 3.1 shows a summary of nanoparticle elution times and 
%ACN elution. There is a strong correlation between the number of charged sulfate groups 
per fluor and the %ACN elution. 3WJ-C5.5 has the highest %ACN elution of 46.39 
followed by 3WJ-SC5.5 at 22.72% and finally 3WJ-A700 at 21.49%. 3WJ with no fluor 
eluted at 14.13 %ACN. HPLC analysis indicates that different chemicals conjugated to 
RNA nanoparticles will increase the nanoparticle’s hydrophobicity to differing degrees.  
Fluorophore hydrophobicity vs biodistribution 
 Following HPLC analysis, the fluors were injected retroorbitally into mice and 
fluorescent signal was whole body imaged 1, 4, and 8 h post-injection. Mice were then 
sacrificed and their organs collected and imaged for fluorescent signal. Fluorescent signal 
from whole body images show low fluorescent signal for A700 and SC5.5 and higher 
fluorescent signal for C5.5 (Fig 3.8A). Organ images of the mice injected with the fluors 
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all show fluorescent signal after 8 h (Fig 3.8B). These observations correlate well with the 
increased hydrophobicity of C5.5 over both SC5.5 and A700. 
3WJ-fluor hydrophobicity vs biodistribution 
 The in vivo properties of the 3WJ-fluor nanoparticles were analyzed by testing their 
biodistribution profiles in mice. Mice were injected retroorbitally and sacrificed at 1, 4, 
and 8 h post-injection. Organs were collected and scanned for fluorescent signal. Whole 
body images indicate faster clearance of 3WJ-SC5.5 and 3WJ-A700 compared to and 3WJ-
C5.5 (Fig 3.8). 3WJ-C5.5 showed high fluorescent signal in the organs compared to mice 
injected with PBS as a blank, primarily accumulating in the liver and kidneys after 8 h (Fig 
3.8B). 3WJ-SC5.5 does show fluorescence in organs after 8 h, albeit much less intense than 
observed for 3WJ-C5.5. 3WJ-A700 shows no fluorescence in organs after 8 h. These in 
vivo results demonstrate a strong correlation between the increased hydrophobicity of the 
fluorophore and increased accumulation of nanoparticles in organs. Furthermore, these 
results show the ability of the 3WJ nanoparticle to increase the solubility of the fluors as 
less accumulation in vital organs of 3WJ-fluor nanoparticles is seen when compared to 
fluors. 
Physical basis for hydrophobicity effect on biodistribution 
 After in vivo results, we sought a physical explanation for our observations. One 
likely explanation for accumulation of the nanoparticles is interaction with proteins and 
cell membranes in vivo. It is our hypothesis that the increased hydrophobicity of the fluors 
conjugated to the 3WJ nanoparticles initiates interaction with the hydrophobic regions of 
proteins and cell membranes, causing the nanoparticles to accumulate in organs. Many 
studies have been done on the hydrophobicity of proteins and how the amino acid 
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arrangement creates pockets of hydrophobicity and hydrophilicity (231-234,236,237). 
These studies have generated amino acid hydrophobicity scales, which are used to predict 
hydrophobic regions in proteins and determine trans-membrane protein regions.  
We hypothesized that the increased hydrophobicity of 3WJ-C5.5 was increasing 
the strength of the interactions between the hydrophobic regions of proteins and cell 
membranes and the nanoparticles. Because the RNA nanoparticles are extremely 
hydrophilic with a hydrophobic fluor attached, we expect them to exhibit an amphipathic 
property. This is akin to trans-membrane proteins, which are amphipathic to cross cell 
membranes.  
A logP (partition coefficient) value is the ratio of a compounds solubility in two 
immiscible solvents, normally octanol: water, and is a good indication of hydrophobicity. 
Additionally, logP values are useful in estimating the biodistribution of drugs. More 
hydrophobic logP values generally indicate accumulation of drugs in hydrophobic areas 
such as the lipid bilayers of cells, while more hydrophilic logP values indicates 
accumulation of drugs in hydrophilic regions such as blood serum (239). A ClogP value 
uses experimentally determined logP values of small fragments, and then adds these values 
together with correction factors to obtain a ClogP value (240). When dealing with complex 
molecules, such as those containing aromaticity, ClogP values tend to be quite accurate. 
ChemDraw version 16.0 was used to predict the ClogP values of the amino acids 
(Tbl 3.2). These values were then plotted alongside hydrophobicity values from different 
hydrophobicity scales (Fig A.2.2). We chose the Cornette(233) hydrophobicity scale as we 
observed the best correlation between predicted ClogP values and Cornette values (Fig 
3.9A). A dotted line represents a neutral value of 0. 
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Next, ClogP values of C5.5, SC5.5, and mono, di, and trinucleotide derivatives of 
the fluors were predicted (Tbl 3.2). The structure of A700 is proprietary, and no structural 
information was available, however, SC5.5 and A700 demonstrate similar hydrophobicity 
based on IPRP-HPLC. The ClogP values were then plotted alongside ClogP values of 
amino acids (Fig 3.9B). Interestingly, C5.5 displays a high ClogP value while SC5.5 
displays an extremely low ClogP value. Only when C5.5 is in trinucleotide form does the 
ClogP value reduce to near zero. ClogP values beyond trinucleotide form could not be 
predicted due to the increased number of atoms and software limitations. However, we 
expect as more nucleotides are added (54 in one 3WJ nanoparticle), the ClogP value would 
drastically decrease. 
Importantly, comparison of the predicted ClogP values of the amino acids with the 
fluors and their nucleotide derivatives provides some insights into the effect of 
hydrophobicity on cell membrane interaction. We see a highly-correlated trend between 
high ClogP value and organ accumulation in vivo. We also see a highly-correlated trend 
between high ClogP value and high value in the Cornette hydrophobicity scale. This shows 
that conjugates with high predicted ClogP values conjugated to a nanoparticle may cause 
interaction with the cell membrane, much like trans-membrane proteins. 
 Interestingly, while 3WJ-SC5.5 and 3WJ-A700 display similar %ACN elution by 
HPLC analysis, they demonstrate different behaviors in vivo. This suggests that the 
interaction of the nanoparticle conjugate with cell membranes is determining organ 
accumulation, not the overall hydrophobicity of the nanoparticle conjugate. Also, factors 
other than hydrophobicity, such as structure of the conjugate, could contribute to 
entrapment in vital organs. 
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RNA nanoparticles solubilize hydrophobic chemicals 
The hydrophilic property of RNA nanoparticles enables them to solubilize many 
hydrophobic chemicals. IPRP-HPLC demonstrates an increase in solubility (decrease in 
%ACN elution) from fluor alone to 3WJ-c-fluor to 3WJ-fluor (Fig A.2.1B-D). 
Interestingly, we see a much larger decrease in %ACN elution for the hydrophobic Cy5.5 
fluor than for both hydrophilic fluors, indicated by more negative slope for Cy5.5 (Fig 
3.10). The effect of RNA nanoparticles increasing solubility is evidenced by decreased 
fluorescent signal in vital organs when comparing 3WJ-fluor to fluor alone (Fig 3.8B).  
However, despite the high overall hydrophilicity, we still see both increased %ACN 
elution and accumulation with hydrophobic cell membranes when using a hydrophobic 
conjugate. This once again leads us to believe that the conjugate itself is interacting with 
cell membranes, and if the interaction of the conjugate with the cell membrane is strong 
enough it can overcome the hydrophilic nature of the RNA nanoparticle and the anionic 
property of RNA. Thus, not only is the overall hydrophilicity of the nanoparticle important, 
but so are the specific surface properties of the nanoparticle. 
While this study uses fluors to demonstrate how hydrophobicity affects 
nanoparticles in vivo, we expect it to extend to other conjugates such as chemical drugs or 
targeting ligands. For future use, it will be beneficial to determine beforehand if a conjugate 
will or will not cause nanoparticles to accumulate non-specifically in vivo. It is possible 
that using a screening method, such as the one presented in this study, will greatly benefit 
nanoparticle engineers looking to optimize their nanoparticle’s physical properties. 
Specifically, for RNA nanoparticles, it could be beneficial to use encapsulation methods to 
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protect the hydrophobic molecules from strong interactions with cell membranes or other 
proteins (148).  
CONCLUSIONS: 
Our study demonstrates a strong correlation between increased hydrophobicity of 
an external conjugate and increased accumulation of nanoparticles in vital organs. 
Comparison of ClogP values of C5.5, SC5.5, and A700 to amino acids showed a strong 
correlation between hydrophobic dyes, which accumulate in vivo, to amino acids that are 
commonly seen in hydrophobic regions of trans-membrane proteins. Our results 
demonstrate a method to pre-screen nucleic acid based nanoparticle conjugates for their 
hydrophobic properties using a common method of HPLC analysis. As shown here, careful 
consideration must be taken when choosing to externally conjugate chemical drugs, fluors, 
or targeting ligands to water soluble nanoparticles, as their effect on water-solubility, and 
in turn in vivo biodistribution, could be detrimental to the safety of patients in future clinical 
settings. This study offers some insight into drug development concerning the reduction of 
organ accumulation of nanoparticles and reduction of drug toxicity and side effects.   
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Table 3.1. Elution Times and %ACN Elution of Fluorophore Species. 
 
 
 
 
 
 
 
 
 
 
 
 
RNA-Dye 
Conjugate
Elution Time 
(min)
%Acetonitrile 
Elution
In vivo Result
# of Sulfate 
Groups
Cy5.5 22.29/26.14 55.41/69.13 High in organs 0
SCy5.5 13.10/16.20 22.69/33.69 Low in organs 4
A700 13.19/15.07 22.97/29.68 Low in organs ?
2'F-3WJ-C 11.48 16.90 - -
2'F-3WJ-C-Cy5.5 20.58 49.31 - 2
2'F-3WJ-C-SCy5.5 13.67 24.72 - 4
2'F-3WJ-C-A700 13.27 23.26 - ?
2'F-3WJ 10.70 14.13 - -
2'F-3WJ-Cy5.5 19.76 46.39 High in organs 0
2'F-3WJ-SCy5.5 13.11 22.72 Low in organs 2
2’F-3WJ-A700 12.77 21.49 No Organs ?
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Table 3.2. Amino Acid Hydrophobicity Comparisons to Fluorophore Species. 
 
 
 
 
Amino Acid Cornette ClogP %ACN Elution
D Aspartic Acid -3.10 -4.19 -
K Lysine -3.10 0.96 -
Q Glutamine -2.80 -0.59 -
P Proline -2.20 0.83 -
T Threonine -1.90 -0.24 -
E Glutamic Acid -1.80 -3.67 -
N Asparagine -0.50 -1.11 -
S Serine -0.50 -0.76 -
G Glycine 0.00 -1.32 -
A Alanine 0.20 1.10 -
H Histidine 0.50 0.36 -
W Tryptophan 1.00 2.63 -
R Arginine 1.40 -0.45 -
Y Tyrosine 3.20 1.97 -
C Cysteine 4.10 0.65 -
M Methionine 4.20 1.37 -
F Phenylalanine 4.40 2.64 -
V Valine 4.70 2.28 -
I Isoleucine 4.80 2.81 -
L Leucine 5.70 2.68 -
SCy5.5-NHS-Ester - -11.59 22.69/33.69
SCy5.5-MonoNT - -14.22 -
SCy5.5-DiNT - -16.06 -
SCy5.5-TriNT - Highly Neg. -
Cy5.5-NHS-Ester - 7.66 69.13
Cy5.5-MonoNT - 5.43 -
Cy5.5-DiNT - 3.59 -
Cy5.5-TriNT - 0.90 -
A700-NHS - ?? 22.97/29.68
MonoNT - -4.67 -
DiNT - -7.16 -
TriNT - -9.85 -
3WJ-SCY5.5 - Highly Neg. 22.72
3WJ-Cy5.5 - Neut to Neg. 46.39
3WJ-A700 - Highly Neg. 21.49
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Figure 3.1. (A) Structures of the 5, 10, and 20 nm 2’F nanosquares. (B) Structures of 10 nm RNA 
triangle, square, and pentagon 
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Figure 3.2. In vivo biodistribution time course fluorescence images of 5, 10, and 20 nm 
2’F nanosquares. Mice were imaged for fluorescent signal using an in vivo imaging system 
(IVIS) scanning for AlexaFluor647 signal. 
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Figure 3.3. Organ images of 5, 10, and 20 nm 2’F nanosquares after 12 and 24 h. Organs 
were fluorescently imaged using an in vivo imaging system (IVIS) scanning for 
AlexaFluor647 signal. 
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Figure 3.4. (A) Gel images of serum degradation of 5, 10, and 20 nm 2’F nanosquares. (B) 
Plots of gel band intensity from serum degradation gels of 5 (green), 10 (red), and 20 (blue) 
nm 2’F nanosquares. 
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Figure 3.5. Organ images of 2’F RNA polygons after 12 and 24 h. Organs were 
fluorescently imaged using an in vivo imaging system (IVIS) scanning for AlexaFluor647 
signal. 
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Figure 3.6. 3WJ Introduction and Dye Conjugation. (A) pRNA-3WJ secondary 
structure and sequences. (B) Atomic force microscopy images of pRNA-3WJ with 60 base 
pair extensions from each helix to show overall shape. (C) Reaction and assembly scheme 
of fluorescently labeled 3WJ nanoparticles. 
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Figure 3.7. 3WJ Assembly and HPLC Analysis. (A) Native PAGE assembly gels of 
fluorescently labeled 3WJ nanoparticles. (B) IPRP-HPLC chromatograms of fluorescently 
labeled nanoparticles. Demonstrates the effect of the fluorophore conjugation on 
hydrophobicity of the nanoparticles. 
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Figure 3.8. Biodistribution in Mice. (A) Whole body fluorescent images of mice IV 
injected with C5.5, SC5.5, A700, 3WJ-C5.5, 3WJ-SC5.5, and 3WJ-A700. Mice were 
scanned after 1, 4, and 8 h of circulation. (B) Fluorescent scans of organs. 
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Figure 3.9. Hydrophobicity Comparison. (A) Plots of Cornette hydrophobicity scale 
values along with predicted ClogP values of the amino acids. A strong correlation is seen 
between the previously determined Cornette hydrophobicity scale and predicted ClogP 
values of the amino acids. The dotted line is a value of zero. (B) ClogP values were 
predicted for SulfoCy5.5 and their mono- and di-nucleotide derivatives (green), Cy5.5 and 
their mono- and di-nucleotide derivatives (blue), and mono-, di-, and tri-nucleotides 
(black). 
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Figure 3.10. RNA nanoparticles solubilize hydrophobic ligands. Each colored line 
represents a different fluorophore: SulfoCy5.5 (blue), AlexaFluor700 (pink), and Cy5.5 
(red). Three species of each fluorophore were plotted: fluorophore alone, 3WJ-c-
fluorophore, and 3WJ-fluorophore. A decreasing %ACN elution is seen as more 
nucleotides are added. Linear fitting was performed for each fluorophore. A more negative 
slope is seen for Cy5.5, indicating the RNA nanoparticle can help to solubilize the 
hydrophobic ligand. 
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Chapter 4: Development of Three-Dimensional RNA Nanocages with 
Novel Small Molecule Encapsulation and Release Mechanism 
 
Chapter 4 was reproduced (with some modification) with permission from 
Khisamutdinov, EF*; Jasinski, DL*; Li, H; Zhang, K; Chiu, W; and Guo, P. “Fabrication 
of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs.” 
Advanced Materials, 2016. 28(45), 9996-20004. DOI: 10.1002/adma.201603180. 
Copyright 2016 Wiley Publishing.  
Special thanks to: Dr. Emil F. Khisamutdinov for help in preparation of data for 
these figures; and to Dr. Luda S. Shlyakhtenko and Dr. Yuri Lyubchencko for AFM images 
in figures 4.2; and to Dr. Kaiming Zhang and Dr. Wah Chiu for cryo-em images and 
reconstructions in figure 4.2; and to Dr. Hui Li for cell data and confocal images in figure 
4.8. 
 
INTRODUCTION: 
In RNA Nanotechnology, canonical Watson-Crick pairs combined with non-
canonical base pair interactions create a large variety of RNA structural building blocks or 
motifs such as multi-way junctions (55,68,73,90,109), kissing loops 
(12,100,101,162,241,241,241,242), and sticky ends (104,104,126) that have been utilized 
to create two-dimensional (2D) RNA structures (243). Combining diverse RNA 
connectivity into one nanostructure imparts complexity and allows for the addition of a 
third dimension in nanoparticle design. As a result, three-dimensional (3D) RNA 
nanoarchitectures have been explored (116,117,124,244). 3D nanostructures are of 
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particular interest as they hold tremendous potential for the encapsulation of small 
molecule drugs and therapeutic RNAs. Importantly, encapsulation may hold the distinct 
ability for controlled release of therapeutic modalities. Previously reported 3D DNA cages 
such as tetrahedrons, cubes, icosahedrons, and triangular prisms have been used as nano-
containers to hold proteins (245,246), gold nanoparticles (247,248), as well as organic 
molecules (249). Although construction of 3D RNA nanocages has been previously 
reported, their potential to encapsulate small reporter molecules, drugs, and proteins is yet 
to be realized.  
RNA aptamers are important candidates for therapeutic and diagnostic applications 
as they display high affinity and specificity for their target molecules. Binding of malachite 
green (MG), a triphenylmethane dye, to its respective RNA aptamer, the malachite green 
aptamer (MGA), causes a drastic increase in MG fluorescence (212,250). This 
fluorophore/RNA complex has been widely utilized as a marker in the construction of 
functional RNA nanoparticles (108,124,126,152,201,251). However, the application of 
MGA in vivo is limited due to RNA specific exo- and endonucleases inside cells. To 
prevent this, ribose ring modification at 2’-C/U in RNA is a common strategy to enhance 
RNA’s nuclease resistance (160). However, due to either structural hindrance or 
redistribution of the nearest neighbor landscape, 2’ ribose sugar or other chemical 
modifications can hamper the activities of aptamers selected with native RNA libraries. 
For example, 2'-fluorine (2’F) modification to the MGA eliminates binding of the 
fluorophore (201). Protection of RNA aptamers would be beneficial as their lifetimes could 
be significantly increased, thereby increasing their utility in vivo. One possibility to extend 
their lifetimes is encapsulation inside nuclease resistant nanocages. 
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  One advancement utilized for constructing RNA architectures was the finding of 
an unusually thermostable three-way junction (3WJ) derived from the pRNA of 
bacteriophage phi29 DNA packaging motor (55). The 3WJ can be used as a vehicle to 
integrate multiple functional RNA modules into one nanoparticle while retaining folding 
and function in vivo (12,55). Utilizing the crystal structure of the 3WJ (168), various RNA 
nanoparticles including triangles, squares, and pentagons were constructed (252). Upon 
systemic injection in mice, the RNA nanoparticles bind to xenograft and metastatic cells 
specifically and strongly with little or no accumulation in the liver or other healthy organs 
(253).  
  Herein, we describe a strategy to fabricate 3D RNA nanocages resembling 
triangular prisms based on pRNA 3WJ. Importantly, this 3D nanoparticle was used to 
demonstrate encapsulation of a small fluorescent dye, MG, while increasing its 
fluorescence half-life in an RNA unfriendly environment. The modularity of the triangular 
nanoprism design also allowed single strand oligonucleotide-drug conjugates to be 
positioned precisely inside the inner cavity of the RNA complex. The functional properties 
of the RNA nanocage to simultaneously carry 5 folate ligands for cell targeting were 
further evaluated in vitro. This work paves the way towards the application of RNA based 
nanocaging as a delivery system for small reporter or therapeutic molecules.  
MATERIALS AND METHODS: 
RNA sequence design and 3D modeling 
RNA sequences were optimized using RNA 2D folding software Mfold 
(www.mfold.bioinfo.rpi.edu) prior to synthesis. Computer models of the RNA prism were 
assembled from two copies previously constructed RNA triangles (126). The vertices of 
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the triangles were assembled by overlapping helical domains of the triangular "arms" to 
position them at the correct angle and distance using the 'autofit' tool in Swiss-PDB Viewer 
(www.spdbv.vital-it.ch) and manual adjustment. The detailed procedure for the triangle 
design can be found in our previous reports (126). Each triangle vertex contains a 21 nt 
ssRNA tethered to the 3’-end using a poly-uracil (poly-U) linker. The poly-U is inserted to 
provide a hinge allowing for the flexibility of the ssRNA when hybridized with its 
complementary sequence of another triangle. The resulting 21 bp RNA duplexes were 
chosen to have similar lowest free-energy secondary structures (calculated ∆G =-39.0 ± 
2.0 kcal/mol). The sequence of the RNA MGA module was extracted from the PDB 
databank (www.pdb.org), PDB ID: 1F1T (212). Detailed 2D structures and sequence of 
the nanoprisms as well as synthetic oligonucleotides containing conjugates are provided in 
Tables A.3.1, A.3.2, and A.3.3. 
RNA synthesis, purification and assembly 
Templates for RNA transcription were prepared by standard protocols described in 
detail elsewhere (105). Briefly, PCR was used to prepare transcription templates using PCR 
reaction kit (Promega Corporation, GoTaq® FlexiDNA Polymerase) for the amplification 
of DNA primers (IDT). Following purification of DNA templates on spin columns 
(QIAGEN), the RNA strands or 2’F-U/C modified RNA strands were transcribed using 
home-made T7 RNA polymerase. The RNA was precipitated with cold ethanol, then the 
pellets dried and resuspended in ddH2O. Homogeneity of individual RNA strands is 
checked by denaturing 10% PAGE. For assembly assays, equimolar RNA strands (0.5 µM 
each) were mixed in 1 X TMS buffer. The RNA mixture was heated to 80 °C for 5 min and 
slowly cooled to 4 °C over one hour in a thermocycler. RNA assembly products were 
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checked on native 6% or 7% PAGE (29:1 acrylamide: bis-acrylamide ratio) in 1 X TBM 
running buffer. All native PAGE experiments were run at 4ºC at constant 90 V for 2 hours. 
Gels were stained in Ethidium Bromide buffer for total RNA strand visualization or in MG 
binding buffer (20 µM MG dye, 10 mM HEPES pH = 7.4, 100 mM KCl, 5mM MgCl2) for 
detection of MG aptamer signal as previously reported (103).  
Cryo-electron microscopy 
2 μl of RNA triangular prism nanoparticle solution (1 mg/ml) was applied onto a 
glow-discharged 200-mesh R1.2/1.3 Quantifoil grid. The grids were blotted for 3 s and 
rapidly frozen in liquid ethane using a Vitrobot Mark IV (FEI). Then the girds were 
transferred to JEM2200FS cryo-electron microscope (JEOL) operated at 200 kV with in-
column filter for screening. Micrographs of 10 nm RNA prism were recorded with a direct 
detection device (DDD) (DE-20 4k×5k camera, Direct Electron, LP) operating in movie 
mode at a recording rate of 25 raw frames per second at 25,000×microscope magnification 
(corresponding to a calibrated sampling of 2.51 Å per pixel) and a dose rate of ~20 
electrons per second per Å2 with a total exposure time of 3 s. Micrographs of 5 nm RNA 
prism were recorded with a 4k × 4k CCD (Gatan) at 80,000× microscope magnification 
(corresponding to a calibrated sampling of 1.36 Å per pixel) and a dose rate of ~20 
electrons per second per Å2 with a total exposure time of 3 s. A total 52 images of 10 nm 
RNA prism and 30 images of 5 nm RNA prism were collected with a defocus range of 2~4 
μm. 
Single particle image processing and 3D reconstruction 
The image processing software package EMAN2 was used for the micrograph 
evaluation, particle picking, CTF correction, 2-D reference-free class averaging, initial 
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model building and 3-D refinement of the cryo-electron microscopy data. We boxed total 
2340 particles for 10 nm RNA prism and 2206 particles for 5 nm RNA prism to generate 
the 2D class averages for building the initial models. Finally, 1514 particles for the 10 nm 
RNA prism and 1648 particles for the 5 nm RNA prism were used for final refinement, 
applying the D3 symmetry. The resolution for the final maps was estimated by the 0.143 
criterion of FSC curve without any mask. 25 Å and 22 Å Gauss low-pass filter were applied 
to the final 3D maps displayed in the Chimera software package. 
AFM images 
For all samples, specially modified mica surfaces (APS mica) were used. The APS 
mica was obtained by incubation of freshly cleaved mica in 167nM 1-(3-aminopropyl) 
silatrane following previously reported protocol (171). The RNA samples were diluted 
with 1 × TMS buffer to a final concentration of 3 - 5 nM. Then, 5-10 µL was immediately 
deposited on APS mica. After 2min incubation on the surface, excess samples were washed 
with DEPC treated water and dried under a flow of Argon gas. AFM images in air were 
acquired using MultiMode AFM NanoScope IV system (Veeco/Digital Instruments, Santa 
Barbara, CA) operating in tapping mode.  
Dynamic light scattering 
The hydrodynamic diameter of the RNA nanoprisms was determined at a 
concentration of 10 µM in 50 µL TMS buffer using a Zetasizer nano-ZS (Malvern 
Instrument, LTD) at 25°C.  
Prism MG degradation assay 
The function of the MGA within the triangular prism nanoparticles was assayed by 
mixing the RNA complex at a concentration of 0.1 μM with 1 μM MG dye in 1X TMS 
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buffer. The solutions were allowed to equilibrate at room temperature for 10 minutes. The 
fluorescence emission spectrum (recorded from 630 – 750 nm) of the complexes was 
measured using a fluorospectrophotometer (Horiba Jobin Yvon) with an excitation 
wavelength positioned at 615 nm. 1 µL of 500 U/µL RNase T1 (Thermo Scientific) was 
added to 99 µL of the above RNA-MG complex directly in a fluorometer cuvette. 
Fluorescence at λmax = 650 nm was immediately recorded and monitored every 1 sec for a 
total time of 3600 sec. Fluorescence life time measurements were performed by the 
software integrated within the fluorometer. The obtained data were fit using exponential 
decay function I(t) = I0 e
 (-t/τ), where I0 is the initial intensity (at time zero) and τ is the mean 
life time defined as the time for the intensity to drop by 1/e or to 37%. All fluorescence 
decay experiments were conducted in triplicate with indication of ± for mean standard error 
(SEM).  
RESULTS AND DISCUSSION: 
Computer-aided rational design and fabrication of 3D RNA nanoprism from planar 
pRNA 3WJ geometry 
The triangular nanoprism was designed employing the structural information of 
pRNA 3WJ following a bottom-up approach (90). As such, two helices of three adjacently 
arranged 3WJs were connected with duplex RNA to form flat triangular nanoparticles, a 
nanoparticle construction method devised previously (126). To extend 2D triangle particles 
into a 3D RNA complex, two triangular nanoparticles (T1 and T2) containing 21 nucleotide 
(nt) single stranded (ss) complementary linker (L) regions on each vertex were tethered 
(Fig 4.1A, Fig A.3.1). Each ssL region was designed to interact specifically with its 
compliment strands L1-L1’, L2-L2’, L3-L3’ forming RNA-RNA duplex of 21 bp. To 
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provide structural flexibility and allow the linkers to bend to a 90° angle necessary for 
triangular prism complex, poly uracils (poly-Us) were embedded between the ssL and 
triangle vertices. This resulted in the formation of a "face-to-face" dimer with a total of 8 
RNA strands. The overall geometry was manually computed using SwissPDB Viewer 
software (254), the structure resembling triangular prism geometry with the pRNA 3WJ 
motif at the corners. The 3D RNA model displays a size of ~11 nm, measured from one 
vertex to an adjacent vertex, and a size of ~10 nm measured from one vertex to its nearest 
edge, as measured by the modeling software (Fig 4.1B). The largest diameter of the inner 
cavity of the prism was measured to be ~7 nm while the height was ~ 6 nm. Based on these 
dimensions, we assume that the central cavity of the prism could accommodate a spherical 
object of approximately 6 nm in diameter.  
Assembly efficiency of the RNA strands into the desired conformation was first 
assayed by 6% native polyacrylamide gel electrophoresis (PAGE). Upon addition of each 
of eight component strands, a step-wise decrease in electrophoretic migration can be clearly 
seen, indicating association of each complimentary ssRNA oligomer into the complex 
RNA structure (Fig 4.2A). The distinct band in lane 7 indicates the formation of a stable 
RNA complex containing all 8 RNA strands. Integration of the intensity of gel bands results 
in an estimated assembly yield of 43.0 ± 3.1%. A large fraction of RNA aggregates are 
localized in the top of lane 7. Presumably, this is due to non-specific interactions between 
the 21nt RNA single stranded sticky ends. Interestingly, the RNA complex with no D and 
d’ stands has much a higher assembly efficiency with estimated yield of 90% (Fig 4.2A, 
Lane 6).  
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DLS was utilized to measure the apparent dimensions of the purified RNA prism. 
As measured by DLS, the hydrodynamic diameter of the RNA complex is 11.5 ± 1.6 nm, 
consistent with the 3D model structure of the nanoprism (Fig 4.2B). AFM imaging of the 
pure RNA complex revealed that the particles do in fact display prismoidal-like 
architecture (Fig 4.2C). AFM is 2D observation of the 3D RNA prism and cannot be used 
to conclusively indicate the formation of the triangular prism geometry, nevertheless, the 
particles do resemble the designed triangular prism in two dimensional projections.   
Cryo-EM imaging studies revealed triangular prism geometry 
To address the concern whether the folding of 8 RNA stands resulted in 3D 
geometry, the purified RNA complex was visualized by single-particle cryo-electron 
microscopy (cryo-EM) (Fig 4.2D, E). Cryo-electron microscopy is a useful method to 
show the true 3D nature of the RNA nanoprisms, as AFM analysis causes distortion of 3D 
nanoparticles imaged in 2D (255). The 3D reconstruction of the RNA nanoparticles was 
achieved implementing single-particle reconstruction using the EMAN2 approach as 
described in the methods section. Reconstruction of the 3D structure of the RNA complex 
were determined at a resolution of 2.5 nm (10 nm RNA prism) and 2.2 nm (5nm RNA 
prism), and demonstrated that the RNA particles have average sizes of 10 nm and 5nm, 
respectively, in agreement with DLS and AFM results. More importantly, the overall 
geometry is similar to computer modeled 3D RNA prisms. It is important to note that the 
reconstruction of the RNA prism by Cryo-EM clearly demonstrates the presence of an inner 
cavity. Collectively, the data from native PAGE, DLS, AFM, and Cryo-EM clearly indicate 
the formation of closed and compact RNA nanoprisms.  
Design and construction of RNA aptamer encapsulated nanoparticle  
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The MGA is a commonly used tool in biochemistry for structure-function 
verification (50,103,153). This is attributed to its unique properties as free MG dye in 
solution displays little to no fluorescent signal, yet when bound to MGA the photoemission 
increases more than 2000-fold (211,256). However, fluorescence can only occur if the 
RNA MGA folds into its authentic 3D conformation. Previous attempts to achieve 
fluorescence using 2’F modified RNA bases resulted in little to no fluorescence (201). 
Therefore, for RNA MGA to remain a useful tool within a cellular environment, it must be 
placed into a container that will protect the RNA. This is a common problem among many 
small RNAs and small molecule drugs with therapeutic utility. Using 2’F modified RNA 
to construct the prism’s frame (2’-fluoro uridine (2’F-U) and 2’-fluoro cytosine (2’F-C)), 
which are known to display resistance to a degrading environment (150), we hypothesize 
that the RNA MGA will be protected when positioned inside the 2’F modified nanocage. 
As a proof-of-principle, we employed the MGA RNA sequence by embedding it 
within the "D" and "d’" strands at their 3' ends. Throughout this chapter, we refer to the 
stable RNA complex formed by six 2’F modified RNA strands without D or d' strands as 
a "frame". It was interesting to find that this complex is highly stable with apparent melting 
temperature (TM) of 74 °C, with the assembly efficiency being Mg
2+ dependent (Fig A.3.2).  
Using SwissPDB Viewer, we first modeled the complex structure of the RNA 
nanocage with encapsulated MGA by positioning the 3D structure of the MGA inside the 
inner cavity formed by the Nanoprism. This allowed us to estimate the distance constraint 
in base pairs required to mount the RNA MGA (extracted from PDB ID: 1F1T (212)) into 
the inner cavity of the prism. The complexation of the RNA MGA within the nanocage 
was evaluated on native PAGE (Fig 4.3). The apparent gel shift of the band localized in 
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lane 4 (2’F-RNA frame with MGA) compared to lane 1 (2’F-RNA frame only) shows 
complexation of the MGA sequences with the frame structure detected by total RNA stain 
with Ethidium Bromide (EB). Staining of the same gel in the presence of MG dye resulted 
in strong fluorescence emission from the distinct band on lane 4, indicating correct folding 
of the RNA MGA (Fig 4.3). We performed additional control experiments based on 
migration properties of the closed (compact) and open (relaxed) 3D RNA complexes as it 
is generally accepted that more compact RNA structures migrate faster in comparison to 
relaxed RNA conformations. To fabricate the open 3D prism conformation, the interaction 
of one of the complementary sticky ends linking two RNA triangles together were 
intentionally disrupted though sequence design. Comparing migration of the open RNA 
prism to the closed version revealed slight differences in migration distance (Fig 4.3: 
Lanes 4 and 5, Fig A.3.3). This indicates that the prism is closed and that the MGA was 
located, presumably, within the inner cavity of the nanocage. Data obtained from the 
mobility shift assay alone do not provide a concrete conclusion whether the RNA MGA 
formed inside of the closed cage; additional data supporting our assumption comes from 
RNase T1 cleavage experiments as described below. 
RNase T1 protection assay confirmed the encapsulation of the MG RNA aptamer by the 
nanocage 
Encapsulation of an RNA module inside the negatively charged RNA nanoprism is 
challenging due to the repulsion forces caused by the negatively charged phosphodiester 
backbone of both the inner cavity of the RNA cage and the RNA MGA. Development of a 
method to overcome this challenge would be exceptionally beneficial as the activity of 
functional RNA modules could be retained by protecting them from enzymatic degradation 
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in vivo. To further confirm that the RNA MGA was localized inside the cavity of the 
nanocage, we treated the RNA complex with endonuclease RNase T1, which specifically 
cleaves unpaired guanosine (Gs) nucleotides (257). While the single stranded Gs are absent 
from the 2’F-RNA prismoidal construct, there are several ss Gs present in the RNA MGA 
itself that are essential for MG binding. Thus, we hypothesize that RNase T1 will cleave 
the exposed Gs of the MGA sequence resulting in the loss of fluorescence. However, if the 
cage were to restrict RNase T1 access to the MG aptamer within the nanoprism, 
fluorescence emission would be retained or decay at a slower rate.  
According to the modeled 3D structure of the prism, the estimated average 
dimensions of the inner cavity of the prism could accommodate a spherical object of about 
6 nm. The average size of the RNase T1 structure was measured (PDB ID: 1YGW) to be  
3.7 nm in diameter (258) (Fig 4.4) allowing RNase T1 to easily access the inner cavity and 
quench the fluorescence of the MGA. To address this obstacle, a nanoprism having a 
smaller cavity size of 3 nm was designed by decreasing the length of the RNA prism helical 
regions by one half. The schematic design of the experiment is summarized in Figure 4.5B. 
The smaller prism is expected to insulate the MGA from RNase T1 cleavage, thus 
extending fluorescence activity.   
The assembly of the small prism is highly efficient, and RNA MGA is functional 
according to native PAGE analysis (Fig 4.5C: Lanes 1 and 2). Next, we carried out time-
dependent MG fluorescence decay in the presence of RNase T1 to test the activity of the 
MGA embedded inside the large and small nanoprisms. Figure 4.5D shows the 
fluorescence decay profiles of the large (black squares) and small (red circles) nanoprisms. 
The calculated lifetimes () were found to be 445.5 sec and 781.4 seconds (s) for the large 
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and small nanoprisms respectively. The small prism displayed a half-life almost double 
that of the large prism, suggesting that RNase T1 has limited access to MGA encapsulated 
inside of the small nanoprism. Complete protection against RNase T1 has not been 
observed presumably due to the dynamic nature of the interacting linker arms of two 
triangles. This is also supported by AFM images where fractions of prisms are in an open 
state, which allows RNase T1 to digest the MGA. Notably, fluorescence emission of the 
small prism was still observed after 1 hour of incubation with RNase T1 while fluorescence 
in the large prism was negligible (Fig 4.5E). Additional control experiments were 
performed using a variety of other RNA control complexes containing RNA MGA. The 
calculated values of  are summarized in Table 4.1. Mean lifetime comparison of the small 
RNA prism to the controls demonstrates that no control construct has greater  than the 
small prism. Thus, the RNase T1 cleavage assay indicates the successful encapsulation of 
MGA encapsulated in both the small and large nanocages. More importantly, we have 
shown that by tuning the size of the inner cavity, fluorescence half-life can be significantly 
increased. This is synonymous with increasing the release time of a drug that can be 
potentially used an in vivo system. 
Encapsulation of oligonucleotide-drug conjugates inside the nanocage 
Taking advantage of the programmability of the D and d’ prism strands, we next 
demonstrated the encapsulation of single stranded oligodeoxynucleotides (ssODN) 
containing functional moieties such as fluorescence reporters and drugs. To this end, one 
long ssRNA was designed to connect D and d’ strands through a 22 nt linker. The resulting 
RNA sequence will be referred as a “core” RNA strand. While the 5’- and 3’-ends of the 
core RNA strand interact with the triangular edges of the prism, its single stranded middle 
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region is designed to localize inside the nanocage. The portion of the core strand inside the 
prism was utilized for encapsulation of either ssDNA or ssRNA carrying different 
functional groups via base pair hybridizations (Fig 4.6A). Hence, we anticipate that the 
encapsulation of the functional moieties will prevent them from enzymatic degradation and 
increase their cellular life-time. Alternatively, this principle can be applied as a safety 
mechanism. For instance, carrying highly toxic compounds that should be released only 
upon reaching its target. 
Due to the programmable nature of the RNA prism, the size of the nano-container 
can be adjusted by simply increasing or decreasing the sides of the prism by complete 
helical turns as shown previously (150,228). This is advantageous as the capacity of the 
RNA nano-container can be controlled enabling encapsulation of diverse size biomolecules 
or inorganic nanoparticles, as well as increase the payload of a single nano-container for 
increased detection sensitivity and increased efficacy in the treatment of disease. Moreover, 
from a medical point of view, size alternation of the nano-prism imparts differences in 
toxicity, cellular binding and internalization, renal clearance, physicochemical features, as 
well as pharmacokinetic and biodistribution profiles. As such, the prismoidal nano-
container provides a unique system to further exploit these factors. 
The principle behind chemical drug encapsulation relies on the conjugation of a 
drug at the 3'/5'-end or at both ends of DNA /RNA oligonucleotides, followed by 
hybridization of this conjugate inside the cavity of the RNA nanoprism. To demonstrate 
this in practice, short DNA sequences (22nt) labeled at the 5’-end with different chemicals 
including folic acid (FA), cyclodextrin, taxol, Cy5 fluorophore, and biotin. To verify the 
formation of the RNA nanoparticle with the conjugated DNA sequence, prism strands and 
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corresponding DNA oligonucleotides were assembled in one-pot by mixing at equimolar 
concentrations, followed by native PAGE analysis (Fig 4.6B). Formation of distinct bands 
corresponding to the frame structure and frame containing the core RNA sequence are 
shown in Figure 4.6, lanes 1 and 2, respectively. The additional lanes correspond to loaded 
nanocage with the 22nt DNA containing a variety of small molecules. Based on the slower 
rate and almost identical distance of all five loaded cargoes as compared to the bands in 
lanes 1 and 2, we can conclude that the conjugated ssDNA were successfully hybridized 
inside the nanocage structure. Additionally, co-migration of Cy5 and EB signal of Cy5 
loaded nanocage indicates correct assembly.  
To demonstrate incorporation and function of the DNA-biotin conjugate within the 
RNA 3D cage, biotin-streptavidin binding was utilized (259) (Fig 4.6C). To separately 
visualize the biotin-nanoprism and the streptavidin, the DNA-biotin conjugate was tagged 
with Cy5 and the streptavidin with Cy3. The ensuing gel shift assay demonstrated 
complexation between the encapsulated biotin and streptavidin as the complex migrates 
much slower than the biotin-nanoprism or streptavidin alone (Fig 4.6C: Lane 1 vs Lane 2 
and 5). Co-localization of EB (RNA), Cy3 (streptavidin), and Cy5 (DNA-biotin) signals 
in the distinct band in lane 1 reveals the functional properties of the encapsulated molecule 
(Fig 4.6C). Although PAGE results cannot directly confirm whether the functionalities 
were located inside the nanocage, results based on computer modeling and fluorescence 
functional assays are a strong indication of the encapsulation mechanism. Utilizing the 
programmability of RNA D and d’ strands as well as modularity of the ssDNA-drug 
conjugates we were able to demonstrate feasibility of the encapsulation approach, in 
addition to RNA MGA aptamer encapsulation, for caging of small molecules and proteins. 
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Varying RNA Chemical Modifications Allows Control over Nanoprism Serum Stability 
and Drug Release 
One potential advantage of RNA 3D nanocontainers is the ability to safely deliver 
and release encapsulated drugs in a fine-tunable fashion. Development of controlled release 
is extremely challenging yet highly desirable in RNA nanotechnology (90). To release the 
encapsulated drug(s), one approach is to use the help of naturally occurring nucleases 
to break down RNA 3D nanoscaffold. It was our hypothesis that changing the percentage 
of 2’F nucleotides in the nanoprism scaffold would result in diverse degradation profiles. 
To change the amount of 2’F nucleotides in the nanoprisms, the ratio of 2’F cytidine 
triphosphate (CTP) and uridine triphosphate (UTP) nucleotides to unmodified CTP and 
UTP were adjusted during in vitro transcription reactions to 4:0, 3:1, 2:2, 1:3, and 0:4, 
respectively. After transcription and purification, five different nanoprisms were 
assembled with 2’F-C/U modifications of approximately 100%, 75%, 50%, 25%, and 0%. 
The degradation profiles of each nanoprism were observed over the course of one hour in 
2% fetal bovine serum (FBS) solution at a final concentration of 200 nM and analyzed on 
3% agarose gel (Fig 4.7A). Gel band intensity was integrated using ImageJ software and 
intensity at each time point was compared to initial gel band intensity for each individual 
nanoprism (Fig 4.7B). As shown by the time course plot, decreasing the percentage of 2’F 
nucleotides increases the digestion rate of the nanoprism scaffold. This approach shows 
feasibility of controlled drug release by degradation of the partially 2’F modified nano-
container, which can be fine-tuned to the scale of minutes. 
In vitro cell binding studies revealed high binding affinity to cancer cells by RNA 
nanocage carrying ssDNA-Cy5. 
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The ability of the RNA nano-container to successfully bind and deliver drugs or 
reporter molecules into cancer cells would tremendously benefit the advancement of 
nanomedicine. To investigate whether the RNA nanocage can serve as a container to 
deliver small molecules, the 2’F RNA frame structure was decorated with 5 copies of DNA 
oligonucleotide-folate conjugates and 1 copy of DNA-Cy5, as shown in Figure 4.8 
(Assembly in Fig A.3.4). Folate-containing nanoconstructs are known to have a strong 
affinity to cancer cells of epithelial origin as these types of cancer cells overexpress folate-
binding protein receptors (260). After incubation of the folate functionalized RNA 
nanoprism with KB cells, strong binding of the RNA complex with the cells was observed 
(Fig 4.8A) in comparison to control complex having the same RNA 3D nanostructure but 
lacking folate molecules. This result demonstrates applicability of the 3D RNA system for 
detection and delivery of the reporter molecules.  
CONCLUSIONS: 
The proof-of-concept for a technique to construct 3D RNA nanocontainers to 
encapsulate small RNA molecules and a method for loading the nanocontainers with model 
drugs was demonstrated. The assembly of RNA triangular nanoprism utilizes pRNA 3WJ 
motifs positioned at the prism vertices, imparting stability into the system and allowing for 
future in vivo delivery.  Loading the container with model drugs (MG) was accomplished 
via diffusion of the model drug into the container with subsequent immobilization by RNA 
receptors (MGA) pre-encapsulated within the nanoprism. The concept of RNA aptamer 
encapsulation is a promising platform for exploring new applications in pharmaceutical 
and materials science. The RNA-directed triangular prism brings together the functionality, 
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biocompatibility, and self-assembly potential with fine control of geometry, positioning, 
and the responsive characteristic of RNA nanoparticles. 
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Table 4.1. Fluorescence half-lives of prism constructs and control constructs. a The 
analysis of the electrophoretic migration of controls 2 and 3 are shown in Figure A.3.4. 
b.The standard error of the mean was obtained from three independent experiments. 
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Figure 4.1. Triangular Nanoprism design and 3D model structure. (A) Fabrication of 
the triangle nanoprism from two planar equilateral RNA triangles. The triangle prism 
nanostructure forms by hybridization of the flexible 21 nt ssRNA “linkers” of each triangle. 
The overall prismoidal construct contains the preserved geometry of the pRNA 3WJ 
structural building block. (B) Computer model structure of the triangular nanoprism 
demonstrating its average dimension in 3D space. 
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Figure 4.2. RNA Triangular nanoprism self-assembly and characterization. (A) 
Assembly efficiency of the RNA triangle nanoprism complex evaluated by 6% native 
polyacrylamide gel electrophoresis (PAGE).  Step-wise association of the 8 RNA strands 
(0.5 µM each) into the final complex was conducted in 1 X TMS buffer using one-pot 
assembly. (B) Typical dynamic light scattering (DLS) data demonstrating average 
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hydrodynamic diameter of the prism.  (C) Atomic force microscopy (AFM) images of the 
triangle nanoprism (5 nM) taken in air. (D) CryoEM image of the large (10 nm) triangular 
RNA prism. Each white box indicates an individual RNA complex. Class averages of RNA 
nanoprisms as observed by cryo-EM. Reconstructed three-dimensional nanoprism at 2.5 
nm resolution. (E) CryoEM image of the small (5 nm) triangular RNA prism. Each white 
box indicates an individual RNA complex. Class averages of RNA nanoprisms as observed 
by cryo-EM. Reconstructed three-dimensional nanoprism at 2.2 nm resolution. 
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Figure 4.3. Assembly of triangular prism and MG fluorescence assay. Fluorescence 
emission in lane 4, and faster migration than in lane 5, indicates the formation of compact 
triangular nanoprisms with encapsulated MG aptamer. 
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Figure 4.4. Swiss PDB viewer was used to fit RNase T1 inside the designed 3D nanoprism. 
The inner cavity of the large prism will fit RNase T1 inside, allowing digestion of the MG 
aptamer. RNase T1 cannot fit inside the small prism, enhancing the fluorescence half-life 
of MG. 
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Figure 4.5. Encapsulation of the RNA MGA and fluorescence assay. (A) Schematic 
design approach for the RNA MGA encapsulation. The RNA MGA sequence is embedded 
within the 3’-end of D and d’ strands. Upon hybridization MGA folds into native 
conformation. (B) Schematic representation of the RNase T1 protection experiment 
demonstrating the relative dimensions of RNase T1 and nanoprisms. (C) Assembly 
efficiency and relative migration of the triangle prisms on native 6% PAGE. The smaller 
RNA prism migrates much faster compared to the regular prism and emits fluorescence 
signal indicating proper folding of the functional RNA complex. Lane “L” is 100 bp DNA 
ladder (Thermo Scientific). (D) Time-dependent fluorescence emission profile of the 0.1 
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µM RNA MGA aptamer in the presence of 500U of RNase T1 and its absence (control). 
(E) The remaining fluorescence signal of the triangle prisms after one hour of RNase T1 
treatment.  
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Figure 4.6. (A) Schematic of ssDNA and ssRNA oligonucleotides with functional modules 
encapsulation inside of the triangular nanoprism. (B) Assembly of encapsulated functional 
modules conjugated to ssRNA and ssDNA oligonucleotides. (C) Encapsulation and 
functional assays of streptavidin encapsulation inside the triangular nanoprism. 
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Figure 4.7. Tuning degradation profile of nanoprism in fetal bovine serum. (A) Gel 
images of nanoprisms with different percentages of 2’F modified pyrimidines used during 
assembly. Nanoprisms of 200 nM concentration were incubated in 2% FBS solution and 
analyzed by 3% agarose gel. (B) Prism relative gel band intensity plotted versus time. The 
intensity of each band was normalized to the zero time point for each nanoprism. 
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Figure 4.8. Evaluation of the RNA triangle prism to carry functional moieties. 
Confocal microscopy images of KB cells incubated with RNA nanoprism decorated with 
5 folates as targeting modules.  
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Chapter 5: Large-scale In Vitro Synthesis and Purification of RNA 
Nanoparticles using Rolling Circle Transcription (RCT) 
 
Chapter 5 was reproduced (with some modification) with permission from Jasinski, 
DL; and Guo, P. “Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle 
Transcription of Fully Double Stranded Circular DNA.” Currently under submission and 
Jasinski, DL; Schwartz, CT; Haque, F; and Guo, P. “Large scale purification of RNA 
nanoparticles by preparative ultracentrifugation.” Methods in Molecular Biology. 2015. 
1297, 67-82. DOI: 10.1007/978-1-4939-2562-9_5. 
 
Chapter 5.1: Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle 
Transcription of Fully Double Stranded Circular DNA 
INTRODUCTION: 
RNA nanotechnology is an emerging field that has grown in complexity and 
diversity, as RNA is an attractive material to construct nanostructures with defined physical 
properties (38,90,126,261-263). Many apparent issues of RNA instability were overcome 
to achieve a nanoparticle platform with potential for treatment of disease, especially cancer 
(62-64,90). Targeting aptamers and functional RNAs such as siRNA, miRNA, ribozymes, 
and riboswitches are available to construct diverse multi-functional nanoparticles. 
Development of RNA nanotechnology has been accelerated by the finding of an unusually 
stable three-way junction (3WJ) RNA motif from the packaging RNA (pRNA) of the phi29 
DNA packaging motor (55). The 3WJ has been used for targeted delivery of therapeutic 
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modalities to multiple cancer types and has been used as a scaffold for the construction of 
RNA nanoparticles with controllable size and shape (56,60,103,148,150,264-266). 
In a lab setting, RNA is most commonly synthesized by two methods: in vitro run-
off transcription and chemical synthesis. While useful and widespread, both methods have 
their limitations. Chemical synthesis is hindered by limits on length and low RNA coupling 
efficiency while in vitro run-off transcription is limited by yield and time efficiency due to 
delayed RNA polymerase binding and initiation (219,267-269). 
Isothermal amplification of nucleic acids, rolling circle amplification (RCA) for 
DNA and rolling circle transcription (RCT) for RNA, are gaining popularity due to the 
simplified processes for amplification and the unique capabilities of RCA and RCT 
(125,270,271). Isothermal reactions can be carried out in conjunction with other biological 
processes or in the presence of sensitive enzymes that would otherwise be destroyed by 
heating during thermocycling. Sensitive detection systems using padlock probes and 
fluorescent nucleic acid sequences have also been used for the detection of antigens or 
nucleic acids such as mRNA or miRNA (272,273). 
 RCT is especially useful as there are many functional RNA motifs, such as 
aptamers, miRNA, siRNA, and ribozymes that can be continually synthesized in a normal 
RCT reaction. Short single stranded (ss) circular DNAs encoding for ribozymes that self-
process into unit length functional ribozymes have been synthesized. These ribozymes 
show biological functionality in trans, cleaving HIV-1 RNA targets (274,275). RCT has 
been used to synthesize siRNA loaded microsponges that show successful gene knockdown 
in vivo (38,270,276). Showing the versatility of RCT, nanowires (277), millimeter sized 
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RNA membranes (278), mRNA nanoparticles (279), and tandem repeats of fluorogenic 
RNA aptamers have all been synthesized (280). 
While functional RNA motifs are useful in therapeutic settings, RNA biology could 
be implemented to produce defined RNA oligomers during RCT by, for example, using 
self-cleaving ribozymes (281-283). Previous methods to create defined RNA oligomers 
include the use of ssDNA oligomers and RNAseH during RCT, allowing site-specific 
cleavage (284). Encoding for a self-cleaving ribozyme in the DNA template for RCT will 
allow simpler experimental processes and more widespread application. Additionally, in 
vivo expression of specific RNA oligomers and RNA nanoparticles could be possible. 
Increased use of nucleic acids in nanoparticle applications necessitates the 
development of high yield synthesis methods other than those available today. RCT’s 
increased transcription efficiency over traditional run-off transcription could help to 
increase the production yield of RNA oligomers and RNA nanoparticles (125). In vitro 
transcription is not limited by length and one-strand or multi-strand nanoparticle assembly 
can occur co-transcriptionally, which has been shown to increase assembly efficiency 
(191,285).  
However, traditional methods of circular DNA preparation for RCT are not 
amenable for DNA templates displaying stable secondary structure. Bacterial RNA 
polymerases are sensitive to secondary structure, falling off template DNA when 
encountering stable DNA hairpins and loops (125,274,286). Ribozymes have a stable 
secondary structure and when combined in the same ssDNA template as an RNA 
nanoparticle sequence, the ∆G of the DNA template is quite low. For successful 
transcription of a circular DNA encoding for self-cleaving ribozymes and nanoparticle 
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sequences, it was necessary to develop a new method for the construction of short circular 
dsDNA for transcription to process in an RCT reaction. While other short dsDNA 
molecules have been constructed through click chemistry, we questioned if disturbing the 
phosphate backbone could cause polymerase stalling and dissociation (287). 
Herein, we describe a method for the construction of short circular dsDNA 
templates that code for self-cleaving ribozymes and RNA oligomers or RNA nanoparticles. 
Upon in vitro transcription, the ribozymes self-cleave with high efficiency, producing large 
amounts of target RNA. The phi29 pRNA 3WJ was assembled from its three component 
strands both co-transcriptionally and by self-assembly after RNA oligomer purification. 
Also, single strand RNA nanoparticles were synthesized via RCT by addition of loops to 
link adjacent 3WJ strands. The malachite green fluorogenic RNA aptamer (MGA) was 
fused to one helix of the 3WJ and malachite green dye (MG) fluorescence was observed in 
real time during in vitro transcription. SYBR GreenII fluorescence, a dsRNA specific 
fluorophore that fluoresces only upon binding to RNA, was also used to monitor 
transcription in real time. Fluorescent signals from transcription reactions using circular 
dsDNA were 8-10 times higher compared to identical sequences in linear dsDNA, 
indicative of the increased efficiency of the RCT reaction. 
MATERIALS AND METHODS: 
Sequence Design 
 Sequences for target oligomers were derived from the pRNA-3WJ nanoparticle as 
reported previously (55). Additional nucleotides were added to the 5’ and 3’ ends of the 
native 3WJ sequences, 5’-GAC-3’ and 5’-GUC-3’ respectively, aiding in ribozyme 
stability and cleavage efficiency. For the synthesis of single stranded RNA nanoparticles, 
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loops (5’-GAGA-3’) were used to join adjacent 5’ and 3’ ends of the multi-strand RNA 
nanoparticles. Ribozyme sequences were adapted from previously solved structures of the 
hammerhead ribozyme (283). For ribozyme efficiency assays, ribozyme sequences were 
mutated to abolish activity as previously described (283). The malachite green aptamer 
sequence was adapted from previously published sequences (212). All sequences are 
summarized in Table A.4.1. 
DNA and RNA Preparation 
RNA oligomers were prepared in vitro using T7 RNA polymerase from linear and 
circular dsDNA containing the T7 promoter. Linear dsDNA was prepared by PCR using 
ssDNA primers purchased from Integrated DNA Technologies (IDT). Circular dsDNA was 
prepared from ultramer oligomers purchased from IDT. The assembly method of circular 
dsDNA is detailed in Figure 5.1. ssDNA anti-sense to the RNA strand (including T7 
promoter, ribozymes, and target RNA) was self-cyclized intramolecularly using Epicentre 
CircLigase following the manufacturer’s protocol. Remaining linear ssDNA was removed 
by addition of DNA Exonuclease I. ssDNA complementary to the cyclized ssDNA was 
annealed by thermal denaturation at 85°C for five minutes followed by slow cooling to 4°C 
at over one hour at 4 µM concentration. Following annealing, T4 DNA ligase closed the 
nick in the circular dsDNA. Ligations were performed at a DNA concentration of 2.5 µM 
in 1 X DNA ligase buffer, 5% (w/v) PEG4000, and a ligase concentration of 0.25 U/µL. 
The ligation mixture was incubated at 25°C for 4 hours followed by heating at 65°C to heat 
denature the enzyme. Control constructs without T4 ligation were also assembled.  
Gel Analysis and Quantification 
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Assembly of linear and circular dsDNA constructs and RNA products was 
confirmed using 10% (29:1) PAGE in a buffer containing 50 mM TRIS, 100 mM NaCl, 
and 5 mM EDTA, and DNA or RNA was stained using ethidium bromide (EB) solution or 
MG dye solution (final concentration of 5 M MG Dye, HEPES pH=7.4, 100 mM KCl, 5 
mM MgCl2).  
Ribozyme Cleavage Efficiency 
 Time course experiments were run to analyze ribozyme cleavage efficiency. A 
typical transcription reaction was quenched at specific time points by addition of DNase. 
Equal aliquots of each time point were then analyzed on PAGE and gel band intensity was 
integrated using ImageJ software (169). Cleavage efficiency was calculated by dividing 
band intensity of the cleaved fractions by total band intensity per lane. Cleavage percentage 
versus time was then plotted using OriginPro.  
Gel Analysis of Transcription Kinetics 
 dsDNA constructs, both linear and circular, were transcribed following typical T7 
in vitro transcription protocols with a 250 nM final DNA concentration. At 0.5, 1, 2, and 4 
hours, transcription reactions were stopped using DNase. Equal aliquots of transcription 
from each time point were analyzed on PAGE and target RNA bands were integrated using 
ImageJ software. Gels were stained separately for total RNA (EB) and MG fluorescence. 
Gel band intensity versus time was then plotted using OriginPro. Gel assays were carried 
out in triplicate with standard deviations indicated by error bars. 
Fluorescence Monitoring of RNA Transcription 
 To monitor transcription in real time, MG dye or SYBR GreenII were added at a 
final concentration of 5 µM to transcription reactions. Solutions were incubated at 37°C in 
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96 well plates and fluorescent signal was monitored every 15 minutes using a BioTek 
Synergy 4 Microplate Reader. MG signal was read from excitation and emission 
wavelengths of 590 nm and 630 nm, respectively. SYBR GreenII fluorescence was read 
from excitation and emission wavelengths of 496 nm and 520 nm, respectively. OriginPro 
was used to plot fluorescent signal versus time. Transcription analysis was performed at 
DNA concentrations of 10, 100, and 250 nM. 
Large-Scale Purification Using Gel Electrophoresis Column 
 Transcription reactions were purified on a BioRad model 491 Prep Cell using 
continuous-elution gel electrophoresis following the manufacturer’s standard protocol. 20 
mL of 8% polyacrylamide gel were prepared in a buffer containing 50 mM TRIS, 100 mM 
NaCl, and 5 mM EDTA. The gel was polymerized and to a column height of 5.5 
centimeters and pre-run at 300 V for 1 hour. Large-scale, 1 mL transcriptions with final 
DNA concentration of 250 nM, transcriptions were diluted to 2 mL with 2X gel loading 
dye and loaded onto the column. After two hours of electrophoresis at 300 V, fractions 
were collected at a rate of .25 mL/min for 4 minutes for a total fraction volume of 1 mL. A 
total of 60 fractions were collected for four hours. Fractions were analyzed by adding 20 
µL of 10 X MG binding buffer (final concentration of 5 M MG Dye, HEPES pH=7.4, 
100 mM KCl, 5 mM MgCl2) to 180 µL of each fraction. Fluorescence was analyzed as 
described previously. RNA concentrations were measured by reading absorbance at 260 
nm. 
RESULTS: 
Sequence Design and Ribozyme Optimization Using Linear dsDNA 
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Due to the processive nature of RCT, long RNA concatamers are the result, unless 
a strategy is devised to reduce the products into defined oligomers. In our case, the goal 
was to produce short RNA oligomers that would then then fold into higher order RNA 
nanoparticles. Thus, self-cleaving ribozymes were incorporated into the sequences to 
cleave the RNA during transcription, resulting in short RNA oligomers. However, as it was 
necessary to optimize ribozyme sequence to obtain high cleavage efficiency, sequences 
were first optimized using traditional run-off transcription of linear dsDNA templates. 
These sequences were then used in the circular constructs, as described in a later section. 
Linear dsDNA containing the T7 RNA polymerase promoter sequence, self-
cleaving ribozymes 5’ and 3’ of the target RNA sequence, and the target RNA sequence 
were designed and constructed using PCR (sequence layout in Fig 5.1). The initial goal 
was the assembly of the pRNA-3WJ, as it is well characterized in our lab. Therefore, the 
target RNA sequences for ribozyme optimization were 3WJ-a, 3WJ-b, and 3WJ-c (55). 
Hammerhead ribozyme sequences were chosen as they are well characterized and display 
high cleavage efficiency (281,283,288,289). Ribozyme sequence optimization was carried 
out experimentally by gel analysis using linear dsDNA. While active site bases of the 
ribozyme sequence must be conserved to maintain cleavage, non-active site duplex 
sequences can be modified, aiding in self-cleavage optimization (281,283).  
Size controls were transcribed to represent the possibilities of RNA transcript 
length with and without cleavage. Failed 5’ and 3’ ribozyme cleavage, failed 5’ ribozyme 
cleavage only, failed 3’ ribozyme cleavage only, and ribozyme only were used as RNA 
size controls (Fig A.4.1A). Ribozyme activity was abolished in RNA size controls by 
sequence mutation (283) to maintain identical sequences in RNA size controls. Target 
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RNA strands were chemically synthesized as size and assembly controls. Cleavage 
efficiency was calculated by comparing target RNA band intensity to total band intensity 
per lane over two-hour time course experiments (Fig A.4.1B). ImageJ software was used 
to integrate the gel band intensity. Cleavage kinetics assays were done using truncated 
versions of the dsDNA. For example, 5’ ribozyme efficiency was assayed using dsDNA 
template with no 3’ ribozyme. The cleavage efficiency of each ribozyme, 5’ and 3’ of the 
target RNA, was calculated independently. Kinetics of full length constructs with 
ribozymes 5’ and 3’ of the target RNA were also assayed (Fig A.4.1B). 
The first iteration of ribozyme sequences contained a two base-pair (bp) “closing” 
duplex resulting in cleavage efficiencies ranging from 36% - 65% cleavage. Upon 
lengthening the “closing duplex” to five bp (Fig A.4.1C), to increase the stability of the 
ribozyme sequence, cleavage efficiencies increased to 65% - 78%. When full length 
constructs with both active ribozymes were tested, cleavage efficiencies were more than 
80% (Tbl A.4.2). 
Circular dsDNA Construction and RCT Reaction 
 Circular and fully double stranded DNA templates were prepared for the RCT 
reaction (Fig 5.1). Ribozyme sequences used in circular dsDNA were identical to those 
optimized previously using linear dsDNA. First, phosphorylated ssDNA complimentary to 
the T7 polymerase promoter, 5’ and 3’ ribozymes, and target RNA sequences was self-
ligated intramoleculary using Epicentre ssDNA Circ Ligase to form circular ssDNA. To 
confirm cyclization, non-denaturing polyacrylamide gel electrophoresis (PAGE) was used 
to visualize DNA bands before and after ssCirc ligation (Fig 5.2A). Upon self-cyclization, 
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an increase in migration rate is seen presumably due to the compact structure of the now 
self-folded ssDNA. 
 To form circular dsDNA, the cyclized ssDNA and phosphorylated ssDNA 
compliment were mixed in equimolar concentrations. ssDNA strands were thermally 
denatured at 85°C for five minutes to remove any secondary structure, and then cooled to 
4°C over one hour. Assembly of the compliment strands was confirmed using PAGE 
analysis. Assembly of the compliment strands resulted in a dramatic decrease in migration 
rate, indicating successful hybridization (Fig 5.2A). Importantly, compared to linear 
dsDNA controls, circular dsDNA migrates much slower, indicating circular conformation. 
After assembly, T4 DNA ligase was used to ligate the nicked circular dsDNA (Fig 5.2A). 
No apparent shift is observed by gel analysis after T4 ligation. Successful T4 ligation can 
be confirmed using in vitro transcription. 
To prove RCT was occurring, ribozyme activity was abolished by sequence 
mutation on one circular dsDNA construct (Fig 5.2B) (283). No ribozyme activity will 
result in template length RNA using linear dsDNA template and long concatemeric RNA 
using circular dsDNA template. The target RNA sequence in this assay was 3WJ-a for both 
active and inactive ribozyme constructs. After in vitro transcription and termination by 
DNase, denaturing PAGE analysis was used to analyze RNA transcripts (Fig 5.2B). 
Significant accumulation of long RNA transcripts is seen from the RCT reaction (Fig 5.2B, 
Lane 5) compared to transcription of both the linear dsDNA template (Fig 5.2B, Lane 3) 
and the nicked circular dsDNA template (Fig 5.2B, Lane 4), indicating successful 
construction of circular dsDNA and successful RCT reaction. When ribozyme activity was 
restored, successful cleavage and release of target RNA strand was observed (Fig 5.2B, 
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Lanes 6-8), evidenced by the appearance of short RNA transcripts not seen in inactivated 
ribozyme constructs. Assembly confirmation of all circular dsDNA constructs is shown in 
Figure A.4.2. 
Co-Transcriptional Assembly of 3WJ Nanoparticles 
RNA nanoparticles have the unique ability to self-assemble co-transcriptionally, as 
they are being transcribed, under isothermal conditions (191,285). To assemble the pRNA 
3WJ co-transcriptionally, 3WJ-b and 3WJ-c were incorporated into separate circular 
dsDNA constructs. The transcription of both 3WJ-b and 3WJ-c constructs were confirmed 
using PAGE analysis. Both constructs demonstrated correct cleavage and release of their 
target RNA in both linear and circular form (Fig 5.2C, red box). Compared to linear 
dsDNA controls, the band patterns of circular dsDNA are identical. Size controls of failed 
transcripts and resulting ribozyme sequences migrate much slower than the target RNA, 
further showing evidence of target RNA release (Fig 5.2C). Additionally, target RNA 
strands are equal in size to that of their chemically synthesized size controls, indicating 
cleavage and release of correct size ssRNA target sequences (Fig A.4.3A). To confirm the 
sequence of released ssRNA was correct, each fragment was isolated by gel purification. 
Assembly of the pRNA-3WJ from the ssRNA fragments isolated from the RCT reactions 
indicates cleavage specificity and target RNA release (Fig A.4.3B). 
pRNA 3WJ nanoparticles were assembled co-transcriptionally by mixing 3WJ-a, 
c, and c dsDNA constructs in an equimolar ratio followed by in vitro transcription. PAGE 
analysis of both linear and circular co-transcription products indicates successful assembly 
of 3WJ nanoparticles when compared to the assembled 3WJ from gel purified RCT product 
(Fig 5.2D). 
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Alternatively, 3WJ nanoparticles were co-transcriptionally assembled from one 
ssRNA oligomer. Circular dsDNA encoding for the full sequence of the pRNA-3WJ, with 
the helix ends closed with loops or aptamer sequences, was constructed (Fig 5.3A). To 
facilitate monitoring of transcription and RNA folding, the MGA was incorporated on one 
of the helix loops (Fig 5.3B). Following transcription, the RCT reaction mixture was 
analyzed by non-denaturing PAGE (Fig 5.3C). Total RNA staining with ethidium bromide 
indicates correct size RNA oligomers compared to the DNA ladder. RCT-3WJ assembled 
from purified 3WJ monomers and one piece 3WJ with loops were used as size controls. 
The one-stranded nanoparticles migrate slower due to increased size from the incorporation 
of loop sequences used to connect helix ends. Additionally, gel staining with MG shows 
binding of the MG-3WJ nanoparticle to its fluorophore, indicating correct sequence and 
folding of the MG-3WJ as the MGA must fold correctly to produce MG fluorescence. No 
MG signal from the 3WJ, which lacks the MGA, indicates specific binding of MG to MGA 
in the MG-3WJ. Higher order concatamers (dimers, trimers, etc.) are present in the RCT 
reactions, indicating that ribozyme cleavage is not 100%. 
Real-Time Monitoring of Transcription by Fluorescence 
 Fusion of the MGA onto the 3WJ allows for monitoring and comparison of 
transcription kinetics between traditional run-off transcription and RCT (Fig 5.4A). Gel 
assays were used to compare the transcription rate of linear and circular dsDNA (Fig 5.4B). 
After in vitro transcription was commenced, DNaseI was added at 0.5, 1, 2, and 4 hours to 
terminate the transcription reaction. After termination, an equal aliquot of transcription 
reaction was analyzed by PAGE. Gels were separately stained for total RNA, ethidium 
bromide (EB), and for MG signal. ImageJ software was used to integrate gel and intensity. 
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The integration results clearly show that RCT generates RNA nanoparticles much faster 
with a higher yield than that of run-off transcription (Fig 5.4C). 
 To monitor transcription rates in real-time, transcription was analyzed using a 
BioTek plate reader monitoring transcription kinetics in a 96-well plate. MGA fluorescence 
was monitored by adding MG dye to a final concentration of 5 M in the transcription 
mixture while total RNA production was monitored by adding SYBR GreenII, an RNA 
specific probe which fluoresces only upon binding to RNA, to a final concentration of 1 X 
to the transcription mixture. Fluorescence measurements were taken every 15 minutes and 
fluorescence intensity was plotted versus time using OrignPro (Fig 5.4D, E). Among three 
different DNA template concentrations of 10(), 100 (), and 250 () nM, the RCT 
reactions (red lines) consistently outperformed run-off transcription (black lines) in both 
nanoparticle production rate and overall transcription yield. Across the three DNA template 
concentrations, RCT produced on average 10 times more RNA at the termination of the 
transcription reaction, consistent with previous findings on the rate of RCT (125,280). 
Interestingly, circular dsDNA template with a nick present, without T4 ligation, is similar 
in transcription rate to linear dsDNA at the same concentration, suggesting that T7 
polymerase does not proceed to RCT with nicked circular dsDNA (Fig 5.4D, E). 
Next, substrate (DNA template) concentration dependent kinetics of total RNA 
transcription was analyzed by comparing SYBR GreenII fluorescence values at different 
time points among different DNA template concentrations (values from Fig 5.4E). Time 
points from 60 – 165 minutes were chosen as these were during and after the highest 
increase of observed fluorescence. Fluorescence values from 10, 100, and 250 nM 
concentrations at each time point were plotted and fit linearly (y = mx + b) (Fig A.4.4A, 
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B). A strong linear correlation is seen between different DNA template concentrations 
relative to their RNA output, represented by SYBR GreenII fluorescence (Fig A.4.4C). 
Interestingly, the slope (x) values for circular DNA template, x average equal to 5.27, are 
much higher than those observed for linear DNA template, x average equal to 1.27. These 
values can be correlated to fluorescence output per nM (RFU/nM) of DNA template. Thus, 
these results support that RCT reaction results in an apparent increase in transcription 
efficiency. At these DNA template concentrations, the relationship appears to be linear. 
However, as biological systems are quite complicated, it is possible that higher DNA 
concentrations could saturate the transcription reaction. 
Large-Scale Purification Post RCT 
 Purification of the MG-3WJ nanoparticles was carried out using a prep-scale 
version of typical gel electrophoresis. The BioRad Model 491 Gel Electrophoresis Prep 
Cell was used to purify large-scale transcription products of RNA nanoparticles transcribed 
from circular dsDNA encoding for the MG-3WJ. Fractions were analyzed for both MG 
fluorescent signal and absorbance at 260 nm (Fig 5.5A). Three distinct peaks were seen by 
MG fluorescence: fractions 5-7 (peak 1), 7-23 (peak 2), and 25-32 (peak 3). PAGE analysis 
was used to determine the identity of each peak compared to crude transcription mixture. 
Each lane was loaded with ~200 ng of RNA sample, based on absorbance at 260 nm. Peak 
1 was smaller in size than the target RNA, peak 2 contained the target RNA, and peak 3 
contained both the target RNA and larger RNA bands. Gel bands were integrated to 
determine purity with peaks 2 and 3 giving averages of 93.6% and 84.2%, respectively. Of 
note is the large absorbance value of the first fractions, which has been attributed to 
remaining nucleotides from the transcription mixture, as no band was seen by gel analysis. 
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DISCUSSION: 
RCT offers many advantages over traditional in vitro transcription methods 
including higher transcription rate (125,280), template DNA economy, and the potential 
for in vivo expression of artificial RNA sequences and RNA nanoparticles (153). The most 
popular method for circular DNA preparation contains a long ssDNA phosphorylated at 
the 5’ end, which is assembled to a splint ssDNA followed by DNA ligation, resulting in 
circular DNA with double stranded promoter region and single stranded regions 
complimentary to the target RNA sequence. Alternatively, ssDNA templates with no 
promoter region can also be transcribed. While this method is amenable for ssDNA 
templates with little secondary structure (∆G of self-folding close to zero or a positive 
value, Tbl A.4.3) (125,275,290,291) or stable dumbbell sequences (38,270,280,292), it 
was not amenable for ssDNA templates encoding for 3WJ based nanoparticles. The ∆G of 
self-folding for the ssDNA templates constructed here range from -11.6 kcal/mol to -27 
kcal/mol (Tbl A.4.3), resulting in stable secondary structures. Transcriptions using current 
methods for preparing circular DNA template were attempted, however the stable 
secondary structure of the sequences hindered transcription, despite successful ligation, 
even in the presence of single stranded binding proteins and elevated transcription 
temperatures at 42°C (data not shown).  
 Therefore, a new method for circular DNA template preparation was conceived 
using dsDNA throughout the entire template DNA. While it well known that RCT 
transcribes much faster than run-off, the real novelty lies in the preparation of dsDNA that 
codes for nanoparticles with stable secondary structure, something that would not have and 
did not work with the traditional DNA preparation method. Removing the issue of stable 
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secondary structure in the DNA template was only possible by making the entire circular 
template double stranded. Making circular dsDNA is a widespread procedure in molecular 
biology with the construction of artificial DNA plasmids, in most cases multiple kilobases 
long, using cloning and other techniques. While the RNA nanoparticle sequence could have 
been cloned directly into a plasmid, complications arise from the inclusion of extra DNA 
such as the origin sequence, antibiotic resistant sequences, among others. Because the goal 
of this method was for in vitro synthesis, these sequences were not necessary and in fact 
would hamper reaction efficiency due to transcription of useless RNA. The most 
straightforward method to make circular dsDNA starting with two long, but identical 
length, phosphorylated ssDNAs, as depicted in Figure 5.1. 
 RCT results in the synthesis of long concatamers of ssRNA due to the progressive 
nature of the polymerase around the circular dsDNA. In this study, RNA oligomers and 
RNA nanoparticles with defined sequences were desired, so a cleavage method was 
devised to release the target RNA sequence from the rest of the transcript. Ribozymes are 
RNA motifs that cleave RNA, and can be engineered to cleave a specific sequence and 
even self-cleave. Their catalytic property was implemented to self-cleave co-
transcriptionally and release specific RNA sequences, in this case those target sequences 
being 3WJ-a, b, and c (Fig 5.2C). This allows a hands-off method for the transcriptional 
production of short and defined RNA oligomers in high yield without the use of additional 
enzymes and will aid in the future scale up of this method for large-scale synthesis of RNA 
nanoparticles in vitro and in vivo.  
 The real power of RCT coupled with release of defined RNA oligomers it the ability 
of RNA nanoparticles to fold co-transcriptionally. As soon as each RNA monomer is 
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released by ribozyme cleavage, it can find its partner sequences in the transcription mixture 
and assemble isothermally into the nanoparticle. This is evidenced by comparison of 
purified monomers assembled into the 3WJ to the co-transcriptional reactions (Fig 5.2D). 
 To increase nanoparticle assembly yield, a second approach was taken to co-
transcriptionally assemble RNA nanoparticles. Alternate to assembling the nanoparticle 
from three individual RNA monomers, loop sequences were used to join the 5’ and 3’ ends 
of adjacent monomers resulting in a nanoparticle from one RNA strand (Fig 5.3A). To 
demonstrate this concept, 3WJ with loops was synthesized as well as 3WJ with one loop 
and the other helix being closed by the malachite green fluorogenic aptamer. Including an 
aptamer in the sequence serves two purposes: (1) monitoring transcription kinetics by 
fluorescence; (2) shows accurate cleavage and correct folding of the RNA nanoparticle, as 
MG will not bind to MGA unless the sequences is correct. A decrease in gel migration 
grate compared to 3WJ assembled form cleaved 3WJ ssRNA “RCT-3WJ” and the 3WJ 
assembled from one RNA piece, “3WJ-Loop,” of the MG-3WJ indicates increased size 
from the addition of the MGA (Fig 5.3C). Both linear and circular constructs show 
identical size. It is important to note that the MG-3WJ from RCT shows upper bands, 
indicating cleavage is not 100%. 
 The advantage to preparing circular dsDNA for transcription is the hypothesis that 
RCT will result in higher amounts of RNA nanoparticles from the same starting DNA 
concentrations, therefore being more efficient and faster in nanoparticle production. To test 
this hypothesis, we performed two methods of transcriptional kinetics monitoring using 
one piece MG-3WJ in linear and circular dsDNA. The first was by gel analysis and band 
intensity comparison. Gel band intensity indicates a much higher rate of transcription and 
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overall RNA production yield, both by total RNA staining and MG staining (Fig 5.4B, C). 
This supports the hypothesis that RCT will result in higher production of RNA 
nanoparticles. The results are also the same for real-time fluorescence monitoring (Fig 
5.4D, E). While the ribozyme cleavage for circular dsDNA is not 100%, gel staining 
represents an accurate comparison of production of RNA nanoparticles as the gel band that 
was quantified was the target RNA nanoparticle. Fluorescence monitoring of the actual 
transcription mixture monitors the entire transcription reaction, including non-cleaved 
RNAs, reflecting slightly less accurate quantification of RNA nanoparticle production 
yield. 
In both cases, a leveling of RNA transcription is observed. We hypothesized that 
buildup of magnesium salts from transcription byproducts or loss of enzyme activity could 
be the cause. To test this, separate transcriptions were performed with the addition of 
inorganic pyrophosphatase enzyme and additional T7 polymerase after two hours of 
transcription. In both cases, the same quenching of transcription occurred (data not shown). 
It is possible that the buildup of significant amounts of RNA in the transcription mixture 
could abolish enzyme activity, due to increased viscosity of the solution. 
Failed ribozyme cleavage during circular transcription leads to long RNA stands, 
which are multimers of the desired RNA product. These impurities are observed by gel 
analysis (Fig 5.4C). It is important to remove unwanted products as nanomedical 
applications require a high degree of product purity. In this application, the most efficient 
method was purification by gel electrophoresis due to somewhat close size of products 
(impurities are as close as only two times larger than desired product). However, typical 
gel set ups are not amenable to large-scale purification due to large sample volumes 
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required for transcription and loss of sample during elution from gels. A continuous elution 
gel electrophoresis apparatus was, therefore, ideal for purification. After purifying of 
transcription samples, a purity of 93.6% was achieved, compared to 44.8% in the crude 
product. 
While this procedure produces native RNA, most applications with RNA 
nanotechnology implement modified nucleotides, such as 2’-fluorine modification to the 
ribose sugar of purines (cytosine and uracil). Modifications increase thermodynamic and 
in vivo stability allowing their use in medical applications. Transcriptions with modified 
nucleotides, using mutant polymerase, were attempted, and while transcription processed 
normally ribozyme cleavage failed resulting in no release of target RNA oligomers. 
Presumably, this is due to the hydrolytic mechanism of ribozyme cleavage, requiring a 2’ 
hydroxyl at the cleavage site (281). The sequence design used contains a cytosine at the 
cleavage site, which contains a fluorine at the 2’ site in modified transcription. This 
sequence was mutated to adenine at the cleavage site and, despite the presence of a 2’ 
hydroxyl, ribozyme cleavage failed (Fig A.4.5). It is apparent that duplex structure is 
extremely important for this ribozyme to maintain activity. Modification of the nucleotides 
to 2’F RNA changes the duplex structure, abolishing ribozyme activity. While this is a 
current challenge in the large-scale production of modified RNA nanoparticles, work is 
underway to find alternate cleavage methods to implement RCT for large-scale synthesis 
using modified nucleotides. Nonetheless, RNA nanoparticles show increased enzymatic 
stability over ssRNA and other endogenous dsRNA due to increased size and their complex 
structure protecting 5’ and 3’ ends from exonucleases. 
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CONCLUSIONS: 
 DNA template used for RCT reactions is generally made up of long ssDNA regions 
with dsDNA in the promoter region for RNA template binding. However, if long stretches 
of ssDNA in the template code for RNA displaying stable structure, such as RNA 
nanoparticles, the ssDNA template will also have stable secondary structure due to the 
complementary mechanism of transcription. Therefore, a new method was devised to 
construct fully double stranded and circular DNA encoding for RNA nanoparticles with 
extremely stable secondary structure. The method for circular dsDNA preparation is 
broadly applicable to the field of RNA nanotechnology as functional nanoparticles, in most 
cases, are stable by nature due to base pairing of complimentary nucleotides within the 
nanoparticle. To release RNA nanoparticles transcribed during RCT, self-cleaving 
ribozymes were coded for in the template allowing release of the target sequence and 
assembly co-transcriptionally. Furthermore, RCT produced eight times as much RNA than 
traditional transcription from dsDNA templates of identical sequence. RNA 
nanotechnology has been emerging as a new drug delivery platform and shows great 
promise to help advance the current state of nanomedicine. The methods introduced here 
allow large-scale production of RNA nanoparticles and will be needed for future clinical 
applications of RNA nanotechnology. As well as large-scale batch synthesis, in vivo 
expression and production of RNA nanoparticles could be possible using the methods 
introduced here, helping to solve the current challenges of scale and cost in RNA 
nanoparticle production. 
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Chapter 5.2: Large-scale Purification of RNA Nanoparticles using Preparative 
Ultracentrifugation 
INTRODUCTION: 
Since the first example of RNA nanotechnology in 1998 (12), RNA has shown to 
be a promising therapeutic delivery system to target cancers, viral infections, and genetic 
diseases (91,293). Recent advances in RNA nanotechnology have led to the construction 
of diverse nanoparticles with varying sizes and structural features 
(50,64,103,105,126,150,152,190). Many of these nanoparticles have the potential for 
imaging, disease diagnosis, and drug and therapeutic RNA delivery (91,293-297). RNA is 
a polymer made up of four different nucleotides: adenine (A), cytosine (C), guanine (G), 
and uracil (U). Much like DNA, RNA can be easily manipulated to form precise structures, 
while at the same time retaining flexibility in structure and diversity in function much like 
proteins (90). 
RNA nanoparticles assemble with high efficiencies; however, fully assembled and 
contamination-free nanocomplexes are required for most in vitro and in vivo applications. 
Besides HPLC, in many cases, purification is performed by polyacrylamide gel 
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electrophoresis (PAGE) or agarose gel electrophoresis (AGE), through which the correctly 
folded structures migrate in a sharp and distinct band and are separated from the faster 
migrating single stranded (ss) RNA and the slower migrating misfolded and aggregate 
structures (105,298). While these methods have proven to be effective, there are downsides 
to using PAGE and AGE. After electrophoresis, the RNA must be extracted from the gel, 
which is labor intensive and often requires an additional purification step to remove 
contaminating gel residue. Also, some nanoparticles do not enter PAGE and AGE gels 
efficiently due to the large branched structures of these complexes. Finally, PAGE and 
AGE lack the scalability needed to purify large quantities of nanostructures. HPLC is often 
used for the purification of chemically synthesized and chemically modified 
oligonucleotides, however HPLC is not conducive to large RNA nanoparticles (299). 
Ultracentrifugation is a useful method for the scalable and efficient purification of RNA 
supramolecular complexes on the large scale (300-302). Here, we describe a scalable, cost-
effective, and contamination-free method to purify RNA synthesized by in vitro 
transcription and supramolecular RNA nanoparticles by preparative ultracentrifugation 
(303-305).  
While analytical ultracentrifugation is used to study molecular interactions, and 
define the properties of the analyte, such as molecular weights, sedimentation coefficient, 
shape, and conformation, preparative ultracentrifugation is primarily used to isolate and 
purify specific particles. There are three main types of preparative ultracentrifugation: 
differential (also known as pelleting), rate-zonal, and density-equilibrium (also known as 
isopycnic). Differential centrifugation separates based on size or molecular weight in a 
process in which successive pelleting steps allows researchers to recover the particle of 
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interest. Rate-zonal centrifugation again resolves particles by size and shape dependent on 
run time but the particle of interest remains isolated in the gradient and is typically 
fractionated and recovered. Equilibrium density centrifugation, however, separates entirely 
on density, independent of run time. In the methods introduced in this chapter, equilibrium 
density and rate zonal gradients are employed. Equilibrium density gradient 
ultracentrifugation is used in the CsCl gradient purification of ssRNA oligomers and rate-
zonal is employed in the sucrose gradient purification of supramolecular RNA 
nanoparticles. 
Post in vitro transcription, RNA is separated from unincorporated nucleotides and 
protein impurities by CsCl equilibrium density gradient ultracentrifugation (Fig 5.6). 
Exploiting the differences in density between proteins, RNA nucleotides, and synthesized 
RNA oligonucleotides enables the large-scale purification of ssRNA, which are then used 
to form multi-strand supramolecular RNA nanoparticles.  
RNA nanoparticles are then constructed from the purified ssRNA oligonucleotides. 
The RNA nanoparticles are purified from misfolded and aggregated complexes and 
unincorporated ssRNA by sucrose gradient rate-zonal ultracentrifugation (Fig 5.7). Post 
centrifugation, fractions are collected and examined on non-denaturing AGE and stained 
with ethidium bromide (EtBr) (Fig 5.8). 
To demonstrate the expected results utilizing this procedure, synthesis and 
purification of RNA nanoparticles utilizing the packaging RNA (pRNA) (306) from the 
phi29 bacteriophage DNA packaging motor was performed. The native pRNA structure 
has previously been engineered to assemble into many nanostructures including dimers, 
trimers, tetramers, hexamers, and larger supramolecular complexes utilizing hand-in-hand 
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and foot-to-foot interactions (12,50,104,105,200). As an example, we show here the 
purification of pRNA monomer and dimer constructs from two distinct pRNA monomers, 
Ab’ and Ba’ (151). Monomers were purified by CsCl equilibrium density gradient 
ultracentrifugation and monomer and dimer constructs were purified by 5-20% sucrose 
gradient rate-zonal ultracentrifugation. The Ab’ and Ba’ pRNA monomers assemble to 
form dimer constructs, a size difference that can be confirmed by traditional native PAGE 
analysis. Despite a size difference of only 120 nucleotides between monomer and dimer, 
the two species can be resolved by sucrose gradient ultracentrifugation. Furthermore, the 
recovered fractions exhibited comparable dimer assembly to RNA nanoparticles purified 
by PAGE (Fig 5.9). 
MATERIALS: 
Prepare all solutions using Millipore water (prepared by purifying deionized water 
to attain a sensitivity of 18.2 MΩ cm-1 at 25°C) that has been incubated at 37°C overnight 
with diethylpyrocarbonate (DEPC) and then autoclaved. All reagents used should be 
analytical grade and RNase and DNase free as RNA is extremely sensitive to RNase 
degradation. All glassware, tubes, and pipette tips used in preparation of reagents and 
buffers should be autoclaved to ensure sterilization. Gloves and lab coats should be worn 
at all times. All waste disposal regulations should be carefully followed. Prepare and store 
reagents at room temperature (RT) unless otherwise noted. 
2.1. For Gradient Preparation 
1) Diethylpyrocarbonate (DEPC) aqueous solution: 0.05% solution in millipore water 
(v/v): Add 5 mL DEPC to 995 mL millipore water and shake the solution vigorously. 
Incubate the solution overnight at 37°C and then autoclave to remove DEPC. 
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2) CsCl Ultracentrifugation Buffer: 1X Tris-EDTA (TE) Buffer (10 mM Tris-HCl, 1 mM 
ethylenediaminetetraacetate (EDTA)). Add about 100 mL water to a 1-L glass beaker 
with a magnetic stir bar (see Note 1). Weigh 1.21 g Tris-HCl, and 0.000292 g EDTA 
(see Note 2) and transfer to the glass beaker. Bring the volume to 900 mL with water 
and then adjust the pH to 8.0 with HCl (see Note 4). Bring the final volume to 1 L and 
autoclave. 
3) Sucrose Ultracentrifugation Buffer: 1X Tris-magnesium saline (TMS) Buffer (50 mM 
Tris-HCl, 100 mM NaCl, and 10 mM MgCl2). Add about 100 mL water to a 1-L glass 
beaker with a magnetic stir bar. Weigh 6.05 g Tris base, 5.844 g sodium chloride, and 
2.03 g MgCl2 hexahydrate and transfer to the glass beaker. Bring the volume to 900 mL 
with water and then adjust the pH to 8.0 with HCl. Bring the final volume to 1 L and 
autoclave. 
4) CsCl Solutions: d=1.65 (0.790 g/mL). Dissolve 79.0 g molecular biology grade CsCl 
in 50 mL of 1X TE buffer in a glass beaker and mix with a magnetic stir bar. Once 
dissolved, dilute to 100 mL with 1X TE buffer in a graduated cylinder. D=1.95 (1.230 
mg/mL). Follow same procedure as before with 116.73 grams of CsCl. Additional 
1.745 g CsCl for sample preparation. (see Note 5) 
5) Sucrose solution: 5%, 10%, 15%, 20% (w/v). To prepare sucrose solutions, dilute 
respective amount of sucrose (e.g. 5 g for 5% w/v) to 100 mL final volume with 1X 
TMS Buffer. Mix in glass beakers and stir with a magnetic beaker. (see Note 5) 
6) Ultracentrifugation tubes: Beckman #326819, 5-mL. 
7) Automated Gradient Maker: BioComp Gradient Master Model 106 (BioComp 
Instruments) gradient maker. 
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8) Long Neck Pipette tips: Bio-Rad 223-9916. 1-200 µL pipette tip for gel loading. 
9) Syringe and Needle: 5-mL BD Syringe, Fisher Scientific. Reusable non-sterile 
hypodermic needle, 3.5 in, Fisher Scientific. 
10) Mild detergent: Alconox Detergent, Fisher Scientific #NC9003111. 
11) Pipette: 1000 µL and 200 µL pipette, Denville Scientific Inc. 
12) Vortexer: VWR Analog Vortex Mixer. 
2.2. For Ultracentrifugation 
1) Analytical Balance: Mettler Toledo AB204-S Analytic Balance.  
2) Ultracentrifuge: Beckman Coulter L-80 Ultracentrifuge (Beckman #392051) (see Note 
6). 
3) Ultracentrifuge Rotor: Beckman Coulter SW 55 Ti Rotor (Beckman #342194) (see 
Note 7).  
4) Ultracentrifugation Bucket: Swinging Bucket for SW 55 Ti Rotor (Beckman #342194) 
(see Note 8). 
5) Ultracentrifugation Bucket Rack: Bucket rack for swinging bucket SW 55 Ti Rotor 
(Beckman #331313). 
6) Ultracentrifugation Spinkote Lubricant: Lubricant for ultracentrifuge (Beckman 
#306812) (see Note 9). 
7) Ultracentrifugation Vacuum Grease: Vacuum seal grease (Beckman #335148) (see 
Note 10). 
2.3. For Fractionation and Sample Analysis 
1) Tubes: Fisherbrand Premium Microcentrifuge tubes, 1.5 mL. Catalog No: 05-408-120. 
Autoclaved.  
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2) Pipette: 200 µL pipette, Denville Scientific Inc. and sterile pipette 200 µL pipette tips 
3) Fraction Collector (Optional): Beckman Coulter Fraction Recovery System, No: 
343890. (see Note 11) 
4) Agarose: Low-melting, molecular biology grade. Fisher BioReagents. Catalog No: 
BP165-25. 
5) Agarose Gel Buffer/Running Buffer: 1X TAE (40 mM Tris-acetate, 1 mM EDTA) with 
10 mM MgCl2. Add about 100 mL water to a 1-L glass beaker with a magnetic stir bar. 
While stirring, add 0.00725 g Tris-acetate, 0.000292 g EDTA, and 2.03 g MgCl2 
hexahydrate and transfer to the glass beaker. Bring the volume to 1-L. 
6) Microwave 
7) Imaging System: Typhoon FLA 7000 imaging system, GE Healthcare. 
8) Agarose Gel Electrophoresis System, mini-sub cell GT system, Bio-Rad. 
9) Ethidium Bromide: 1% Solution, Molecular Grade. Fisher BioReagents Catalogue No: 
BP1302-10. 
10) Sample Concentration: Amicron Ultra 0.5 mL Centrifugal Filters, Millipore. 
METHODS: 
Carry out all procedures at RT unless otherwise specified. 
3.1: CsCl Equilibrium Density method RNA Purification 
This method details the purification of RNA prepared by in vitro transcription using 
T7 RNA polymerase as described in detail previously (105). CsCl centrifugation will 
remove unincorporated nucleotides as well as proteins and other impurities from the 
transcription reaction mixture based on differences in density. The sample being used for 
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centrifugation in the following procedure can be used directly after in vitro transcription 
without further modification (Figure 1). 
3.1.1: Preparation of d=1.65-1.95 CsCl Gradient 
1. Prepare two CsCl solutions with densities of 1.65 (0.790 g/mL) and 1.95 (1.23 g/mL) 
as detailed previously. (see Note 5) 
2. Prepare CsCl sample solution with density equal to 1.75 (1.164 g/mL). Dilute the 
sample from RNA transcription to 1.0 mL (maximum sample volume for 5 mL 
centrifuge tube is 1.0 mL) with 1X TE buffer. To the diluted sample add 1.7452 g CsCl 
and mix thoroughly with a vortexer (see Note 5). Adjust the final volume to 1.5 mL. 
3. Pipette the 1.5 mL sample in CsCl solution, d=1.75, into a 5.0 mL ultracentrifuge tube 
(Beckman #326819). 
4. Using a syringe and long needle, pipette the d=1.95 CsCl solution to the bottom of the 
ultracentrifuge tube, below the sample CsCl solution 
5. On top of the sample solution, pipette 1.5 mL of d=1.65 CsCl solution. 
6. Cap the centrifuge tube. (see Note 12) 
3.1.2: Ultracentrifugation Procedure 
At all times, be gentle when handling the tubes with the prepared CsCl gradients. 
Too rough of handling will disturb the gradient and affect the sample purification. 
1) Place the ultracentrifuge tube into the centrifugation buckets. 
2) Using an analytical balance, measure and record the weight of each bucket and 
respective bucket top with the tube inside. It is extremely important to equilibrate 
weights of buckets that will be across from each other when attached to the rotor (see 
Note 13). To make the weights equal, use water to match weights between the pairs of 
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buckets. For each 0.01 gram of difference, pipette 10 µL of water into the bucket with 
less weight (see Note 14). 
3) Once the buckets are balanced, tightly secure the tops of the buckets to prevent leaking. 
Finally, secure the buckets onto the swinging-bucket rotor (Beckman SW Ti 55) (see 
Note 15). 
4) Holding onto the base and the top of the rotor, carefully place the rotor into the 
ultracentrifuge (Beckman L-80 ultracentrifuge) (see Note 16). 
5) Bring the temperature down to 4.0°C and turn on the vacuum to equilibrate the rotor 
and sample. Wait until the final temperature and lowest pressure (<20 microns) are 
reached before commencing rotation (see Note 17). 
6) Spin the rotor (Beckman SW 55 Ti) at 45,000 RPM (246, 078 x g) for 16 hours. (see 
Note 18). 
7) After centrifugation, wait for the rotor to come to a complete stop and the RPM reading 
on the ultracentrifuge reaches "0." Once the rotor has stopped, release the vacuum and 
open the lid. Carefully grabbing the base and the top of the rotor, remove the rotor form 
the ultracentrifuge and place it back on the rotor stand. 
8) Remove the rotor buckets and place them back in the bucket holder rack. Remove the 
tubes and place them in a sample rack. It is important to now thoroughly clean and dry 
the buckets as excess moisture can cause damage to the buckets. 
9) Proceed to section 3.3 for fractionation and sample analysis. 
3.2: Rate-zonal sucrose gradient for Nanoparticle Separation or cushioned Rate-Zonal 
Sucrose Gradient 
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This method details the separation of the final nanoparticle assembly from incorrect 
structures such as misformed aggregates and unincorporated strands. The RNA assemblies 
should be annealed prior to purification by ultracentrifugation in 1X TMS buffer. 
Maximum sample volume for ultracentrifugation is 500 µL. 
3.2.1: Preparation of 5-20% (v/v) sucrose density gradient preparation 
3.2.1.1: Gradient preparation by gradient maker 
1) Prepare two sucrose solutions, 5% and 20% (w/v), in 1X TMS buffer by diluting 5 g 
and 20 g, respectively, of sucrose to 100 mL volume in a graduated cylinder. Transfer 
to a glass beaker and use a magnetic stir bar to thoroughly mix the solutions. 
2) Into a 5.0 mL polypropylene (Beckman #326819) ultracentrifuge tube, cleaned with a 
mild detergent and thoroughly dried, pipette 2.4 mL of 5% sucrose solution. In a 5-mL 
syringe with a long tip needle, carefully syringe 2.4 mL of 20% (w/v) sucrose solution 
to the bottom of the ultracentrifuge tube. Insert the cap of the centrifuge tube into the 
top of the tube (see Note 12). 
3) In this method, the gradient was made using the BioComp Gradient Master Model 106 
(BioComp Instruments) gradient maker (see Note 19). For the specified gradient, 5%-
20% sucrose (w/v), set the gradient maker to spin for one minute and thirteen seconds 
at an angle of 86° at 16 RPM. After the gradient maker is done, remove the 
ultracentrifuge tube and place in a sample holder rack (see Note 20). 
3.2.1.2: Gradient preparation by manual layering (if gradient maker not available) 
This method details the procedure to make the 5%-20% (w/v) sucrose gradient if 
there is no automated gradient maker available. 
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1) By the same procedure previously detailed, make 5%, 10%, 15%, and 20% (w/v) 
sucrose solutions. 
2) Using the prepared solutions, layer from most dense (20%) to least dense (5%) with 
1.2 mL of each solution. Carefully layer the solutions into a 5.0-mL (Beckman 
#326819) ultracentrifuge tube using a long-tip hypodermic needle. (see Note 21) 
3) Incubate the tube overnight at 4°C to form a continuous gradient, ideally in a cold room 
(see Note 22). 
3.2.2: Sample loading and ultracentrifugation procedure 
At all times, be gentle when handling the tubes with the prepared sucrose gradients. 
Too rough of handling will disturb the gradient and affect the sample purification. 
1. Before being loaded, ensure the sample is in its native annealing buffer (see Note 23). 
To load the sample, slowly pipette a maximum volume of 100 µL on top of the 
previously prepared sucrose gradient (see Note 24). 
2. Using an analytical balance, measure and record the weight of each bucket and 
respective cap with the tube inside. It is extremely important to equilibrate weights of 
buckets that will be across from each other when attached to the rotor (see Note 13). 
Use water to equal bucket weights. For each 0.01 gram of difference, pipette 10 µL of 
water into the bucket with less weight (see Note 14). 
3. Once the buckets are balanced, tightly secure the tops of the buckets to prevent leaking. 
Finally, secure the buckets onto the swinging-bucket rotor (Beckman SW Ti 55) (see 
Note 15). 
4. Holding onto the base and the top of the rotor, carefully place the rotor into the 
ultracentrifuge (Beckman L-80 ultracentrifuge) (see Note 16). 
153 
 
5. Bring the temperature down to 4.0°C and turn on the vacuum to equilibriate the rotor 
and sample. Wait until the final temperature and lowest pressure (<20 microns) are 
reached before commencing rotation (see Note 17). 
6. Spin the rotor (Beckman SW 55 Ti) at 50,000 RPM (303, 800 x g) for 7 hours. (see 
Note 18). 
7. After centrifugation, wait for the rotor to come to a complete stop and the RPM reading 
on the ultracentrifuge has reached "0." Once the rotor has stopped, release the vacuum 
and open the lid. Carefully grabbing the base and the top of the rotor, remove the rotor 
from the ultracentrifuge and place it back on the stand. 
8. Remove the rotor buckets and place them back in the bucket holder rack. Remove the 
tubes and place them in a sample rack. It is important to now thoroughly clean and dry 
the buckets as excess moisture can cause damage to the buckets. 
3.2.3 Preparation of Cushioned Sucrose Gradient for Rate-Zonal Purification of RNA 
Nanoparticles 
This method details the use of a high-density sucrose “cushion” at the bottom of 
the gradient during the rate-zonal purification of RNA nanoparticles (Fig 5.9E). Utilizing 
a cushion has multiple advantages. For low amounts of sample, the sample can be run to 
the bottom of the gradient and then stopped at the cushion. This allows the samples to be 
collected at a higher concentration (fewer fractions) while avoiding pelleting. Pelleting can 
sometimes lead to damage of sensitive samples during resuspension. Additionally, using a 
cushion enhances the collection of nanoparticles that display multiple conformations, 
which would otherwise spread to multiple fractions. Importantly, when purifying 
nanoparticles that contain small molecule therapeutics or reporter molecules, a cushion will 
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help to purify the nanoparticle complex from free small molecules by allowing large 
separation between the two species. The size of the complex can easily separate from free 
drug due to the buoyancy of the small molecule, which will prevent the small molecule 
from co-localizing in the denser (lower) portion of the gradient. 
1. First prepare the 5-20% sucrose gradient as described earlier in section 3.2.1. However, 
when using the BioComp gradient maker reduce the volume of each solution to 2.3 mL 
and when manually layering each solution decrease the volume of each solution to 1.15 
mL. This will account for the additional volume needed for the high-density sucrose 
cushion. 
2. After preparation of the 5-20% sucrose gradient, with decreased volume, use a pipette 
to load .2 mL of 60% sucrose solution to the bottom of the gradient. Slowly pipette the 
60% sucrose solution down the side of the ultracentrifuge tube, from the top of the 
gradient. Because of the high density of the solution, it will fall to the bottom of the 
tube forming a sucrose cushion. 
3. Let the cushion settle for 5 minutes being careful not to disturb the solution in the tube. 
4. For sample loading and fractionation follow the same procedures detailed for sucrose 
gradient rate-zonal ultracentrifugation without use of the cushion. 
3.3: Fractionation and sample analysis/recovery (Same for CsCl and Sucrose) 
During this step it is important to keep track of each fraction when removing it from 
the tubes. Pre-label autoclaved tubes to ensure accuracy of fractions. 
1) To remove fractions, use a pipette to remove 200 µL from the very top of the CsCl or 
sucrose gradient and place in a pre-labeled tube to ensure accuracy of fraction numbers 
(see Note 25). 
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2) Continue to remove 200 µL fractions from the very top of the tube until the tubes are 
completely empty (see Note 26). 
3) Prepare a 2.0% non-denaturing agarose gel containing 1X EtBr gel stain (2.0 grams 
agarose, diluted to 100 mL in 1X TAE Buffer containing 10 mM-Mg) (see Note 27). 
4) Into each well of the agarose gel load 10 µL aliquots of each fraction. Run for 30 
minutes at 120 V at RT in 1 X TAE buffer with 10 mM MgCl2. 
5) After the gel has finished running, scan on a Typhoon FLA 7000 laser scanner for EtBr 
signal. Similar gel scanning devices can also be used. (see Note 28) 
6) Combine the fractions containing the desired products and reconstitute into the native 
folding buffer, 1X TMS, using Amicron Ultra 0.5 mL centrifugal filters (see Note 29). 
EXPECTED RESULTS: 
Synthesis and purification of RNA nanoparticles utilizing the pRNA from the phi29 
bacteriophage was performed. In nature, the pRNA forms a hexameric ring that is used in 
gearing the phi29 DNA packaging motor (12,306). Previously, the native pRNA structure 
was engineered to assemble into diverse RNA nanoparticles including dimers, trimers, 
tetramers, hexamers, and larger supramolecular complexes utilizing hand-in-hand and 
foot-to-foot interactions (12,50,104,105,200). As demonstration of expected results, we 
show here the purification of pRNA monomer and dimer constructs from two different 
pRNA monomers, Ab’ and Ba’ (151). Monomers were purified by CsCl density gradient 
ultracentrifugation and dimer constructs by 5-20% sucrose gradient rate-zonal 
ultracentrifugation. The Ab’ and Ba’ pRNA monomers assemble via hand-in-hand kissing 
loops to form dimer constructs (Fig 5.9A). CsCl density gradient ultracentrifugation was 
used to purify RNA directly after in vitro transcription from the proteins and DNA template 
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using the procedures detailed here. Post in vitro RNA transcription, the reaction mixture 
contains proteins and DNA template, which are undesired products. The DNA template is 
degraded by DNase enzyme and the proteins are easily separated from the RNA product 
by the difference in their densities. The high density of RNA results in the products 
migrating to the densest portion of the gradient. Despite a small size difference between 
monomers and dimer, ~120 nucleotide monomer and ~240 nucleotide dimer, the monomer 
and dimer can be separated by sucrose density gradient ultracentrifugation following the 
procedures detailed here (Fig 5.9C). The recovered fractions demonstrated comparable 
dimer assembly to RNA nanoparticles purified by PAGE (Fig 5.9D). 
NOTES: 
1) Adding reagents to already circulating water helps to dissolve them easily. If there is 
trouble dissolving the reagents the glass beaker can be heated gently to 37°C. However, 
pH must be adjusted at room temperature. 
2) Use caution when handling EDTA. EDTA is a skin, eye, and respiratory tract irritant 
3) MgCl2 will absorb moisture from the air. Be sure to handle as quickly as possible and 
then recap the reagent bottle tightly to prevent moisture absorption. 
4) Use caution when handling concentrated HCl. HCl is a strong acid and is very 
corrosive. HCl is a strong eye, skin, and respiratory tract irritant. HCl can cause severe 
burns, be sure to handle with gloves and wear splash goggles to prevent it from getting 
in eyes. 
5) Be sure to mix vigorously enough to have a homogeneous mixture of CsCl or sucrose 
and 1X TE buffer. 
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6) Be sure regular maintenance has been carried out on the ultracentrifuge to ensure proper 
operation and safety for the user.  
7) Before use, inspect rotor to make sure there are no cracks or disfigurements, use of 
damaged buckets could result in danger to the user and damage to the ultracentrifuge. 
8) Before use inspect buckets for cracks and/or disfigurements, use of damaged buckets 
could result in danger to the user and damage to the ultracentrifuge. 
9) Before using the ultracentrifuge, be sure the rotation bearings are properly lubricated. 
10) Prior to ultracentrifugation ensure the vacuum seal is properly greased. A badly greased 
vacuum seal will not allow the proper low-pressure environment to be reached and 
ultracentrifugation will not be able to commence. 
11) The Beckman Coulter Fraction Recovery System works by puncturing a whole in the 
bottom of the ultracentrifugation tube and collection occurs from the bottom of the 
tube. This system can be a viable alternative to the method described here, however 
this equipment is optional. 
12) When capping the ultracentrifuge tube make sure to cap at an angle to prevent air 
bubbles from forming in the gradient. Keep air bubbles out while preparing the 
gradient. When syringing higher density CsCl or sucrose do so slowly and with extreme 
care to avoid mixing the high density with the low-density solutions. The gradient used 
will not be identical for all complexes. In some cases the ideal gradient to use must be 
experimentally determined. 
13) Each bucket is labeled with a number 1-6, 1 is across from 4, 2 from 5, 3 from 6. It is 
important that each pair be identical in weight and are placed across from each other 
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on the rotor. Also, even if six samples are not being run, it is important that all buckets 
be in place during centrifugation and run with equal weight. 
14) Do not pipette into the ultracentrifuge tube, pipette into the space surrounding the tube 
inside the bucket. 
15) Before beginning ultracentrifugation, make sure each bucket is securely fixed to the 
rotor. Do this by gently but firmly tugging down on each bucket once it is attached to 
the rotor. However, while doing this do not disturb the gradient and sample in the tube. 
16)  The rotor must rotate freely to ensure proper function of the ultracentrifuge. Ensure 
that the connection is sufficiently greased (Beckman #306812) and test by rotating the 
rotor clockwise by hand. If it moves freely it is sufficiently lubricated. 
17) A proper vacuum seal is required to hold the vacuum constant. Make sure the seal is 
sufficient, if not apply grease to ensure a proper seal (Beckman #335148). 
18) The optimal centrifugation time depends on the exact mass and shape of the RNA 
complex. This should be experimentally determined. Avoid excessive centrifugation as 
this may lead to sample pelleting at the bottom of the tube, which will negatively affect 
the purification of the RNA assembly. Pelleting time, or k-factor, can be calculated 
quickly by equation t=k/s, where t is run time in hours required to pellet a particle of 
known sedimentation coefficient s (in Svedberg units, S). The k-factor is a function of 
the maximum and minimum radius of a rotor and the run speed in RPM. The k-factor 
for the SW-55 Ti rotor at 45,000 RPM is 72.4. After determining the sedimentation 
coefficient of the particle of interest, the pelleting time can be calculated and a shorter 
time should be used. 
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19) This exact model of gradient maker is not required. Follow the gradient maker protocol 
for correct angle, speed, and duration. 
20) Always prepare gradients with location in mind. Try to move the formed gradients as 
little as possible as moving the gradients can disturb the final density gradient. 
21) Pipette as carefully as possible when stacking the different densities of CsCl or sucrose. 
Taking care not to mix the different gradients will lead to a better quality gradient. 
22) A cold room is preferred over a refrigerator. Repeated opening and closing of a 
refrigerator door will disturb the gradient during its equilibration. 
23) Sample should be in its native annealing buffer, 1X TMS. 
24) When pipetting the sample onto the top of the gradient take great care to pipette slowly 
and get as narrow a band as possible of the sample. This will lead to higher resolution 
during ultracentrifugation. 
25) 200 µL may not be an ideal volume for every purification situation. In a case where the 
RNA complex is not as well separated a lower fraction volume may be ideal, in cases 
where resolution is high larger fraction volumes may be ideal. This should be 
experimentally determined. 
26) Be sure to use a new pipette tip with each fraction to avoid contamination. 
27) Be careful handling EtBr, it is thought to act as a mutagen because it intercalates with 
dsDNA and dsRNA. 
28) Be sure to include a molecular weight marker in the agarose gel to determine which 
fractions are the correctly formed complexes. 
29) Follow the manufacturer's protocol. The size of the RNA complex being purified will 
determine the specific filter to be used. Centrifugal force less than 4500g should be 
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used in order to minimize sample damage and loss. Typically this will result in 50-100 
μL of purified RNA complex. 
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Figure 5.1: Scheme for Circular dsDNA Assembly. ssDNA CircLigase is first used to 
self-cyclize a phosphorylated ssDNA. Following hybridization of the complementary 
strand, T4 DNA ligase is used to close the nick. T7 RNA polymerase transcribes the 
sequence, which contains self-cleaving ribozymes to release the target RNA sequence. The 
target RNA sequence can be a defined RNA oligomer or nanoparticle sequence. 
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Figure 5.2: Transcription and Cleavage Confirmation. (A) Assembly of circular 
dsDNA. This is a representative gel of the general assembly analysis. (B) Assembly of 
circular dsDNA is confirmed by inactivating the ribozyme in the sequence. Inactive 
ribozymes leads to concatamerized RNA, while cleavage results in short oligomers. (C) 
Circular and linear transcription for dsDNA constructs encoding for release of the 3WJ 
ssRNA oligomers. (D) Assembly of the 3WJ occurs co-transcriptionally by mixing 
equimolar amounts of dsDNA encoding for the release of 3WJ-A, B, and C strands. 
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Figure 5.3: One-Strand RNA Nanoparticle Assembly. (A) Schematic for modified 
design of self-cleaving ribozyme. A portion of one ribozyme is positioned 5’ of the 
nanoparticle sequence while the other portion is located 3’ of the nanoparticle sequence. 
Self-cleavage occurs after transcription of the entirety of the dsDNA template. (B) Circular 
dsDNA was assembled to code for the 3WJ and MG-3WJ nanoparticles assembled from 
one long piece of RNA. (C) PAGE gels showing assembly of the one-stranded 
nanoparticles. Gels were stained with both ethidium bromide (total RNA) and MG dye, 
which shows correct folding and release of the nanoparticles. 
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Figure 5.4: Transcription Kinetics. (A) Comparison of linear transcription and circular 
transcription. MG-3WJ was used as fluorescence can be an indicator for the progression of 
transcription. (B, C) Gel analysis of transcription. Bands were integrated and plotted. (D, 
E) Monitoring of transcription using MG fluorescence (specific to nanoparticle folding, 
panel D) and SYBR GreenII (RNA specific, panel E). 
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Figure 5.5: Gel-electrophoresis Column Purification. (A) MG fluorescence and 
absorbance at 260 nm were used to analyze fractions after purification. (B) PAGE gel 
analysis determines the identity of the peaks from fluorescence and absorbance analysis.  
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Figure 5.6. Mechanism for CsCl equilibrium density gradient. (A) Different densities 
of CsCl salt solution are loaded into centrifuge tube with sample in medium density 
solution. (B) Post centrifugation, when equilibrium is reached, a gradient is formed with 
the migration of particles separating by their density (specific gravity). 
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Figure 5.7. Mechanism of separation for sucrose gradient rate-zonal 
ultracentrifugation. (A) Before centrifugation, the sample is loaded on the top of the 
gradient in a thin band. (B) After centrifugation, the particles separate based on shape and 
mass. Higher mass particles migrate faster to the higher density portion of the gradient and 
lower mass particles stay in the lower density portion at the top of the gradient. 
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Figure 5.8. Gradient formation, sample loading and analysis scheme of sucrose 
gradient rate-zonal ultracentrifugation and expected results. (A) Formation of gradient 
by automated gradient maker. (B) Formation of gradient by manual layering. (c) Sample is 
loaded in a thin band on top of the gradient. After centrifugation the particles are separated 
by size. (D) Alternate method for the formation a cushioned sucrose rate-zonal density 
gradient using 60 % sucrose solution pipetted to the bottom of a preformed sucrose 
gradient. (E) Expected AGE analysis results. AGE analysis reveals the identity of each 
fraction. After AGE analysis the target particle fractions are combined and concentrated. 
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Figure 5.9. pRNA monomer and dimer purification. (A) Schematic Representation of 
pRNA monomer (Ab′ and Ba′) and dimer complex (Ab′–Ba′). The pRNA dimer is formed 
by two distinct pRNA monomers, termed Ab′ and Ba′ (B) The two pRNA monomers are 
purified by CsCl density gradient ultracentrifugation and analyzed by agarose gel 
electrophoresis. The monomer sedimented toward the bottom of the tube, an example of 
differential centrifugation. (C) 5–20 % sucrose gradient was used to purify the pRNA 
dimer complex (red ). As a reference, pRNA monomer was also examined under the same 
conditions (black). (D) Post centrifugation, fraction 7 was recovered and native PAGE was 
used to examine the assembly of pRNA dimers purified by ultracentrifugation (UC, Lane 
3) compared to those purified by PAGE (Lane 6). Lanes 1 and 2 are pRNA monomers 
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purified by CsCl ultracentrifugation, used as size controls in the gel; Lanes 4 and 5 were 
purified by PAGE as a comparison to results obtained by purification using 
ultracentrifugation. Comparable assembly of the pRNA dimer complex is observed 
between each method  
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Chapter 6: Summary of Thesis Achievements and Outlook 
 
This chapter was reproduced (with some modification) with permission from 
Jasinski, D; Haque, F; Binzel, DW; and Guo, P. “Advancement of the Emerging Field of 
RNA Nanotechnology.” ACS Nano, 2017. DOI: 10.1021/acsnano.6b05737. Copyright 
2017 American Chemical Society. 
 
SUMMARY: 
 This thesis work describes the development of RNA nanoparticles with diverse and 
controllable sizes, shapes, and physical properties. Before this work, RNA nanotechnology 
was somewhat limited in its diversity of nanoparticles. As mentioned previously, size and 
shape diversity are paramount for in vivo drug delivery systems, since these properties have 
profound effects on biodistribution, circulation time, toxicity, and interactions with the in 
vivo environment. Thermodynamically stable and serum resistant 2’F RNA triangles, 
squares, and pentagons were constructed using a modular design approach with the pRNA-
3WJ as the base unit. The same angle of the 3WJ was used to construct the nanoparticles, 
displaying diversity in shape from one RNA motif. Nanosquares were tuned in size by 
modulating RNA duplex length between adjacent 3WJ modules. The nanosquares 
displayed homogeneous size and narrow size distribution, as evidenced by DLS 
measurements. Upon IV administration of the diverse size RNA nanosquares, differences 
in biodistribution profiles were seen. A strong correlation between increased size of 
nanosquares and increased circulation time is evident by time course fluorescent images of 
mice whole body and organs. While triangle, square, and pentagon RNA nanoparticles 
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demonstrated similar biodistribution after 24 h, different fluorescent intensities in organs 
at 12 h suggest diverse elimination pathways. The tunable nature of RNA nanoparticles 
lends this platform advantages when precise control over size, and therefore in vivo 
properties, is desired. Additionally, 3D RNA nanoprisms were constructed and used for a 
unique small molecule encapsulation technique. A fragile RNA aptamer enclosed within 
the stable frame of the nanoprism protected the small molecule cargo from degradation and 
prevented leaking of the small molecule drug. Finally, a method for the large scale in vitro 
production of RNA nanoparticles was developed. Rolling circle transcription (RCT) was 
used to transcribe fully double stranded circular DNA encoding for self-cleaving ribozymes 
to release target RNA. The target RNA was either single stranded RNA oligomers, which 
co-transcriptionally assembled into RNA nanoparticles, or one-stranded RNA 
nanoparticles, which also folded co-transcriptionally and produced functional RNA 
nanoparticles. 
RNA NANOTECHNOLOGY OUTLOOK:  
 RNA nanotechnology for drug delivery has garnered much attention recently as it 
has tremendous potential to help treat many diseases. Certainly, improvements are 
necessary to push this innovative platform towards clinical trials and bring the product to 
the market. Some of the challenges and possible solutions are discussed below. 
Limited therapeutic payload 
Currently, RNA nanoparticles have limited small molecule drug loading capacity. 
Single drugs can be labeled onto the terminal ends of RNA strands and incorporated into 
RNA nanoparticles. Whole chain labeling methods can increase chemical drug payload, 
but can cause misfolding of RNA nanoparticles due to steric hindrance and compromise 
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the release of the drugs. Computational approaches can help to identify locations where 
drugs can be introduced without disrupting the folding of the nanoparticle. Ensuring the 
drugs are orientated out of plane from the RNA nanostructure can also minimize any 
structural defects in the scaffold.  
Intercalation is another viable approach to increase drug loading capacity, but drug 
release profiles need to be closely evaluated as premature release of the drug leads to non-
specific side effects. For instance, if the pRNA-3WJ nanoparticle is used as a delivery 
vector for targeting solid tumors, the projected half-life of the intercalated drug release 
should be more than 4 h, as extensive biodistribution studies revealed that the vast majority 
of the systemically administered pRNA-3WJ nanoparticles localize in the tumor site within 
1-4 hrs. 
RNAi is considered the next frontier of cancer therapy, and is thought by many to 
have potential to “drug the undruggable.” However, like chemical drug conjugation, RNA 
nanoparticles are limited in the number of RNAi molecules that can be delivered to cells. 
However, this limitation may not be an issue as studies report that there are only about 103–
105 Dicer molecules per cell and oversaturation of therapeutic RNAs can lead to non-
specific binding and off-target gene knockdown (308). Too much shRNA delivered to cells 
can cause cytotoxic effects (309), thus, a lower payload of RNAi may not be an issue in 
the end. However, nanoparticle systems such as RNA microsponges have the potential for 
delivering high payloads of siRNAs (38) and their utility in broader preclinical studies will 
be improved if the particle size can be reduced to avoid organ accumulation.  
Endosome escape to fulfill the promise of RNAi 
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Like most nanoparticle platforms, RNA nanoparticles enter cells through receptor-
mediated endocytosis. Thus, intracellular RNA nanoparticle trafficking becomes the next 
challenge. Early endosomal vesicles are the first destination of RNA nanoparticles. Once 
sorted, RNA nanoparticles are transferred to late endosomes and lysosomes, where they 
are trapped without reaching their intended target. Fortunately, endosomal escape using 
small 8-nt anti-miRNA LNA fragments in RNA nanoparticle delivery was successful and 
cancer regression efficient (58), but the efficacy of endosomal escape of siRNA in RNA 
nanoparticles is still unknown as cancer regression after siRNA delivery via receptor 
mediated endocytosis is relatively low (56,310). To date, there is very limited knowledge 
on different cellular endocytosis or internalization pathways that govern subsequent 
intracellular processing and endosomal escape of RNA nanoparticles. Nevertheless, there 
are well-characterized tools available to enhance endosome escape such as chemical 
functional groups including acid-cleavable and pH sensitive (311). The pH-sensitive 
materials undergo high amounts of protonation thereby inducing an influx of ions into the 
endosome, resulting in osmosis and endosome rupture - referred to as 'proton-sponge' 
effect.  
Large-scale production and purification of RNA nanoparticles 
One of the major bottlenecks for future clinical applications is the large-scale 
production, large-scale purification, and cost of RNA nanoparticle production. Typically, 
RNA nanoparticles are designed to be modular composed of multiple short strands that are 
well within the limits of chemical synthesis (maximum of 80 nt). Over the years, the cost 
of RNA oligo synthesis has progressively decreased due to improvements in chemical 
synthesis efficiency. However, large-scale purification remains a challenge. HPLC and gel 
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electrophoresis purification have limited capabilities with somewhat low yields. Due to the 
special nature of RNA nanotechnology, the size of the assembled nanoparticle is 
significantly different from its building blocks, thus, preparative ultracentrifugation has 
recently been employed (312) and looks to be a promising approach for purification of 
fully assembled RNA nanoparticles with high yield.  
CONCLUSIONS: 
RNA nanotechnology has come a long way since its inception in 1998 (12). Some 
of the most exciting advancements happened only within the last five years. The design of 
elegant nanostructures with precise arrangement of functional modules in 3D space and 
self-assembly in a programmable 4D structure with controlled manner have greatly 
advanced the field. Progress in the understanding of the principle for structure-based design 
will enhance the capacity to make more intricate RNA nanoparticles with diverse function 
that one day can mimic naturally occurring RNA nanomachines like the ribosome. RNA 
nanoparticles display many advantages over other nanoparticle systems; however, the 
development of RNA nanoparticles as drugs lags behind that of liposome and polymer 
systems, which have been in clinical trials for years. To reach clinical applications, the 
development of RNA nanoparticles should broaden beyond that of just their construction 
and focus more on applying the advantages of RNA nanotechnology. 
FUTURE STUDIES: 
 Chapter 2 details a novel modular design technique for constructing RNA 
nanoparticles followed by a unique multi-strand assembly process that results in stable and 
tunable nanoparticle scaffolds. This method has been well developed, and the construction 
of RNA nanoparticles with tunable size, shape, and stabilities has been realized. This 
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system allows a platform for studying how nanoparticle properties affect in vivo PK/PD 
properties. 
 However, further development and optimization of this nanoparticle platform is 
still preferable. For example, stretching of the 3WJ angle was shown to decrease stability, 
despite increasing the number of base pairs and theoretical stability based on nearest 
neighbor parameters. In-depth investigation of this phenomenon is desirable. It is apparent 
that the stretching of the 3WJ angle is causing the decrease in stability, therefore, 
modifying the 3WJ could be one possibility to retain stability despite angle stretching. One 
possible way in which this could be accomplished is adding flexibility to the inner angles 
of the 3WJ by addition of unpaired uracil bases, a common bulge seen in RNA structures 
that imparts flexibility into their 3D conformations.  
 In addition to increasing flexibility of the 3WJ, and in turn increasing the stability 
of the nanoparticles constructed from this 3WJ, nanoparticle rigidity has been shown to 
influence interactions with the immune system. We believe these nanoparticles to be 
relatively rigid and locked into their geometrical configurations. By imparting flexibility 
into the 3WJ module, it is possible that flexibility could be introduced into the higher order 
nanostructures, thus reducing interaction with the immune system and possible toxicity 
caused by the nanoparticles in vivo. 
Future work utilizing these nanoparticles also lies on the biological side. That is, a 
systematic study utilizing this platform could results in a full set of size/shape/property 
relationships with other factors such as biodistribution, cellular entry pathways, and drug 
delivery efficacies. More work needs to be done studying how physical properties can 
influence the way in which RNA nanoparticles enter cells, as cell entry pathways go a long 
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way in determining therapeutic effect. By studying a property-efficacy relationship, it 
could be possible to optimize the drug delivery pathways for numerous cell and cancer 
types.  
While the biodistribution studies in this thesis demonstrate a clear relationship 
between increased size of RNA nanoparticles and their increased circulation time, 
fluorescence is not a quantitative measure. Despite using near-infrared fluorophores, which 
have shown potential penetration depths of up to 5-7 mm (307), quantitative labeling, such 
as radiolabeling, could show statistical differences in nanoparticle accumulation in organs 
and tumors among diverse nanoparticles. Additionally, more investigation to reveal a 
molecular basis for different biodistributions of different size and shape RNA nanoparticles 
would be extremely beneficial for our understanding of RNA nanoparticle interaction with 
the in vivo environment. 
The overall goal of nanotechnology is to increase delivery efficacy of the 
administered dose of therapeutic, whether it be chemical drug, protein therapeutic, or 
RNAi. However, as nanoparticles have significant size, the immune system recognizes 
nanoparticles as foreign objects, thus engulfing them in macrophages, filtering them out 
through the kidneys, or if they enter cells, sequestering them in organelles such as 
endosomes and lysosomes, where they are eventually degraded. This drastically reduces 
the amount of therapeutic that can be effective. To this point, the cellular trafficking 
pathways of RNA nanoparticles is not known. Due to the fact that many RNA nanoparticles 
use chemical ligands or RNA aptamers to enter cells, it is assumed that the particles enter 
the cells via receptor mediated endocytosis, where they are most likely trafficked to 
endosomes and degraded by the acidic environment. It is a necessary step to determine how 
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RNA nanoparticles are trafficked. Once this step has been taken, it will be possible to 
examine how nanoparticles with different sizes, shapes, and physical properties (ie 
stability, hydrophobicity, solubility, charge, etc) enter cells, and which particles show the 
largest advantages in regards to drug delivery efficacy. With all these factors taken into 
consideration, it could be possible to optimize which particles to use to maximize cellular 
entry and drug efficacy. According to literature on other nanoparticle systems, the smaller 
particles will enter cells to a higher degree. However, as shown in this thesis, the smaller 
particles appear to circulate out of the body faster. Thus, a balance should be struck 
between circulation time, cellular entry and entrapment, and accumulation in healthy 
organs such as the liver, spleen, and kidneys.  
 In this thesis was also demonstrated a novel method for the protection of a small 
molecule model drug by binding to a fragile RNA aptamer inside a stable RNA 
nanoparticle frame. This study is the first to show encapsulation of a small molecule within 
an RNA nanocage. However, the increase in half-life needs to be extended to at least 4 
hours, as this is the time it takes for RNA nanoparticles to circulate to tumors and 
accumulate in an amount high enough to be therapeutically relevant. Other techniques, 
such as developing more stable aptamers to hold their small molecule cargo more tightly, 
or construction techniques to prevent breathing of the stable frame and invasion by 
nucleases, could help to overcome this challenge. It is possible that this system could be 
extremely helpful in the delivery of vaccines and other protein cargoes to specified targets. 
Preventing off target effects of proteins is extremely important as some potent proteins can 
cause high immune responses in vivo.  
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Finally, this thesis demonstrated a method for large-scale in vitro synthesis and 
purification of RNA oligomers and RNA nanoparticles. This method overcame the hurdle 
of transcribing a ssDNA sequence with stable secondary structure by constructing circular 
double stranded DNA. Despite this advancement, the resulting nanoparticles will be 
susceptible to degradation in vivo, as they are not chemically modified after the RCT and 
ribozyme cleavage process. Currently, there are no ribozymes available that are both 2’F 
modified and can cleave 2’F RNA. It is conceivable that this type of ribozyme could be 
made by in vitro selection (SELEX). Following the selection of a modified ribozyme, this 
process would result in the production of a high yield of RNA nanoparticle that could be 
used in nanomedicine and biomedical applications. Additionally, this method is currently 
challenged by the cost of synthesizing long single stranded DNA oligoes. A new method 
of double stranded circular DNA synthesis, such as the assembly of multiple short DNA 
oligoes into circular double stranded DNA, would be beneficial to reduce cost of DNA 
preparation. 
It is possible that the increased production of RNA nanoparticles could decrease 
their folding efficiency. Certain downstream steps of nanoparticle synthesis could be 
necessary to produce the high-quality RNA nanoparticles constructed from traditional 
methods. This could be achieved by thermal denaturation followed by a typical annealing 
procedure. Thus, all mis-folding occurring from expedited transcription rates would be 
avoided. 
In addition to in vitro methods for RNA nanoparticle synthesis, the RCT method 
developed in this thesis will also lend itself to in vivo production of stable RNA 
nanoparticles. This would allow RNA nanoparticles to be produced by bacterial cells, thus 
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drastically increasing production scale and drastically decreasing cost. However, to 
produce 2’F modified nanoparticles for use in nanomedicine, bacterial cells would need to 
be modified in order to produce and incorporate modified nucleotides. While the challenge 
of this project is significant, it is not at all impossible due to the increased knowledge and 
techniques of bacterial engineering and molecular engineering. If this bacterial engineering 
project were to be achieved, the cost and scale-up challenges of RNA nanoparticle 
production would be eliminated, thus allowing a clear path to clinical translation and 
testing of RNA nanoparticles. 
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Appendix 1: Supplemental Data for Chapter 2 
Appendix 1 was reproduced (with some modification) with permission from: 
Khisamutdinov, EF*; Li, H*; Jasinski, DL*; Chen, J; Fu, J; and Guo, P. “Enhancing 
immunomodulation on innate immunity by shape transition among RNA triangle, square, 
and pentagon nanovehicles.” Nucleic Acids Research, 2014. 42(15), 9996-20004. DOI: 
10.1093/nar/gku516. Copyright 2014 Oxford Publishing; Jasinski, DL; Khisamutdinov, 
EF; Lyubchenko, YL; and Guo P. “Physicochemically tunable polyfunctionalized RNA 
square architecture with fluorogenic and ribozymatic properties.” ACS Nano. 2014. 8(8), 
7620-7629. DOI: 10.1021/nn502160s. Copyright 2014 American Chemical Society. 
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Figure A.1.1. Sequences and secondary structures of RNA polygons. RNA polygons 
and quantified assembly yields (a) triangle, (b) square and (c) pentagon.  
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Figure A.1.2. RNA polygons dissociation constant determination. From left to right, 
7% Native PAGE gels titration data for formation of triangle, square, and pentagon 
polygons.  Below, the gels is the plot used to determine the equilibrium concentration for 
each polygon which were then used to calculate the apparent dissociation constant. 
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Figure A.1.3. AFM images of RNA polygons. Population distribution of RNA triangle 
(a), square (b), and pentagon (c) polygons per 0.5 mm2 of mica surface obtained from AFM 
analysis.  
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Figure A.1.4. Secondary structure and sequences for 5, 10, and 20 nm RNA nanosquares. 
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Figure A.1.5. Total strand participation in square assembly. 7% native PAGE and 
whole chain Cy5 labeling were used to confirm the participation of each strand in the 
assembly of the square nanoparticle.  Each strand was individually end radiolabeled and 
the radiolabeled strand was varied for each sample. The “*” denotes which strand is 
labeled.  The first four lanes show the stepwise assembly of the RNA square. 
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Figure A.1.6. Melting temperature profiles of small, medium, and large squares. 
Melting temperature = 50% Square Formation).  The small square (top panel) melted at 
~26 °C, the medium square (middle panel) melted at 54 °C, and the large square (bottom 
panel) still showed square fractions at 80 °C, indicating melting temperature above 80 °C.  
All nanoparticles were assembled in Tris-HCl buffer containing 100 mM NaCl and 0.1 mM 
MgCl2 at 0.5 μM RNA concentrations. 
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Figure A.1.7. Fetal bovine serum (FBS) degradation testing of square nanoparticle 
hybrids: RNA (A), 2’F Hybrid (B), DNA Hybrid (C).  The top row of gels is scanned 
for FITC signal and bottom row gels are scanned for total RNA by ethidium bromide 
staining.  ImageJ software was used to integrate the intensities of the FITC bands and then 
compared to untreated integration to calculate the percent degradation of each hybrid at 
specified time points. 
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Figure A.1.8. Temperature gradient gel electrophoresis (TGGE) analysis of total 
RNA square (A, D), 2’F RNA hybrid square (B, E), and DNA hybrid square (C,F). A, 
B, and C were carried out under .2 mM Mg ion concentration conditions and D, E, 
and F were carried out under 10 mM Mg ion conditions. A temperature gradient, 
perpendicular to electric current, of 30°C - 75°C was used to determine the melting 
temperature of the three square nanoparticles.  ImageJ software was used to analyze the 
gels and integrate the intensities of the bands. Melting temperatures were taken to be 50% 
square formation compared to 100% formation in lane two.  Lane one in each gel represents 
a single short strand monomer RNA strand. 5’-[γ-32P]-ATP labeling was used with a total 
RNA concentration of 80 nM. In D, E, and F no melting temperature is reached under 10 
mM Mg ion conditions. 
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Figure A.1.9. Secondary structure diagram with primary sequences of the multi-
functional square. Including Luciferase siRNA, RNA Spinach aptamer, RNA Malachite 
Green (MG) aptamer, and Hepatitis B Virus (HBV) ribozyme.  Short strand B incorporates 
the spinach aptamer at its 5' end, short strand C incorporates the MG aptamer at its 5' end, 
and short strand D incorporates the HBV ribozyme at its 5' end and the luciferase siRNA 
sense strand sticky end at its 3' end.  Chemically synthesized RNA oligo is used for the 
anti-sense luciferase siRNA strand. 
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Figure A.1.10.  Fluorescence signal testing in native PAGE.  MG dye stain (A), Spinach 
dye stain (B), and total RNA by ethidium bromide staining (C).  7% native PAGE was run 
with stepwise assembly of the multifunctional square nanoparticle. The gel was then 
simultaneously stained with MG and Spinach dyes and scanned for both signals separately.  
The gel was then total RNA stained with ethidium bromide and scanned for ethidium 
bromide signal. 
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Appendix 2: Supplemental Data for Chapter 3 
Appendix 2 was reproduced (with some modification) with permission from: 
Jasinski, DL; Li, H; and Guo, P. “The Effect of Size and Shape of RNA Nanoparticles on 
Biodistribution.” Molecular Therapy. Under Revision. Copyright 2017 Elsevier Inc.; 
Jasinski, DL; Yin H; Li, Z; and Guo P. “The Hydrophobic Effect from Conjugated 
Chemicals or Drugs on in Vivo Biodistribution of RNA Nanoparticles.” Human Gene 
Therapy. Under Revision. Copyright 2017 Mary Ann Liebert Publishing. 
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Figure A.2.1. HPLC Hydrophobicity Comparisons. %ACN elution for fluorophores 
alone (A), Cy5.5 species (B), SulfoCy5.5 species (C), and AlexaFluor700 species (D). 
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Figure A.2.2. Amino Acid Hydrophobicity Comparison Plots. Predicted ClogP values, 
determined using ChemDraw Pro 16, were compared to four different previously 
determined hydrophobicity scales of amino acids. Cornette scale (233) (A), Kyte-Doolittle 
scale (236) (B), Eisengerg Scale (234) (C), and the Engelman GES scale (237) (D). 
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Figure A.2.3. Chemical Structures of Fluorophores and Nucleic Acids. The chemical 
structures of Cy5.5 and SulfoCy5.5 mono-, di-, and tri-nucleotide derivatives. 
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Appendix 3: Supplemental Data for Chapter 4 
Appendix 3 was reproduced (with some modification) with permission from 
Khisamutdinov, EF*; Jasinski, DL*; Li, H; Zhang, K; Chiu, W; and Guo, P. “Fabrication 
of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs.” 
Advanced Materials, 2016. 28(45), 9996-20004. DOI: 10.1002/adma.201603180. 
Copyright 2016 Wiley Publishing. Special thanks to Dr. Emil F. Khisamutdinov for help 
in preparation of data for these figures. 
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Table A.3.1. Prism sequences and control construct sequences. 
 
 
 
Supplementary Table S1. RNA nanoprism 2D structures and sequences utilized in this project. 
RNA triangle prism
A
 Nucleic Acid sequence 5’ → 3’ 
A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
C GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
2xD/d' GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGC 
a' GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
b' GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC 
c' GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
Prism with RNA MGA 
A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
C GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
D-MGA GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG 
a' GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
b' GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC 
c' GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
d'-MGA GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG 
Control open prism #1 
A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
C GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
D-MGA GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG 
a' GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
c' GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
d'-MGA GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG 
Small prism with RNA MGA 
A GGCCAGCGAAUCCUACGACCUUUGUUAUCGCGUUUUGCGAGUUGUC 
B GGCGCGAUAAUCCGUCUUCCUUUGUUGAGACCUUUUGAGACGUACC 
C GGUCUCAAUCAUGGCCACUUUGUUCGCUGGUUUUCCCAGCUUGG 
D-MGA GACGGUGGUCGUAGGUGUGGUCAUGUGGAA UUUUUU GCGUCCGACAUCC 
a' GGCGUCAAUCUGUCCGCCUUUGUUGAGCCCUUUUCCAAGCUGGG 
b' GGAAUCAAUCUAUACACCUUUGUUGACGCCUUUUGACAACUCGC 
c' GGGCUCAAUCGAUAGAGCUUUGUUGAUUCCUUUUGGUACGUCUC 
d'-MGA GACAGUGGUGUAUAGUGCUCUAUCGUGGCG UUUUU 
GGAUGGUAACGAAUGACGC 
	
A B 
C 
D 
a' B 
c' 
d' 
MGA 
A B 
C 
D 
a' b' 
c' 
d' 
A B 
C 
D 
a' b' 
c' 
d' 
MGA 
A B 
C 
D 
a' b' 
c' 
d' 
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Table A.3.2. Sequences of Prism Control Constructs 
 
 
 
Control open prism #2 
2xA GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
2xB GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
2xC GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
D-MGA GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG 
d'-MGA GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG 
Control open prism #3 (dimer) 
2xA GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
2xB GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
2xC GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
D-MGA GGAAGACGGUCAUGUGUAUGGUAAUCGUAGGUCAUGUGUAUGCGUGGUAGGUG
UCAUGUGUAUGCUUUUUUCGAGGAUCCCGACUGGCAUAG 
d'-MGA GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUCUAUGCCAGGUAACGAAUGGAUCCUCG 
2xD/d’ GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGC 
2xa’ GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
2xb’ GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC 
2xc’ GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
 
 
 
 
 
 
	
A B 
C 
D 
A B 
C 
d' 
MGA 
A B
C
D
a' b'
c'
d'
C
MGA
A B
C
D
a' b'
c'
d'
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Table A.3.3. Prism sequences and control construct sequences. 
 
 
2’F-RNA frame + Core
B
 
2’f-A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
2’f-B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
2’f-C GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
D/d’-core GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUG
UCAUGUGUAUGGCUUUUUUAAUCCCGCGGCCAUGGCGGCCGGGAGUUUUUUGG
ACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUAUCGUUGUC
AUGUGUAUGGC 
2’f-a' GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
2’f-b' GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC 
2’f-c' GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
2’F-RNA frame + DNA-FA
C
 
1DNA-FA GTATGGTAATCGTAGGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG 
 2DNA-FA GTATGCGTGTATATTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG 
3DNA-FA GTATGCGTGGTAGGTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG 
4DNA-FA GTATGCTCTATCGTTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG 
5DNA-FA GTATGCTGGAAGACGGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG 
6DNA-FA GTATGGCGGACACTTGTCATGTTTTTATCCCGCCGCCATGGCGGCCGGGAG 
1xDNA-Cy5 GTATGCGTGGTAGGTGTCATGTTTTTATCCCGCGGCCATGGCGGCCGGGAG-Cy5 
2’f-A GGCCAGCGAAUCAUGGCCUACGAUUACCAUACUUUGUUAUCGCGUUUUGCGAG
UUGUCCACUGCAGGCC 
2’f-B GGCGCGAUAAUCAUGGCCGUCUUCCAGCAUACUUUGUUGAGACCUUUUGAGAC
GUACCACGAGCGUACC 
2’f-C GGUCUCAAUCAUGGCACCUACCACGCAUACUUUGUUCGCUGGUUUUCCCAGCUU
GGCAAGCGCAUAU 
2’f-a' GGCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUGUUGAGCCCUUUUAUAUGCG
CUUGCCAAGCUGGG 
2’f-b' GGAAUCAAUCAUGGCAAUAUACACGCAUACUUUGUUGACGCCUUUUGGCCUGC
AGUGGACAACUCGC 
2’f-c' GGGCUCAAUCAUGGCAACGAUAGAGCAUACUUUGUUGAUUCCUUUUGGUACGC
UCGUGGUACGUCUC 
  
 
ssDNA conjugates complementary to the core 
DNA-folate FA-TCCCGGCCGC CATGGCCGCG GGATT 
 
DNA-cyclodextrin TCCCGGCCGC CATGGCCGCG GGATT-CLDXT 
 
DNA-biotin TCCCGGCCGC CATGGCCGCG GGATT-biotin 
 
DNA-taxol TCCCGGCCGC CATGGCCGCG GGATT-TXL 
 
DNA-Cy5 TCCCGGCCGC CATGGCCGCG GGATT-Cy5 
 
Cy3-DNA-biotin  
 
Cy3-TCCCGGCCGC CATGGCCGCG GGATT-biotin 
 
A
 Triangle prism can be formed using RNA as well as 2’F U/C modified RNA strands. The sequence for the 
complementary linkers are underlined 
B
 The D/d’-core RNA sequence locating inside of the prism is underlined. This underlined sequence portion is 
complementary to the ssDNA-drug conjugates.  
C
 The RNA complementary sequences for the 3’-end labeled DNA-FA is underlined 
D
 The bolded nucleotides correspond to CpG motif  
A B 
C 
D 
a' b' 
c' 
d' 
A B
C
a' b'
c'
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Figure A.3.1. Detailed sequence design and schematic for the assembly of 3D triangular 
nanoprisms from previously designed flat RNA triangle nanoparticles. 
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Figure A.3.2. (A)  Magnesium effect on assembly of triangular nanoprism. Higher 
concentrations of magnesium ions dictate higher assembly efficiencies. (B) TGGE melting 
gel analysis of 2’F prism frame. Melting temperature is taken to be 50% assembled 
nanoparticle. 
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Figure A.3.3. Control PAGE experiments excluding prism dimer and open prism 
constructs from gel shift assembly experiments. Decrease in migration in lanes 2 and 3 
indicate that the prism dimer and open prism, formed by sequence engineering, will migrate 
much slower than the closed prism, as expected. 
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Figure A.3.4. Analysis of the 2’f-RNA frame hybridization with DNA-folate and DNA-
Cy5 strands. Experiments were conducted on 6% native PAGE. The same gel was first 
scanned using Cy5 channel to detect signal from Cy5 fluorophore following staining in EB 
for total nucleic acid visualization. Lane Cy5 contains the following complex: 0.5 M 2’f-
RNA frame, 2.5 M DNA-FA, and 0.5 M DNA-Cy5; L = DNA ladder Thermo Scientific 
O’GeneRuler 1 kb 
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Appendix 4: Supplemental Data for Chapter 5 
Appendix 4 was reproduced (with some modification) from Jasinski, DL; and Guo, 
P. “Co-Transcriptional Assembly of RNA Nanoparticles via Rolling Circle Transcription 
of Fully Double Stranded Circular DNA.” Under Submission and Jasinski, DL; Schwartz, 
CT; Haque, F; and Guo, P. “Large scale purification of RNA nanoparticles by preparative 
ultracentrifugation.” Methods in Molecular Biology. 2015. 1297, 67-82. DOI: 
10.1007/978-1-4939-2562-9_5. 
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Table A.4.1. Sequence of constructs. 
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Table A.4.2. Table summarizing the cleavage efficiencies of the ribozymes in each of the 
sequences, broken down for 5’ and 3’ ribozyme of each sequence, as well as total cleavage 
efficiency of the full-length constructs (those containing both 5’ and 3’ ribozymes) 
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Table A.4.3. Summary of sequences used in publications with RCT reactions 
(38,125,270,275,280,290-292). The DeltaG of most templates are close to 0 or positive, 
indicating unstable secondary structure, which is suitable for transcription using bacterial 
polymerases. Besides dumbbell sequences (denoted by a “*” before the reference), which 
have previously been shown as suitable substrates for transcription.  Templates from this 
manuscript display a large negative DeltaG value, demonstrating the need for a fully double 
stranded circular DNA template. 
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Fig A.4.1. (A) PAGE analysis shows active RCT constructs along with size controls of 
inactivated ribozyme constructs. Size controls allow confirmation of ribozyme cleavage 
and release of target RNA oligomers. (B) Typical experiment run to determine cleavage 
efficiency of self-cleaving ribozymes. The target sequence (green box) intensity was added 
with the cleaved ribozyme (blue box) intensity and then divided by the total band intensity 
(red + blue + green box) per well. A plot on the right shows the ribozyme cleavage 
efficiency over time, comparing first generation design (RCT-1.0) to the second generation 
design (RCT-1.1). The construct containing 3WJ-B sequence is shown here. While a better 
curve was desired for ribozyme cleavage kinetics, ribozymes self-cleave as they are being 
209 
 
transcribed, making it difficult to obtain time points of low percent cleavage. (C) An 
increase in ribozyme efficiency is attributed to increasing the length of the duplex in the 
“closing” region of the ribozyme sequence, shown in red boxes. 
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Figure A.4.2. PAGE analyzing the assembly of circular dsDNA constructs containing the 
T7 promoter used for transcription reactions. 
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Figure A.4.3. (A) Ribozyme cleaved 3WJ ssRNA oligomers were compared to chemically 
synthesized sequences identical to those of the target sequence. Evidenced by identical 
migration rate, we can conclude that the cleaved RNA oligomers are the same size as 
chemically synthesized controls. (B) RCT cleaved 3WJ ssRNA oligomers were purified by 
PAGE band isolation. After elution from gel pieces assembly was tested on native PAGE. 
A stepwise assembly from monomer to dimer and finally trimer complex demonstrate the 
ssRNA from RCT reactions are indeed the correct sequences. 
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Figure A.4.4. (A/B) Plots and linear fitting of DNA template concentration, x-axis, versus 
RNA output, as monitored by SYBR GreenII fluorescence. (C) Values of slope and 
intercept, along with their standard errors and R-Squared values of the fits. 
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Figure A.4.5. (A) Ribozyme cleavage with native sequences was attempted with modified 
nucleotides, fluorine substitution on the 2’ hydroxyl of the ribose sugar (2’F) of C and U 
bases, the pyrimidines. As evidenced by no short RNA fragments after gel analysis, the 2’F 
modifications abolish ribozyme activity. (B) Because hammerhead ribozymes proceed by 
a hydrolysis mechanism, we hypothesized that removal of the 2’OH hindered ribozyme 
activity. Therefore, the C at the cleavage site was replaced with an A, thus the 2’OH would 
still be present, as only pyrimidines are modified with 2’F. However, cleavage activity was 
still zero. It is apparent that modification to the duplex structure by the 2’F modification 
stops ribozyme activity. 
Copyright © Daniel L. Jasinski 2017 
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